Engineered glycosyltransferases and methods for glucosylating steviol glycosides

Engineered GT and SuS enzymes with specific mutations enhance the production of rebaudiosides by optimizing β-glucose linkage formation, addressing the cost and efficiency challenges in large-scale glycoconjugate synthesis.

JP7584401B2Active Publication Date: 2024-11-15TATE & LYLE SOLUTIONS USA LLC
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
JP2021504769
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2018-07-31
Filing Date
2019-07-17
Publication Date
2024-11-15
Estimated Expiration
2039-07-17

AI Technical Summary

Technical Problem

Existing methods for large-scale production of glycoconjugates using glycosyltransferases are costly due to the high demand for glycosyl donors and the inhibition caused by nucleotide by-products, necessitating improved enzymatic systems for efficient and cost-effective synthesis.

Method used

Engineering of glycosyltransferase (GT) and sucrose synthase (SuS) enzymes with specific polypeptide sequences and mutations to enhance β-glucose linkage formation, allowing for the production of rebaudioside compounds like rebaudioside M, A, I, and D, through optimized enzymatic processes.

Benefits of technology

The engineered enzymes achieve high sequence identity and efficiency in producing rebaudiosides with β-glucose linkages, reducing costs and improving the scalability and effectiveness of glycoconjugate synthesis.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007584401000112
    Figure 0007584401000112
  • Figure 0007584401000113
    Figure 0007584401000113
  • Figure 0007584401000114
    Figure 0007584401000114
Patent Text Reader

Abstract

The present invention provides engineered glycosyltransferase (GT) enzymes, polypeptides having GT activity, and polynucleotides encoding these enzymes, as well as vectors and host cells comprising these polynucleotides and polypeptides. The present invention provides engineered sucrose synthase (SuS) enzymes, polypeptides having SuS activity, and polynucleotides encoding these enzymes, as well as vectors and host cells comprising these polynucleotides and polypeptides. The present invention further provides compositions comprising the GT enzymes and methods of using the engineered GT enzymes to produce products with β-glucose linkages.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical Field]

[0001] This application claims priority to U.S. Provisional Patent Application No. 62 / 712,199, filed July 30, 2018, and U.S. Provisional Patent Application No. 62 / 712,327, filed July 31, 2018, both of which are incorporated herein by reference in their entirety for all purposes.

[0002] The present invention provides engineered glycosyltransferase (GT) enzymes, polypeptides having GT activity, and polynucleotides encoding these enzymes, as well as vectors and host cells comprising these polynucleotides and polypeptides. The present invention provides engineered sucrose synthase (SuS) enzymes, polypeptides having SuS activity, and polynucleotides encoding these enzymes, as well as vectors and host cells comprising these polynucleotides and polypeptides. The present invention further provides compositions comprising GT enzymes and methods of using engineered GT enzymes to generate products with β-glucose linkages. The present invention further provides compositions and methods for producing rebaudiosides (e.g., rebaudioside M, rebaudioside A, rebaudioside I, and rebaudioside D). The present invention also provides compositions comprising SuS enzymes and methods of using them. Methods for producing GT and SuS enzymes are also provided.

[0003] Reference to a sequence listing, table, or computer program An official copy of the Sequence Listing has been submitted via EFS-Web contemporaneously with the present application as an ASCII text file with the filename "CX8-180USP1A_ST25.txt," created on July 31, 2018, and measuring 8,929 kilobytes in size. This Sequence Listing filed via EFS-Web is a part of the present application and is incorporated herein by reference in its entirety. [Background technology]

[0004] Glucosyltransferases (GTs) are enzymes that post-translationally transfer glycosyl residues from activated nucleoside sugars to monomeric and polymeric acceptor molecules (e.g., other sugars, proteins, lipids, and other organic substrates). Therefore, these enzymes utilize activated donor sugar substrates containing a substituted phosphate leaving group. The donor sugar substrate (i.e., "glycosyl donor") is typically activated as a nucleoside diphosphate sugar. However, other sugars, such as nucleoside monophosphate sugars, lipid phosphates, and unsubstituted phosphates are also used (see, e.g., Lairson et al., Ann. Rev. Biochem., 77:25.1-25.35

[2008] ). GTs are classified as either retaining or inverting enzymes based on the stereochemistry of the substrate and reaction product. In reactions in which the stereochemistry of the donor anomeric bond is preserved (e.g., alpha to alpha), the GT is a retaining enzyme. In reactions where stereochemistry is inverted (e.g., alpha to beta), GT is an inverting enzyme. These glycosylated products are involved in various metabolic pathways and processes. Indeed, the biosynthesis of numerous disaccharides, oligosaccharides, and polysaccharides requires the action of various glycosyltransferases. The transfer of glucosyl moieties can alter the acceptor's biological activity, solubility, and intracellular transport properties. GT has been used for the targeted synthesis of specific compounds (e.g., glycoconjugates and glycosides) and for the production of differentially glycosylated drugs, biological probes, or natural product libraries. In some methods, the large-scale use of GT for glycoconjugate synthesis requires large amounts of glycosyl donors, thus increasing the cost of such procedures. Nucleotide recycling systems have been developed to enable the resynthesis of glycosyl donors from released nucleotides. These recycling systems also reduce the amount of nucleotide byproducts formed during the reaction, thereby reducing the inhibition caused by GT. Nevertheless, improved methods suitable for the large-scale production of glycoconjugates by GT remain needed. [Prior art documents] [Non-patent literature]

[0005] [Non-Patent Document 1] Lairson et al., Ann. Rev. Biochem. (2008) 77:25.1–25.35 Summary of the Invention [Means for solving the problem]

[0006] The present invention provides engineered glycosyltransferase (GT) enzymes, polypeptides having GT activity, and polynucleotides encoding these enzymes, as well as vectors and host cells comprising these polynucleotides and polypeptides. The present invention provides engineered sucrose synthase (SuS) enzymes, polypeptides having SuS activity, and polynucleotides encoding these enzymes, as well as vectors and host cells comprising these polynucleotides and polypeptides. The present invention further provides compositions comprising GT enzymes and methods of using engineered GT enzymes to generate products with β-glucose linkages. The present invention further provides compositions and methods for producing rebaudiosides (e.g., rebaudioside M, rebaudioside A, rebaudioside I, and rebaudioside D). The present invention also provides compositions comprising SuS enzymes and methods of using them. Methods for producing GT and SuS enzymes are also provided. The present invention provides engineered glycosyltransferase variants comprising a polypeptide sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 2. In some embodiments, the engineered glycosyltransferase comprises a polypeptide that is at least 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 20. In some additional embodiments, the polypeptide sequence of the engineered glycosyltransferase is 41 / 72 / 233 / 338, 41 / 72 / 338, 41 / 144 / 233, 41 / 233, 41 / 233 / 338, 61, 61 / 87 / 91 / 107, 61 / 87 / 91 / 259, 61 / 91 / 431, 61 / 107, 61 / 259 / 428, 61 / 407 / 428, 61 / 411, 72, 72 / 76, 72 / 76 / 163 / 197, 72 / 76 / 195 / 233, 72 / 76 / 197 / 204, 72 / 76 / 207 / 233, 72 / 76 / 207 / 338, 72 / 81, 72 / 81 / 195 / 233, 72 / 139 / 195 / 204, 72 / 144 / 338, 72 / 200 / 204 / 207, 72 / 207, 76 / 144 / 197 / 200, 76 / 195 / 197 / 204 / 207 / 233, 76 / 197 / 207 / 233, 76 / 233, 81 / 139 / 144 / 195 / 200 / 204 / 207 / 233, 81 / 144 / 233, 81 / 197 / 200 / 207 / 233 / 338, 81 / 233 / 338, 81 / 338, 107, 107 / 2 and 259, wherein the positions are numbered with reference to SEQ ID NO:20.In some additional embodiments, the polypeptide sequence of the engineered glycosyltransferase is 41E / 72P / 233Q / 338A, 41E / 72P / 338A, 41E / 144Q / 233T, 41E / 233Q, 41E / 233Q / 338V, 41E / 233T, 41E / 233T / 338V, 61D, 61D / 87K / 91L / 107L, 61D / 87K / 91L / 259T, 61D / 107V, 61D / 259T / 428I, 61D / 40 7T / 428I, 61E / 87K / 91L / 107V, 61E / 91L / 431M, 61E / 411T, 72P, 72P / 76S, 72P / 76S / 163A / 197K, 72P / 76S / 207V / 338V, 72P / 7 6T, 72P / 76T / 195Q / 233T, 72P / 76T / 197K / 204T, 72P / 76T / 207V / 233Q, 72P / 81T, 72P / 81T / 195Q / 233Q, 72P / 139N / 195Q / 204T , 72P / 144Q / 338V, 72P / 200R / 204T / 207V, 72P / 207V, 76S / 144Q / 197K / 200R, 76S / 195Q / 197K / 204T / 207V / 233T, 76S / 197K / 207V / 233Q, 76S / 233T, 81T / 139N / 144Q / 195Q / 200R / 204T / 207V / 233Q, 81T / 144Q / 233Q, 81T / 197K / 200R / 207V / 233Q / 338A, and at least one mutation or set of mutations selected from 81T / 233Q / 338V, 81T / 338V, 107V, 107V / 259T, 139N / 144Q / 233Q, 144Q / 233T, 144Q / 233T / 338V, 156S / 407T, 163A / 233T / 338A, 200R / 204T / 207V / 233T, 233Q / 338V, and 259T, where these positions are numbered with reference to SEQ ID NO:20.In some additional embodiments, the polypeptide sequence of the engineered glycosyltransferase is A41E / T72P / W233Q / C338A, A41E / T72P / C338A, A41E / M144Q / W233T, A41E / W233Q, A41E / W233Q / C338V, A41E / W233T, A41E / W233T / C338V, Q61D, Q61D / A87K / Q91L / A107L, Q61D / A87K / Q91L / E259T, Q61D / A107V, Q61D / E259T / K428I, Q61D / I407 T / K428I, Q61E / A87K / Q91L / A107V, Q61E / Q91L / D431M, Q61E / R411T, T72 P, T72P / R76S, T72P / R76S / L163A / Q197K, T72P / R76S / I207V / C338V, T72P / R76T, T72P / R76T / H195Q / W233T, T72P / R76T / Q197K / D204T, T72P / R76T / I207V / W233Q, T72P / H81T, T72P / H81T / H195Q / W233Q, T72P / K139N / H195Q / D204T, T72P / M144Q / C338V, T72P / K200R / D204T / I207V, T72P / I207V, R 76S / M144Q / Q197K / K200R, R76S / H195Q / Q197K / D204T / I207V / W233T, R76 S / Q197K / I207V / W233Q, R76S / W233T, H81T / K139N / M144Q / H195Q / K200R / D204T / I207V / W233Q, H81T / M144Q / W233Q, H81T / Q197K / K200R / I207V / W2 and at least one mutation or set of mutations selected from 33Q / C338A, H81T / W233Q / C338V, H81T / C338V, A107V, A107V / E259T, K139N / M144Q / W233Q, M144Q / W233T, M144Q / W233T / C338V, C156S / I407T, L163A / W233T / C338A, K200R / D204T / I207V / W233T, W233Q / C338V, and E259T, wherein these positions are numbered with reference to SEQ ID NO: 20.

[0007] In some further embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from 71, 80, 81, 81 / 270, 83, 85, 97, 124, 263, 286, 334, 402, 420, and 456, where these positions are numbered with reference to SEQ ID NO: 20. In some additional embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations selected from 71G, 71T, 80D, 80P, 80Q, 81A, 81L, 81M, 81S, 81T, 81V, 81V / 270K, 83D, 85T, 85V, 97V, 124P, 263C, 286L, 334V, 402I, 420R, and 456K, where these positions are numbered with reference to SEQ ID NO: 20. In some additional embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations selected from Q71G, Q71T, T80D, T80P, T80Q, H81A, H81L, H81M, H81S, H81T, H81V, H81V / Q270K, P83D, A85T, A85V, A97V, A124P, T263C, V286L, I334V, E402I, E420R and S456K, wherein these positions are numbered with reference to SEQ ID NO:20.

[0008] In some additional embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from 41 / 72 / 233 / 338, 41 / 72 / 338, 61, 61 / 91 / 431, 61 / 259 / 428, 61 / 407 / 428, where these positions are numbered with reference to SEQ ID NO:20. In some additional embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations selected from 41E / 72P / 233Q / 338A, 41E / 72P / 338A, 61D, 61D / 259T / 428I, 61D / 407T / 428I, 61E / 91L / 431M, 81T / 139N / 144Q / 195Q / 200R / 204T / 207V / 233Q, and 81T / 197K / 200R / 207V / 233Q / 338A, wherein these positions are numbered with reference to SEQ ID NO: 20. In some additional embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations selected from A41E / T72P / W233Q / C338A, A41E / T72P / C338A, Q61D, Q61D / E259T / K428I, Q61D / I407T / K428I, Q61E / Q91L / D431M, H81T / K139N / M144Q / H195Q / K200R / D204T / I207V / W233Q, and H81T / Q197K / K200R / I207V / W233Q / C338A, wherein these positions are numbered with reference to SEQ ID NO: 20.

[0009] In still some further embodiments, the polypeptide sequences of the engineered glycosyltransferases are 73 / 81 / 144 / 207 / 259, 73 / 81 / 144 / 207 / 285 / 451, 73 / 81 / 259 / 285 / 426 / 451, 73 / 81 / 259 / 451, 73 / 111 / 285 / 451, 73 / 144 / 207 / 252 / 426 / 451, 73 / 144 / 207 / 259 / 285 / 426 / 451, 73 / 144 / 207 / 259 / 285 / 451, 73 / 144 / 207 / 259 / 285 / 451, 73 / 144 / 207 / 259 / 426 / 451, 73 / 144 / 259 / 285, 73 / 259 / 426 / 451, 73 / 259 / 451, 81 / 111 / 144 / 207 / 285 / 451, 81 / 111 / 259 / 451, 81 / 144 / 207 / 252 / 285 / 426, 81 / 144 / 207 / 259 / 451, 81 / 144 / 252 / 259 / 285 / 451, 81 / 144 / 259, 81 / 144 / 259 / 285, 81 / 144 / 259 / 451, 81 / 207 / 252 / 259 / 451, 81 / 207 / 285 / 426 / 451, 81 / 285, 81 / 285 / 451, 111 / 1 44 / 207 / 252 / 285 / 426 / 451, 111 / 144 / 252 / 259 / 285 / 451, 111 / 144 / 259 / 285 / 426 / 451, 111 / 207 / 285, 144 / 207 / 252 / 259, 144 / 207 / 259, 144 / 207 / 259 / 285 / 451, 144 / 207 / 259 / 426 / 451, 144 / 207 / 285 / 426, 144 / 207 / 451, 144 / 252 / 259 / 285, 144 / 252 / 259 / 285 / 451, 144 / 252 / 259 / 426, 144 / 252 / 2 and 285 / 451, wherein the positions are numbered with reference to SEQ ID NO:36.

[0010] In some additional embodiments, the polypeptide sequence of the engineered glycosyltransferase is 73S / 81T / 144Q / 207V / 259T, 73S / 81T / 144Q / 207V / 285S / 451Q, 73S / 81T / 259T / 285S / 426I / 451Q, 73S / 81T / 259T / 451Q, 73S / 111T / 285S / 451Q, 73S / 144Q / 207V / 252P / 426I / 451Q, 73S / 144Q / 207V / 259T / 285S / 426I / 451Q, 73S / 144Q / 207V / 259T / 285S / 426I / 451Q, 73S / 144Q / 207V / 259T / 285S / 45 1Q, 73S / 144Q / 207V / 259T / 426I / 451Q, 73S / 144Q / 259T / 285S, 73S / 259T / 42 6I / 451Q, 73S / 259T / 451Q, 81T / 111T / 144Q / 207V / 285S / 451Q, 81T / 111T / 25 9T / 451Q, 81T / 144Q / 207V / 252P / 285S / 426I, 81T / 144Q / 207V / 259T / 451Q, 8 1T / 144Q / 252P / 259T / 285S / 451Q, 81T / 144Q / 259T, 81T / 144Q / 259T / 285S, 81 T / 144Q / 259T / 451Q, 81T / 207V / 252P / 259T / 451Q, 81T / 207V / 285S / 426I / 45 1Q, 81T / 285S, 81T / 285S / 451Q, 111T / 144Q / 207V / 252P / 285S / 426I / 451Q, 1 11T / 144Q / 252P / 259T / 285S / 451Q, 111T / 144Q / 259T / 285S / 426I / 451Q, 111 T / 207V / 285S, 144Q / 207V / 252P / 259T, 144Q / 207V / 259T, 144Q / 207V / 259T / 2 85S / 451Q, 144Q / 207V / 259T / 426I / 451Q, 144Q / 207V / 285S / 426I, 144Q / 207 V / 451Q, 144Q / 252P / 259T / 285S, 144Q / 252P / 259T / 285S / 451Q, 144Q / 252P / 259T / 426I, 144Q / 252P / 259T / 426I / 451Q, 144Q / 259T / 285S, 144Q / 285S, 14 4Q / 285S / 451Q, 144Q / 451Q, 207V, 207V / 252P / 259T / 451Q, 207V / 252P / 451Q,and at least one mutation or set of mutations selected from 207V / 259T, 207V / 259T / 426I / 451Q, 207V / 285S / 426I / 451Q, 207V / 451Q, 252P / 259T, 259T, 259T / 285S / 451Q, 285S, and 285S / 451Q, wherein these positions are numbered with reference to SEQ ID NO: 36. In some additional embodiments, the engineered glycosyltransferase polypeptide sequence is E73S / H81T / M144Q / I207V / E259T, E73S / H81T / M144Q / I207V / E285S / V451Q, E73S / H81T / E259T / E285S / A426I / V451Q, E73S / H81T / E259T / V451Q, E73S / S111T / E285S / V451Q, E73S / M144Q / I207V / S252P / A426I / V451Q, E73S / M144Q / I207V / E259T / E285S / A426I / V451Q, E73S / M144Q / I207V / E259T / E285S / V451Q, E73S / M144Q / I207V / E259T / A426I / V451Q, E73S / M144Q / E259T / E285S, E73S / E259T / A426I / V451Q, E73S / E259T / V451Q, H81T / S111T / M144Q / I207V / E285S / V451Q, H81T / S111T / E259T / V451Q, H81T / M144Q / I207V / S252P / E285S / A426I, H81T / M144Q / I207V / E259T / V451Q, H81T / M144Q / S252P / E259T / E285S / V451Q, H81T / M144Q / E259T, H81T / M144Q / E259T / E285S, H81T / M144Q / E259T / V451Q, H81T / I207V / S252P / E259T / V451Q, H81T / I207V / E285S / A426I / V451Q, H81T / E285S, H81T / E285S / V451Q, S111T / M144Q / I207V / S252P / E285 S / A426I / V451Q, S111T / M144Q / S252P / E259T / E285S / V451Q, S111T / M144Q / E259T / E285S / A426I / V451Q, S111T / I207V / E285S,M144Q / I207V / S252P / E259T, M144Q / I207V / E259T, M144Q / I207V / E259T / E285S / V4 51Q, M144Q / I207V / E259T / A426I / V451Q, M144Q / I207V / E285S / A426I, M144Q / I207V / V451Q, M144Q / S252P / E259T / E285S, M144Q / S252P / E259T / E285S / V451Q, M144Q / S 252P / E259T / A426I, M144Q / S252P / E259T / A426I / V451Q, M144Q / E259T / E285S, M144 and E285S / V451Q, wherein these positions are numbered with reference to SEQ ID NO: 36. In still some further embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from 81 / 111 / 144 / 207 / 285 / 451, 144 / 207 / 252 / 259, 144 / 207 / 259 / 285 / 451, 144 / 252 / 259 / 426, 144 / 252 / 259 / 426 / 451, and 144 / 285 / 451, where these positions are numbered with reference to SEQ ID NO:36. In some additional embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations selected from 81T / 111T / 144Q / 207V / 285S / 451Q, 144Q / 207V / 252P / 259T, 144Q / 207V / 259T / 285S / 451Q, 144Q / 252P / 259T / 426I, 144Q / 252P / 259T / 426I / 451Q, and 144Q / 285S / 451Q, where these positions areIn some additional embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations selected from H81T / S111T / M144Q / I207V / E285S / V451Q, M144Q / I207V / S252P / E259T, M144Q / I207V / E259T / E285S / V451Q, M144Q / S252P / E259T / A426I, M144Q / S252P / E259T / A426I / V451Q, and M144Q / E285S / V451Q, wherein these positions are numbered with reference to SEQ ID NO: 36.

[0011] In still some further embodiments, the polypeptide sequence of the engineered glycosyltransferase is 80 / 81, 80 / 81 / 85, 80 / 81 / 85 / 238, 80 / 81 / 85 / 251 / 259, 80 / 81 / 85 / 252 / 256 / 259, 80 / 81 / 85 / 259, 80 / 81 / 251 / 252 / 259, 80 / 85, 80 / 85 / 238, 80 / 85 / 238 / 251 / 259, 80 / 85 / 251, 80 / 85 / 251 / 252, 80 / 85 / 251 / 252 / 256 / 259, 80 / 85 / 251 / and at least one mutation or set of mutations at one or more positions selected from 252 / 259, 80 / 85 / 251 / 259, 80 / 85 / 259, 80 / 259, 81 / 85, 81 / 85 / 251 / 252, 81 / 85 / 259, 85, 85 / 238, 85 / 251, 85 / 251 / 252 / 256, 85 / 251 / 259, 85 / 256 / 259, 175 / 402, 251 / 252 / 259, 259, 270 / 402, and 420, where these positions are numbered with reference to SEQ ID NO: 174.In some additional embodiments, the polypeptide sequences of the engineered glycosyltransferases are 80D / 81A, 80D / 81A / 85V, 80D / 81A / 85V / 238G, 80D / 81A / 85V / 251M / 259T, 80D / 81A / 85V / 252P / 256G / 259T, 80D / 81A / 85V, 80D / 85V / 23 8G, 80D / 85V / 238G / 251M / 259T, 80D / 85V / 251I / 252P / 256G / 259T, 80D / 85V / 251I / 259T, 8 0D / 85V / 251M, 80D / 85V / 251M / 252P, 80D / 85V / 251M / 252P / 256G / 259T, 80D / 85V / 259T, 80D / 259T, 80P / 81A / 85V / 259T, 80P / 81A / 251I / 252P / 259T, 80P / 85V, 80P / 85V / 251M / 252P / 2 59T, 81A / 85V, 81A / 85V / 251M / 252P, 81A / 85V / 259T, 85V, 85V / 238G, 85V / 251F, 85V / 251F / and at least one mutation or set of mutations selected from 259T, 85V / 251M / 252P / 256G, 85V / 256G / 259T, 175D / 402I, 251I / 252P / 259T, 259T, 270K / 402I, and 420R, where these positions are numbered with reference to SEQ ID NO: 174.In some additional embodiments, the polypeptide sequence of the engineered glycosyltransferase is selected from the group consisting of T80D / T81A, T80D / T81A / A85V, T80D / T81A / A85V / A238G, T80D / T81A / A85V / A251M / E259T, T80D / T81A / A85V / S252P / L256G / E259T, T80D / A85V, T80D / A85V / A238 G, T80D / A85V / A238G / A251M / E259T, T80D / A85V / A251I / S252P / L256G / E259T, T80D / A85V / A251I / E259T, T 80D / A85V / A251M, T80D / A85V / A251M / S252P, T80D / A85V / A251M / S252P / L256G / E259T, T80D / A85V / E259T, T80D / E259T, T80P / T81A / A85V / E259T, T80P / T81A / A251I / S252P / E259T, T80P / A85V, T80P / A85V / A251M / S 252P / E259T, T81A / A85V, T81A / A85V / A251M / S252P, T81A / A85V / E259T, A85V, A85V / A238G, A85V / A251F, A and at least one mutation or set of mutations selected from 85V / A251F / E259T, A85V / A251M / S252P / L256G, A85V / L256G / E259T, E175D / E402I, A251I / S252P / E259T, E259T, Q270K / E402I, and E420R, where these positions are numbered with reference to SEQ ID NO: 174. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from 3, 5, 7, 99, 153, 232 / 317, 252, 273, 299, 326, 393, 404, 409, 422, 443, 451 and 455, where these positions are numbered with reference to SEQ ID NO: 174.In some additional embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations selected from 3S, 5A, 5H, 5L, 5T, 7A, 7Q, 99V, 153C, 232I / 317L, 252A, 273K, 299M, 326A, 326E, 326N, 326S, 393I, 404M, 404V, 409S, 422I, 443A, 451E, 451V, 455M and 455R, wherein these positions are numbered with reference to SEQ ID NO: 174. In some additional embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations selected from N3S, S5A, S5H, S5L, S5T, T7A, T7Q, E99V, A153C, V232I / Y317L, S252A, S273K, V299M, G326A, G326E, G326N, G326S, V393I, G404M, G404V, A409S, M422I, S443A, Q451E, Q451V, S455M and S455R, wherein these positions are numbered with reference to SEQ ID NO: 174. In still some further embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from 80 / 81 / 85, 80 / 85, 80 / 85 / 251 / 259, 85, 85 / 251 / 252 / 256, 175 / 402, and 270 / 402, where these positions are numbered with reference to SEQ ID NO: 174. In some additional embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations selected from 80D / 81A / 85V, 80D / 85V / 251I / 259T, 80P / 85V, 85V, 85V / 251M / 252P / 256G, 175D / 402I, and 270K / 402I, where these positions are numbered with reference to SEQ ID NO: 174.In some additional embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations selected from T80D / T81A / A85V, T80D / A85V / A251I / E259T, T80P / A85V, A85V, A85V / A251M / S252P / L256G, E175D / E402I, and Q270K / E402I, where these positions are numbered with reference to SEQ ID NO: 174.

[0012] In still some further embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from 81 / 85, 81 / 85 / 175 / 259 / 402, 81 / 85 / 251, 81 / 85 / 251 / 259, 81 / 85 / 259, 81 / 85 / 259 / 402, 85, 85 / 175, 85 / 175 / 251, 85 / 175 / 251 / 259 / 402, 85 / 175 / 259, 85 / 175 / 259 / 402, 85 / 175 / 402, 85 / 259, 85 / 259 / 402, and 85 / 402, wherein these positions are numbered with reference to SEQ ID NO:406. In some additional embodiments, the polypeptide sequence of the engineered glycosyltransferase is 81A / 85V, 81A / 85V / 175E / 259T / 402E, 81A / 85V / 251I, 81A / 85V / 251I / 259T, 81A / 85V / 259T, 81A / 85V / 259T / 402E, 85V, 85V / 175E, 85V / 175E / 251I, 85 and at least one mutation or set of mutations selected from V / 175E / 251I / 259T / 402E, 85V / 175E / 259T, 85V / 175E / 259T / 402E, 85V / 175E / 402E, 85V / 259T, 85V / 259T / 402E, and 85V / 402E, wherein these positions are numbered with reference to SEQ ID NO:406.In some additional embodiments, the polypeptide sequence of the engineered glycosyltransferase is selected from the group consisting of T81A / A85V, T81A / A85V / D175E / E259T / I402E, T81A / A85V / A251I, T81A / A85V / A251I / E259T, T81A / A85V / E259T, T81A / A85V / E259T / I402E, A85V, A85V / D175E, A85V / D175E / A251I , A85V / D175E / A251I / E259T / I402E, A85V / D175E / E259T, A85V / D175E / E259T / I402E, A85V / D175E / I402E, A85V / E259T, A85V / E259T / I402E, and A85V / I402E, wherein these positions are numbered with reference to SEQ ID NO:406.

[0013] In still some further embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from 153, 153 / 326, 153 / 326 / 443, 153 / 326 / 443 / 455, 232, 232 / 273 / 299, 232 / 393 / 451, 299 / 451, 326, 404 and 451, where these positions are numbered with reference to SEQ ID NO:408. In some additional embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations selected from 153C, 153C / 326S, 153C / 326S / 443A, 153C / 326S / 443A / 455M, 232I, 232I / 273K / 299M, 232I / 393I / 451E, 299M / 451E, 326E, 326S, 404V and 451E, wherein these positions are numbered with reference to SEQ ID NO: 408. In some additional embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations selected from A153C, A153C / G326S, A153C / G326S / S443A, A153C / G326S / S443A / S455M, V232I, V232I / S273K / V299M, V232I / V393I / Q451E, V299M / Q451E, G326E, G326S, G404V and Q451E, wherein these positions are numbered with reference to SEQ ID NO: 408. In some further embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from 25, 116, 146, 170, 173, 227, 296, 300, 315, 327, 330, 361, 408, 412, 438, 448 and 449, where these positions are numbered relative to SEQ ID NO:408.In some additional embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations selected from 25A, 116D, 116R, 116S, 146G, 170C, 170G, 170P, 170S, 170T, 173S, 227T, 296V, 300S, 315T, 327Y, 330G, 330T, 361C, 408C, 408T, 412A, 412K, 412S, 438Q, 448H, and 449S, wherein these positions are numbered with reference to SEQ ID NO: 408. In some additional embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations selected from L25A, E116D, E116R, E116S, S146G, D170C, D170G, D170P, D170S, D170T, R173S, S227T, R296V, A300S, K315T, F327Y, E330G, E330T, T361C, N408C, N408T, R412A, R412K, R412S, A438Q, E448H and R449S, wherein these positions are numbered with reference to SEQ ID NO: 408. In some additional embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from 153, 232, 232 / 393 / 451, and 451, where these positions are numbered with reference to SEQ ID NO: 408. In some additional embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations selected from 153C, 232I, 232I / 393I / 451E, and 451E, where these positions are numbered with reference to SEQ ID NO: 408. In some additional embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations selected from A153C, V232I, V232I / V393I / Q451E, and Q451E, where these positions are numbered with reference to SEQ ID NO: 408.

[0014] In some embodiments, the polypeptide sequences of the engineered glycosyltransferases are 146 / 170 / 196, 146 / 170 / 196 / 232, 146 / 170 / 196 / 232 / 423, 146 / 170 / 196 / 232 / 451 / 455, 146 / 170 / 196 / 408 / 451, 146 / 170 / 232, 146 / 170 / 232 / 423, 146 / 170 / 232 / 423 / 448 / 451 / 455, 146 / 170 / 259, 146 / 196, 146 / 196 / 2 32, 146 / 196 / 232 / 259 / 448 / 451, 146 / 196 / 455, 146 / 232 / 259 / 455, 146 / 232 / 315, 146 / 232 / 315 / 423 / 451 / 455, 146 / 232 / 326, 146 / 232 / 448, 146 / 232 / 451, and 146 / 413 / 451 / 455, wherein these positions are numbered with reference to SEQ ID NO:440. In some additional embodiments, the polypeptide sequence of the engineered glycosyltransferase is 146G / 170S / 196I, 146G / 170S / 232I, 146G / 170S / 232I / 423K / 448H / 451E / 455M, 146G / 170T / 196I / 232I, 146G / 170T / 196I / 232I / 423K, 146G / 170T / 196I / 232I / 451E / 455R, 146G / 170T / 196I / 408T / 451E, 146G / 170T / 232I / 423K, 146G / 170T / 259E, 146G / 196I, and 146G / 413M / 451E / 455M, wherein these positions are numbered with reference to SEQ ID NO:440.In some additional embodiments, the engineered glycosyltransferase polypeptide sequence is S146G / D170S / W196I, S146G / D170S / V232I, S146G / D170S / V232I / R423K / E448H / Q451E / S455M, S146G / D170T / W196I / V232I ... 146G / D170T / W196I / V232I / R423K, S146G / D170T / W196I / V232I / Q451E / S455R, S146G / D1 70T / W196I / N408T / Q451E, S146G / D170T / V232I / R423K, S146G / D170T / T259E, S146G / W196 I, S146G / W196I / V232I, S146G / W196I / V232I / T259E / E448H / Q451E, S146G / W196I / S455R , S146G / V232I / T259E / S455M, S146G / V232I / K315S, S146G / V232I / K315S / R423K / Q451E / S and S146G / V413M / Q451E / S455M, S146G / V232I / G326E, S146G / V232I / E448H, S146G / V232I / Q451E, and S146G / V413M / Q451E / S455M, wherein these positions are numbered with reference to SEQ ID NO: 440.

[0015] In some additional embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from 9, 12, 107, 131, 156, 161, 169, 199, 204, 209, 233, 262, 289, 337, and 417, where these positions are numbered with reference to SEQ ID NO: 440. In some additional embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations selected from 9L, 12Q, 107C, 131A, 156S, 161E, 169T, 199S, 204M, 209Y, 233K, 262A, 289A, 337N, 337W, and 417V, where these positions are numbered with reference to SEQ ID NO: 440. In some additional embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations selected from V9L, R12Q, A107C, P131A, C156S, L161E, E169T, A199S, D204M, E209Y, Q233K, S262A, K289A, S337N, S337W and P417V, wherein these positions are numbered with reference to SEQ ID NO: 440. In some additional embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from 146 / 170 / 196, 146 / 170 / 196 / 232, 146 / 170 / 196 / 232 / 451 / 455, 146 / 170 / 232, 146 / 170 / 232 / 423 / 448 / 451 / 455, 146 / 196 / 232, 146 / 196 / 232 / 259 / 448 / 451, and 146 / 232 / 448, where these positions are numbered with reference to SEQ ID NO:440.In some additional embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations selected from 146G / 170S / 196I, 146G / 170S / 232I, 146G / 170S / 232I / 423K / 448H / 451E / 455M, 146G / 170T / 196I / 232I, 146G / 170T / 196I / 232I / 451E / 455R, 146G / 196I / 232I, 146G / 196I / 232I / 259E / 448H / 451E, and 146G / 232I / 448H, wherein these positions are numbered with reference to SEQ ID NO:440. In some additional embodiments, the engineered glycosyltransferase polypeptide sequence is S146G / D170S / W196I, S146G / D170S / V232I, S146G / D170S / V232I / R423K / E448H / Q451E / S455M, S146G / D170T / W196I / V232I, S146G / D170T / W and at least one mutation or set of mutations selected from 196I / V232I / Q451E / S455R, S146G / W196I / V232I, S146G / W196I / V232I / T259E / E448H / Q451E, and S146G / V232I / E448H, where these positions are numbered with reference to SEQ ID NO: 440. In still some further embodiments, the polypeptide sequences of the engineered glycosyltransferases are 9 / 12 / 107 / 161 / 199 / 209 / 337, 9 / 12 / 161 / 169 / 199 / 209 / 337, 9 / 12 / 199 / 204 / 209 / 337 / 455, 9 / 12 / 199 / 209 / 337 / 451 / 455, 9 / 107 / 131 / 20 4 / 259 / 417 / 451, 9 / 107 / 156 / 161 / 199 / 204 / 417 / 455, 9 / 107 / 161 / 209 / 259 / 289 / 451 / 455, 9 / 131 / 156 / 209 / 289 / 337, 9 / 131 / 204 / 337 / 451, 9 / 156 / 169 / 204 / 337, 9 / 169 / 204 / 289 / 337 / 451 / 455, 9 / 204, 9 / 204 / 259 / 289, 9 / 337, 12 / 14 / 107 / 204 / 289 / 455, 12 / 107 / 131 / 204 / 289 / 337 / 417 / 451 / 455, 12 / 107 / 156 / 209 / 289 / 455, 107 / 161 / 169 / 199 / 204 / 259 / 451, 107 / 199 / 204 / 289, 107 / 199 / 209 / 259 / 451 / 455, 107 / 204, 156 / 169 / 199 / 204 / 209 / 259 / 289, 161 / 204 / 417, 204 / 451 / 455, 289, and 451 / 455, which positions are numbered with reference to SEQ ID NO:520.In some additional embodiments, the polypeptide sequences of the engineered glycosyltransferases are 9L / 12Q / 107C / 161E / 199S / 209Y / 337N, 9L / 12Q / 161E / 169T / 199S / 209Y / 337W, 9L / 12Q / 199S / 204M / 209Y / 337N / 455R, 9L / 12Q / 199S / 209Y / 337W / 451E / 455R, 9L / 107C / 131A / 204M ...99S / 204M / 209Y / 337N, 9L / 12Q / 199S / 204M / 209Y / 337N, 9L / 12Q / 199S / 204M / 209Y / 337N, 9L / 12Q / 199S / 204M / 209Y / 337N, 9L / 12Q / 199S / 204M / 209Y / 337N, 9L / 12Q / 199S / 204M / 209Y / 337W, 9L / 12Q / 199S / 204M / 209Y / 337N, 9L / 12 59E / 417V / 451E, 9L / 107C / 156S / 161E / 199S / 204M / 417V / 455R, 9L / 107C / 161E / 209Y / 259E / 289A / 451E / 455R, 9L / 13 1A / 156S / 209Y / 289A / 337N, 9L / 131A / 204M / 337N / 451E, 9L / 156S / 169T / 204M / 337N, 9L / 169T / 204M / 289A / 337W / 451 E / 455R, 9L / 204M, 9L / 204M / 259E / 289A, 9L / 337W, 12Q / 14I / 107C / 204M / 289A / 455R, 12Q / 107C / 131A / 204M / 289A / 33 7W / 417V / 451E / 455R, 12Q / 107C / 156S / 209Y / 289A / 455R, 107C / 161E / 169T / 199S / 204M / 259E / 451E, 107C / 199S / 204 M / 289A, 107C / 199S / 209Y / 259E / 451E / 455R, 107C / 204M, 156S / 169T / 199S / 204M / 209Y / 259E / 289A, 161E / 204M / 417V, 204M / 451E / 455R, 289A, and 451E / 455R, wherein these positions are numbered with reference to SEQ ID NO: 520.In some additional embodiments, the polypeptide sequence of the engineered glycosyltransferase is V9L / R12Q / A107C / L161E / A199S / E209Y / S337N, V9L / R12Q / L161E / E169T / A199S / E209Y / S337W, V9L / R12Q / A199S / D204M / E209Y / S337N / S455R, V9L / R12Q / A199S / E209Y / S337W / Q451E / S455R, V9L / A107C / P131A / D204M / T25 9E / P417V / Q451E, V9L / A107C / C156S / L161E / A199S / D204M / P417V / S455R, V9L / A107C / L161E / E209Y / T259E / K289A / Q451E / S455R, V9L / P 131A / C156S / E209Y / K289A / S337N, V9L / P131A / D204M / S337N / Q451E, V9L / C156S / E169T / D204M / S337N, V9L / E169T / D204M / K289A / S337W / Q451E / S455R, V9L / D204M, V9L / D204M / T259E / K289A, V9L / S337W, R12Q / V14I / A107C / D204M / K289A / S455R, R12Q / A107C / P131A / D204M / K 289A / S337W / P417V / Q451E / S455R, R12Q / A107C / C156S / E209Y / K289A / S455R, A107C / L161E / E169T / A199S / D204M / T259E / Q451E, A107C / A and at least one mutation or set of mutations selected from 199S / D204M / K289A, A107C / A199S / E209Y / T259E / Q451E / S455R, A107C / D204M, C156S / E169T / A199S / D204M / E209Y / T259E / K289A, L161E / D204M / P417V, D204M / Q451E / S455R, K289A, and Q451E / S455R, wherein these positions are numbered with reference to SEQ ID NO: 520.In some further embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from 16, 53, 54, 78, 80, 95, 111, 221, 257, 336, 349, 391, 410, 413, 426, and 430, where these positions are numbered with reference to SEQ ID NO: 520. In some additional embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations selected from 16M, 53Q, 54P, 78V, 80A, 95W, 111C, 111G, 111S, 221A, 257A, 336R, 349V, 391R, 410V, 413L, 426S, and 430Q, where these positions are numbered with reference to SEQ ID NO: 520. In some additional embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations selected from L16M, K53Q, T54P, L78V, T80A, H95W, T111C, T111G, T111S, F221A, L257A, K336R, I349V, L391R, I410V, V413L, A426S and K430Q, wherein these positions are numbered with reference to SEQ ID NO: 520. In some additional embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from 9 / 12 / 199 / 204 / 209 / 337 / 455, 9 / 131 / 156 / 209 / 289 / 337, 9 / 204, 12 / 14 / 107 / 204 / 289 / 455, 107 / 161 / 169 / 199 / 204 / 259 / 451, 107 / 199 / 204 / 289, and 204 / 451 / 455, where these positions are numbered with reference to SEQ ID NO:520.In some additional embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations selected from 9L / 12Q / 199S / 204M / 209Y / 337N / 455R, 9L / 131A / 156S / 209Y / 289A / 337N, 9L / 204M, 12Q / 14I / 107C / 204M / 289A / 455R, 107C / 161E / 169T / 199S / 204M / 259E / 451E, 107C / 199S / 204M / 289A, and 204M / 451E / 455R, wherein these positions are numbered with reference to SEQ ID NO: 520. In some additional embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations selected from V9L / R12Q / A199S / D204M / E209Y / S337N / S455R, V9L / P131A / C156S / E209Y / K289A / S337N, V9L / D204M, R12Q / V14I / A107C / D204M / K289A / S455R, A107C / L161E / E169T / A199S / D204M / T259E / Q451E, A107C / A199S / D204M / K289A, and D204M / Q451E / S455R, wherein these positions are numbered with reference to SEQ ID NO: 520. In still some further embodiments, the polypeptide sequence of the engineered glycosyltransferase is 16, 16 / 59 / 80 / 413, 16 / 80, 16 / 80 / 111, 16 / 80 / 111 / 257, 16 / 80 / 221 / 257 / 336 / 410, 16 / 80 / 221 / 336 / 410, 16 / 80 / 257, 16 / 111 / 221, 16 / 111 / 221 / 257 / 391, 16 / 221, 16 / 221 / 257, 16 / and at least one mutation or set of mutations at one or more positions selected from 221 / 257 / 336 / 391, 16 / 221 / 410, 16 / 257, 16 / 257 / 336 / 413 / 420, 80 / 111 / 221 / 257 / 410, 111 / 221 / 257 / 336 / 391, 111 / 221 / 257 / 391, 221, and 221 / 257, where these positions are numbered with reference to SEQ ID NO: 626. In some additional embodiments, the polypeptide sequence of the engineered glycosyltransferase is 16M, 16M / 59Q / 80A / 413L, 16M / 80A, 16M / 80A / 111C, 16M / 80A / 111S / 257A, 16M / 80A / 221A / 257A / 336R / 410V, 16M / 80A / 221A / 336R / 410V, 16M / 80A / 257A, 16M / 111C / 221A / 257A / 391R, 16M / 111S / 221A, 16M / 221A, 16M / 221A / and 221A / 257A, wherein the positions are numbered with reference to SEQ ID NO: 626.In some additional embodiments, the polypeptide sequence of the engineered glycosyltransferase is selected from the group consisting of L16M, L16M / H59Q / T80A / V413L, L16M / T80A, L16M / T80A / T111C, L16M / T80A / T111S / L257A, L16M / T80A / F221A / L257A / K336R / I410V, L16M / T80A / L257A, L16M / T111C / F221A / L257A / L391R, L16M / T111S / F221A, L16M ... and F221A / L257A, wherein the positions are numbered with reference to SEQ ID NO: 626. In some further embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from 5, 7, 14, 65, 91, 99, 102, 118, 138, 194, 254, 286, 416, 418, and 420, where these positions are numbered with reference to SEQ ID NO: 626. In some additional embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations selected from 5L, 5M, 5N, 5Q, 7L, 14L, 65V, 91V, 99L, 99S, 102R, 118S, 118V, 138I, 194P, 254G, 254T, 254V, 286L, 416E, 418D, and 420A, where these positions are numbered with reference to SEQ ID NO: 626.In some additional embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations selected from S5L, S5M, S5N, S5Q, T7L, V14L, I65V, Q91V, E99L, E99S, K102R, A118S, A118V, L138I, S194P, S254G, S254T, S254V, V286L, D416E, E418D and E420A, wherein these positions are numbered with reference to SEQ ID NO: 626. In still some further embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from 16 / 80 / 221 / 257 / 336 / 410, 16 / 111 / 221, 16 / 221 / 257, 16 / 221 / 410, 16 / 257, 80 / 111 / 221 / 257 / 410, and 221, where these positions are numbered with reference to SEQ ID NO:626. In some additional embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations selected from 16M / 80A / 221A / 257A / 336R / 410V, 16M / 111S / 221A, 16M / 221A / 257A, 16M / 221A / 410V, 16M / 257A, 80A / 111S / 221A / 257A / 410V, and 221A, wherein these positions are numbered with reference to SEQ ID NO: 626. In some additional embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations selected from L16M / T80A / F221A / L257A / K336R / I410V, L16M / T111S / F221A, L16M / F221A / L257A, L16M / F221A / I410V, L16M / L257A, T80A / T111S / F221A / L257A / I410V, and F221A, wherein these positions are numbered with reference to SEQ ID NO: 626.

[0016] In still some further embodiments, the polypeptide sequence of the engineered glycosyltransferase is selected from the group consisting of 5, 5 / 14 / 99, 5 / 14 / 416, 5 / 91, 5 / 91 / 102 / 118, 5 / 91 / 102 / 254 / 418, 5 / 91 / 106 / 254 / 286, 5 / 91 / 118 / 194 / 254 / 286, 5 / 91 / 118 / 194 / 254 / 41 8, 5 / 91 / 118 / 194 / 418, 5 / 91 / 118 / 254 / 286 / 418, 5 / 91 / 118 / 286, 5 / 91 / 194 / 254, 5 / 91 / 194 / 418, 5 / 91 / 254, 5 / 91 / 254 / 286, 5 / 102 / 418, 5 / 118 / 194 / 286 / 418, 5 / 118 / 254, 5 / 118 / 286, 5 / 194, 5 / 25 4 / 286, 5 / 418, 7 / 14, 7 / 14 / 65 / 99, 7 / 14 / 99 / 416, 14, 14 / 65 / 99 / 416, 14 / 99, 14 / 99 / 254, 14 / 99 / 254 / 416, 14 / 99 / 254 / 416 / 455, 14 / 99 / 416, 14 / 167, 14 / 254, 14 / 455, 91, 91 / 102 / 194, 91 / 118, 91 / 118 / 194, 91 / 118 / 194 / 286, 91 / 118 / 194 / 418, 91 / 118 / 286, 91 / 194 / 254 / 286, 91 / 286, and 118 / 286 / 418, which positions are numbered with reference to SEQ ID NO: 678.

[0017] In some additional embodiments, the polypeptide sequences of the engineered glycosyltransferases are 5L / 14L / 99L, 5L / 14L / 416E, 5N, 5N / 91V, 5N / 91V / 102R / 118V, 5N / 91V / 102R / 254T / 418D, 5N / 91V / 106I / 254T / 286L, 5N / 91V / 118S / 194P / 254T / 418D, 5N / 91V / 118S / 254T / 286L / 418D, 5N / 91 V / 118S / 286L, 5N / 91V / 118V / 194P / 254T / 286L, 5N / 91V / 118V / 194P / 418D, 5N / 91V / 194P / 254T, 5N / 91V / 194P / 418D, 5N / 91V / 254T, 5N / 91V / 254T / 286L, 5N / 102R / 418D, 5N / 118S / 194P / 286L / 418D, 5N / 118S / 286L, 5N / 118V / 254T, 5N / 194P, 5N / 254T / 286L, 5N / 418D, 7L / 14L, 7L / 14L / 65V / 99L, 7L / 14L / 99S / 416E, 14L, 14L / 65V / 99L / 416E, 14L / 99L, 14L / 99L / 254G , 14L / 99L / 254G / 416E, 14L / 99L / 254G / 416E / 455R, 14L / 99L / 416E, 14L / 99S / 416E, 14L / 167E, 14L / 254G, 14L / 455R, 91V , 91V / 102R / 194P, 91V / 118V, 91V / 118V / 194P, 91V / 118V / 194P / 286L, 91V / 118V / 194P / 418D, 91V / 118V / 286L, 91V / 194P / 254T / 286L, 91V / 286L, and 118V / 286L / 418D, wherein these positions are numbered with reference to SEQ ID NO: 678.In some additional embodiments, the polypeptide sequences of the engineered glycosyltransferases are S5L / V14L / E99L, S5L / V14L / D416E, S5N, S5N / Q91V, S5N / Q91V / K102R / A118V, S5N / Q91V / K102R / S254T / E418D, S5N / Q91V / S106I / S254T / V286L, S5N / Q91V / A118S / S194P / S254T / E418D, S5N / Q91V / A118S / S254T / V286L / E418D, S5N / Q91V / A118S / V286L, S5N / Q91V / A118V / S194P / S254T / V286L, S5N / Q91V / A118 V / S194P / E418D, S5N / Q91V / S194P / S254T, S5N / Q91V / S194P / E418D, S5N / Q91V / S254T, S5N / Q91V / S254T / V286L, S5N / K102R / E418D, S5N / A118S / S194P / V286L / E418D, S5N / A118S / V286L, S5N / A118V / S254T, S5N / S194P , S5N / S254T / V286L, S5N / E418D, T7L / V14L, T7L / V14L / I65V / E99L, T7L / V14L / E99S / D416E, V14L, V14L / I65V / E99L / D416E, V14L / E99L, V14L / E 99L / S254G, V14L / E99L / S254G / D416E, V14L / E99L / S254G / D416E / S455R , V14L / E99L / D416E, V14L / E99S / D416E, V14L / D167E, V14L / S254G, V14L / S455R, Q91V, Q91V / K102R / S194P, Q91V / A118V, Q91V / A118V / S194P, Q91V / A118V / S194P / V286L, Q91V / A118V / S194P / E418D, Q91V / A118V / V286L, Q91V / S194P / S254T / V286L, Q91V / V286L, and A118V / V286L / E418D, wherein these positions are numbered with reference to SEQ ID NO: 678.In some additional embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from 5 / 91 / 106 / 254 / 286, 5 / 91 / 118 / 286, 5 / 91 / 254 / 286, 14, 14 / 65 / 99 / 416, 14 / 99, and 14 / 99 / 254, where these positions are numbered relative to SEQ ID NO:678. In some additional embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations selected from 5N / 91V / 106I / 254T / 286L, 5N / 91V / 118S / 286L, 5N / 91V / 254T / 286L, 14L, 14L / 65V / 99L / 416E, 14L / 99L, and 14L / 99L / 254G, wherein these positions are numbered with reference to SEQ ID NO: 678. In some additional embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations selected from S5N / Q91V / S106I / S254T / V286L, S5N / Q91V / A118S / V286L, S5N / Q91V / S254T / V286L, V14L, V14L / I65V / E99L / D416E, V14L / E99L, and V14L / E99L / S254G, wherein these positions are numbered with reference to SEQ ID NO: 678.

[0018] The present invention also provides engineered glycosyltransferases comprising a polypeptide sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO:12. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from 16, 16 / 127 / 169, 16 / 134, 16 / 143 / 423, 16 / 169, 16 / 169 / 398 / 399, 16 / 169 / 423, 16 / 398, 16 / 398 / 399, 16 / 398 / 427, 16 / 423, 16 / 423 / 427, 134, 143, 399 / 423, and 423 / 427, where these positions are numbered with reference to SEQ ID NO:24. In some additional embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations selected from 16T, 16T / 127V / 169E, 16T / 134S, 16T / 143G / 423L, 16T / 169E, 16T / 169E / 398M / 399K, 16T / 169E / 423L, 16T / 398M, 16T / 398M / 399K, 16T / 398M / 427S, 16T / 423L, 16T / 423L / 427S, 134S, 143G, 399K / 423L, and 423L / 427S, wherein these positions are numbered with reference to SEQ ID NO:24. In some additional embodiments, the polypeptide sequence of the engineered glycosyltransferase is L16T, L16T / Q127V / P169E, L16T / A134S, L16T / P143G / R423L, L16T / P169E, L16T / P169E / A398M / Q399K, L16T / P169E / R423L, L16T / A398M, L16 and at least one mutation or set of mutations selected from T / A398M / Q399K, L16T / A398M / R427S, L16T / R423L, L16T / R423L / R427S, A134S, P143G, Q399K / R423L, and R423L / R427S, where these positions are numbered with reference to SEQ ID NO:24.In some additional embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from 3, 8, 11, 41, 44, 56, 60, 122, 135, 137, 138, 139, 158, 164, 176, 221, 232, 233, 235, 248, 249, 281, 284, 285, 301, 322, 372, 392, 400, 421, 426, 427, 433, 440, 443, and 446, wherein these positions are numbered with reference to SEQ ID NO:24. In some additional embodiments, the polypeptide sequence of the engineered glycosyltransferase is 3I, 3V, 8R, 11L, 11P, 41M, 44E, 56A, 60T, 122C, 135V, 137T, 138K, 138R, 139T, 158H, 158V, 164A, 164E, 164N, 164Q, 164S, 176S, 221D, 232A, 233S, 233T, 235L, 235 M, 248M, 249R, 281S, 284V, 285A, 301G, 322R, 372S, 392V, 400C, 421A, 421G, 426S, 427A, 427W, 433G, 433T, 440L, 440M, 443G, 443H, and 446L, wherein these positions are numbered with reference to SEQ ID NO:24. In some additional embodiments, the polypeptide sequence of the engineered glycosyltransferase is selected from the group consisting of H3I, H3V, V8R, Q11L, Q11P, F41M, Y44E, K56A, P60T, L122C, L135V, Q137T, G138K, G138R, I139T, F158H, F158V, H164A, H164E, H164N, H164Q, H164S, R176S, E221D, P232A, P233S, P233T, Q235L, Q and R446L, wherein the positions are numbered with reference to SEQ ID NO:24.In some further embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from 16, 16 / 127 / 169, and 16 / 169, where these positions are numbered with reference to SEQ ID NO: 24. In some additional embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations selected from 16T, 16T / 127V / 169E, and 16T / 169E, where these positions are numbered with reference to SEQ ID NO: 24. In some additional embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations selected from L16T, L16T / Q127V / P169E, and L16T / P169E, where these positions are numbered with reference to SEQ ID NO: 24.

[0019] In some further embodiments, the polypeptide sequences of the engineered glycosyltransferases are 3 / 22 / 198 / 421, 3 / 22 / 421, 3 / 201 / 248 / 322, 3 / 201 / 248 / 322 / 392, 13 / 233 / 331 / 440, 13 / 440 / 443, 22 / 32 / 56 / 60 / 198 / 248 / 322 / 392 / 421, 22 / 56, 22 / 56 / 137 / 198 / 201 / 248 / 322 / 392, 22 / 56 / 137 / 198 / 248 / 392 / 421, 22 / 56 / 137 / 322, 22 / 56 / 137 / 322 / 392 / 423, 22 / 56 / 198 / 202 / 248, 22 / 56 / 198 / 248 / 322 / 392 / 421, 22 / 56 / 198 / 248 / 421 / 423, 22 / 56 / 421 / 423, 22 / 60 / 392 / 421, 22 / 137, 22 / 137 / 198 / 202 / 248, 22 / 198 / 202 / 248 / 392, 22 / 248 / 392, 22 / 392, 22 / 421, 22 / 421 / 423, 22 / 423, 44 / 164 / 233, 44 / 164 / 233 / 329 / 331, 44 / 331, 125, 125 / 233 / 443 / 446, 164 / 221 / 233 / 331 / 440 / 446, 164 / 233 / The nucleic acid sequence of the present invention comprises at least one mutation or set of mutations at one or more positions selected from 331 / 440, 164 / 233 / 446, 164 / 331, 164 / 440, 164 / 443, 198 / 202 / 392, 221 / 329 / 331, 233, 233 / 446, 329, 421 / 423, and 443 / 446, which positions are numbered with reference to SEQ ID NO: 858. In some additional embodiments, the engineered glycosyltransferase polypeptide sequences are 3I / 22G / 198Q / 421G, 3I / 22G / 421G, 3I / 201A / 248M / 322R, 3I / 201A / 248M / 322R / 392V, 13Q / 233S / 331V / 440M, 13Q / 440M / 4 43G, 22G / 32L / 56A / 60T / 198Q / 248M / 322R / 392V / 421G, 22G / 56A, 22G / 56A / 137T / 198Q / 201A / 248M / 322R / 392V, 22G / 56A / 137T / 198Q / 248M / 392V / 421G, 22G / 56A / 137T / 322R,22G / 56A / 137T / 322R / 392V / 423L, 22G / 56A / 198Q / 202Y / 248M, 22G / 56A / 198Q / 248M / 32 2R / 392V / 421G, 22G / 56A / 198Q / 248M / 421G / 423L, 22G / 56A / 421G / 423L, 22G / 60T / 392V / 421G, 22G / 137T, 22G / 137T / 198Q / 202Y / 248M, 22G / 198Q / 202Y / 248M / 392V, 22G / 248M / 3 92V, 22G / 392V, 22G / 421G, 22G / 421G / 423L, 22G / 423L, 44E / 164A / 233S, 44E / 164E / 233S , 44E / 164E / 233S / 329L / 331V, 44E / 331V, 125L, 125L / 233S / 443G / 446L, 164A / 233S / 446 L, 164A / 331V, 164A / 440M, 164A / 443G, 164E / 221D / 233S / 331V / 440M / 446L, 164E / 233S / and at least one mutation or set of mutations selected from 331V / 440M, 198Q / 202Y / 392V, 221D / 329L / 331V, 233S, 233S / 446L, 329L, 421G / 423L, and 443G / 446L, where these positions are numbered with reference to SEQ ID NO: 858. In some additional embodiments, the polypeptide sequence of the engineered glycosyltransferase is selected from the group consisting of H3I / A22G / G198Q / S421G, H3I / A22G / S421G, H3I / G201A / I248M / L322R, H3I / G201A / I248M / L322R / I392V, L13Q / P233S / I331V / I440M, L13Q / I440M / C443G, A22G / I32L / K56A / P60T / G198Q / I248 M / L322R / I392V / S421G, A22G / K56A, A22G / K56A / Q137T / G198Q / G201A / I248M / L322R / I392V, A22G / K56A / Q137T / G198Q / I2 48M / I392V / S421G, A22G / K56A / Q137T / L322R, A22G / K56A / Q137T / L322R / I392V / R423L, A22G / K56A / G198Q / I202Y / I248M,A22G / K56A / G198Q / I248M / L322R / I392V / S421G, A22G / K56A / G198Q / I248M / S421G / R423L, A22 G / K56A / S421G / R423L, A22G / P60T / I392V / S421G, A22G / Q137T, A22G / Q137T / G198Q / I202Y / I24 8M, A22G / G198Q / I202Y / I248M / I392V, A22G / I248M / I392V, A22G / I392V, A22G / S421G, A22G / S 421G / R423L, A22G / R423L, Y44E / H164A / P233S, Y44E / H164E / P233S, Y44E / H164E / P233S / A329L / I331V, Y44E / I331V, F125L, F125L / P233S / C443G / R446L, H164A / P233S / R446L, H164A / I331V , H164A / I440M, H164A / C443G, H164E / E221D / P233S / I331V / I440M / R446L, H164E / P233S / I331V / I440M, G198Q / I202Y / I392V, E221D / A329L / I331V, P233S, P233S / R446L, A329L, S421G / R423L, and C443G / R446L, wherein these positions are numbered with reference to SEQ ID NO: 858. In some additional embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from 3 / 22 / 198 / 421, 13 / 440 / 443, 22 / 56 / 198 / 202 / 248, 22 / 137, 22 / 198 / 202 / 248 / 392, 164 / 221 / 233 / 331 / 440 / 446, 164 / 233 / 331 / 440, and 233 / 446, where these positions are numbered relative to SEQ ID NO:858. In some additional embodiments, the engineered glycosyltransferase polypeptide sequence is 3I / 22G / 198Q / 421G, 13Q / 440M / 443G, 22G / 56A / 198Q / 202Y / 248M, 22G / 137T, 22G / 198Q / 202Y / 248M / 392V,and at least one mutation or set of mutations selected from 164E / 221D / 233S / 331V / 440M / 446L, 164E / 233S / 331V / 440M, and 233S / 446L, where these positions are numbered with reference to SEQ ID NO: 858. In some additional embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations selected from H3I / A22G / G198Q / S421G, L13Q / I440M / C443G, A22G / K56A / G198Q / I202Y / I248M, A22G / Q137T, A22G / G198Q / I202Y / I248M / I392V, H164E / E221D / P233S / I331V / I440M / R446L, H164E / P233S / I331V / I440M, and P233S / R446L, wherein these positions are numbered with reference to SEQ ID NO: 858.

[0020] In some further embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from 83 / 202 / 233, 164, 164 / 202, 164 / 202 / 233 / 331, 164 / 202 / 248 / 272, 164 / 202 / 331, 164 / 202 / 331 / 423, 164 / 423, 202 / 233, 202 / 233 / 248, 202 / 233 / 248 / 423, 202 / 248, 202 / 331, 202 / 421 / 423, 202 / 423, 202 / 446, 233, 248, and 423, wherein these positions are numbered with reference to SEQ ID NO:994. In some additional embodiments, the polypeptide sequence of the engineered glycosyltransferase is 83Y / 202I / 233S, 164E, 164E / 202I, 164E / 202I / 233S / 331V, 164E / 202I / 248I / 272C, 164E / 202I / 331V, 164E / 202I / 331V / 423L, 164E / 423L, 202I / 233S, 2 and at least one mutation or set of mutations selected from 02I / 233S / 248I, 202I / 233S / 248I / 423L, 202I / 248I, 202I / 331V, 202I / 421G / 423L, 202I / 423L, 202I / 446L, 233S, 248I, and 423L, wherein these positions are numbered with reference to SEQ ID NO:994.In some additional embodiments, the polypeptide sequence of the engineered glycosyltransferase is selected from the group consisting of H83Y / Y202I / P233S, H164E, H164E / Y202I, H164E / Y202I / P233S / I331V, H164E / Y202I / M248I / R272C, H164E / Y202I / I331V, H164E / Y202I / I331V / R423L, H164E / R423L, Y202I / P233S , Y202I / P233S / M248I, Y202I / P233S / M248I / R423L, Y202I / M248I, Y202I / I331V, Y202I / S421G / R423L, Y202I / R423L, Y202I / R446L, P233S, M248I, and R423L, wherein these positions are numbered with reference to SEQ ID NO:994. In some embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from 7, 9, 10, 54, 73, 84, 106, 115, 116, 132, 165, 286, 309, 389, 406, 422, and 438, where these positions are numbered with reference to SEQ ID NO:994. In some additional embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations selected from 7T, 9L, 10P, 54L, 54M, 73R, 73S, 84L, 106S, 115A, 116I, 132R, 165P, 286G, 309E, 389E, 406H, 406M, 406Q, 422A, 422T, 422V, 438A, and 438T, wherein these positions are numbered with reference to SEQ ID NO:994.In some additional embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations selected from G7T, S9L, D10P, S54L, S54M, A73R, A73S, Y84L, A106S, N115A, L116I, K132R, E165P, N286G, K309E, D389E, S406H, S406M, S406Q, K422A, K422T, K422V, E438A, and E438T, wherein these positions are numbered with reference to SEQ ID NO:994. In some further embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from 83 / 202 / 233, 164, 164 / 202, 164 / 423, 202 / 233 / 248, and 233, where these positions are numbered with reference to SEQ ID NO: 994. In some additional embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations selected from 83Y / 202I / 233S, 164E, 164E / 202I, 164E / 423L, 202I / 233S / 248I, and 233S, where these positions are numbered with reference to SEQ ID NO: 994. In some additional embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations selected from H83Y / Y202I / P233S, H164E, H164E / Y202I, H164E / R423L, Y202I / P233S / M248I, and P233S, wherein these positions are numbered with reference to SEQ ID NO:994.

[0021] In still some further embodiments, the polypeptide sequences of the engineered glycosyltransferases are 7 / 9 / 73 / 165 / 286, 7 / 9 / 165 / 286, 7 / 9 / 422, 7 / 116 / 165 / 286, 7 / 165, 9 / 73 / 116 / 165 / 286 / 422, 9 / 286 / 389, 54, 54 / 84, 54 / 406, 73, 73 / 116 / 165 / 286 / 389, 73 / 116 / 286, 73 / 116 / 286 / 422, 73 / 165 / 28 and at least one mutation or set of mutations at one or more positions selected from: 6, 73 / 286 / 389, 73 / 286 / 422, 73 / 422, 84, 115, 116, 116 / 165, 116 / 165 / 286 / 422, 116 / 389, 165, 165 / 286, 165 / 389, 165 / 389 / 422, 286, 286 / 422, 389 / 422, and 422, wherein these positions are numbered with reference to SEQ ID NO: 1080. In some additional embodiments, the polypeptide sequences of the engineered glycosyltransferases are 7T / 9L / 73R / 165P / 286G, 7T / 9L / 165P / 286G, 7T / 9L / 422A, 7T / 116I / 165P / 286G, 7T / 165P, 9L / 73R / 116I / 165P / 286G / 422A, 9L / 286G / 389E, 54L / 84L, 54M, 54M / 406M, 73R, 73R / 116I / 165P / 286G / 389E, 73R / 116I / 286G, 73R / 116I / 286G / 422A, 73R / 165P / 286G, 73R / 286G / 389E, 73R / 286G / 422A, 73R / 286G / 422T, 73R / 422T, 84L, 115A, 116I, 116I / 165P, 116I / 165P / 286G / 422A, 116I / 389E, 165P, 165P / 286G, 165P / 389E, 165P / 389E / 422T, 286G, 286G / 422A, 389E / 422A, and 422T, wherein these positions are numbered with reference to SEQ ID NO: 1080.In some additional embodiments, the polypeptide sequence of the engineered glycosyltransferase is G7T / S9L / A73R / E165P / N286G, G7T / S9L / E165P / N286G, G7T / S9L / K422A, G7T / L116I / E165P / N286G, G7T / E165P, S9L / A73R / L 116I / E165P / N286G / K422A, S9L / N286G / D389E, S54L / Y84L, S54M, S54M / S406M, A73R, A7 3R / L116I / E165P / N286G / D389E, A73R / L116I / N286G, A73R / L116I / N286G / K422A, A73R / E165P / N286G, A73R / N286G / D389E, A73R / N286G / K422A, A73R / N286G / K422T, A73R / K422 T, Y84L, N115A, L116I, L116I / E165P, L116I / E165P / N286G / K422A, L116I / D389E, E165P , E165P / N286G, E165P / D389E, E165P / D389E / K422T, N286G, N286G / K422A, D389E / K422A, and K422T, where these positions are numbered with reference to SEQ ID NO: 1080. In some further embodiments, the engineered glycosyltransferase polypeptide sequence comprises at least one mutation or set of mutations at one or more positions selected from 185 / 190, 219, 220, 255, 257, 302, 385, 395, 395 / 437, 399, 401, 409, 412, 416, 434, 441, 445, 447, and 449, where these positions are numbered with reference to SEQ ID NO: 1080.In some additional embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations selected from 185L / 190P, 219L, 220A, 255R, 257H, 302A, 302H, 302L, 302R, 302T, 385M, 385P, 385S, 395A, 395D, 395H, 395N, 395S / 437L, 399R, 401V, 409L, 412K, 416N, 434I, 441A, 441K, 441L, 441R, 441S, 445K, 445R, 447A, 447R, 447S, 447V, 449A, 449H, and 449T, wherein these positions are numbered with reference to SEQ ID NO: 1080. In some additional embodiments, the polypeptide sequence of the engineered glycosyltransferase is selected from the group consisting of F185L / T190P, C219L, T220A, P255R, N257H, N302A, N302H, N302L, N302R, N302T, V385M, V385P, V385S, G395A, G395D, G395H, G395N, G395S / E437L, Q399R, L401V , T409L, I412K, K416N, A434I, Q441A, Q441K, Q441L, Q441R, Q441S, N445K, N445R, N447A, N447R, N447S, N447V, Y449A, Y449H, and Y449T, wherein these positions are numbered with reference to SEQ ID NO: 1080. In some further embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from 9 / 73 / 116 / 165 / 286 / 422, 54, 54 / 84, 54 / 406, 73 / 116 / 286 / 422, 116 / 165 / 286 / 422, and 286 / 422, where these positions are numbered with reference to SEQ ID NO: 1080.In some additional embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations selected from 9L / 73R / 116I / 165P / 286G / 422A, 54L / 84L, 54M, 54M / 406M, 73R / 116I / 286G / 422A, 116I / 165P / 286G / 422A, and 286G / 422A, wherein these positions are numbered with reference to SEQ ID NO: 1080. In some additional embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations selected from S9L / A73R / L116I / E165P / N286G / K422A, S54L / Y84L, S54M, S54M / S406M, A73R / L116I / N286G / K422A, L116I / E165P / N286G / K422A, and N286G / K422A, wherein these positions are numbered with reference to SEQ ID NO: 1080.

[0022] In still some further embodiments, the polypeptide sequence of the engineered glycosyltransferase is selected from the group consisting of 54, 54 / 185 / 190, 54 / 185 / 190 / 219 / 257 / 302 / 385 / 389 / 395 / 445 / 447 / 449, 54 / 185 / 190 / 219 / 385, 54 / 185 / 190 / 219 / 385 / 389 / 395 / 399 / 441 / 445 / 447 / 449, 54 / 185 / 190 / 219 / 385 / 395 / 399 / 441 / 445 / 447 / 449, 54 / 185 / 190 / 219 / 385 / 445 / 447 ... 5 / 190 / 219 / 389 / 395 / 399 / 441 / 445 / 447 / 449, 54 / 185 / 190 / 302, 54 / 185 / 190 / 302 / 395 / 399, 54 / 185 / 190 / 385 / 447 / 449, 54 / 185 / 190 / 389 / 395, 54 / 185 / 190 / 389 / 441 / 445 / 447 / 449, 54 / 185 / 190 / 389 / 445, 54 / 185 / 190 / 395 / 399 / 441 / 445 / 447 / 449, 54 / 185 / 219 / 389, 54 / 185 / 257 / 389 / 441 / 445 / 447 / 449, 5 4 / 185 / 302 / 385 / 399 / 445 / 447, 54 / 185 / 385 / 389 / 395 / 441 / 445 / 449, 54 / 185 / 385 / 395 / 399 / 445 / 447 / 449, 54 / 185 / 389 / 395 / 445 / 447, 54 / 190 / 219 / 257 / 302, 54 / 190 / 219 / 257 / 395 / 445 / 447 / 449, 54 / 190 / 257, 54 / 190 / 257 / 302 / 399, 54 / 190 / 257 / 309 / 385 / 389 / 395 / 399 / 445, 54 / 190 / 257 / 385 / 389, 54 / 19 0 / 257 / 395 / 445 / 449, 54 / 190 / 302 / 389, 54 / 190 / 302 / 389 / 395 / 399 / 445 / 447, 54 / 190 / 385 / 389 / 395 / 441 / 445, 54 / 190 / 385 / 395, 54 / 190 / 385 / 445 / 447 / 449, 54 / 190 / 395, 54 / 190 / 395 / 445 / 447, 54 / 219 / 302 / 395 / 441 / 445 / 447, 54 / 219 / 385 / 389 / 395 / 441 / 445 / 447, 54 / 257, 54 / 257 / 385 / 449, 54 / 257 / 389,54 / 257 / 399、54 / 257 / 441 / 447、54 / 257 / 441 / 449、54 / 302 / 385 / 399 / 441 / 445 / 447、54 / 302 / 385 / 399 / 441 / 445 / 449、54 / 385、54 / 385 / 389 / 441 / 445 / 447 / 449、54 / 389 / 395 / 399 / 447 / 449、185 / 190 / 219 / 257 / 389 / 395 / 445 / 447、185 / 190 / 257 / 302 / 395 / 441 / 445 / 447、185 / 190 / 257 / 385 / 389 / 399、185 / 190 / 257 / 385 / 399 / 445 / 447、185 / 190 / 257 / 389 / 395、185 / 190 / 257 / 389 / 395 / 399 / 441 / 447 / 449、185 / 190 / 385 / 389 / 441 / 445 / 447、185 / 190 / 389 / 447 / 449、185 / 190 / 395 / 399、185 / 219 / 257 / 399 / 445 / 447、185 / 257 / 385 / 395 / 399 / 445 / 447、185 / 302 / 395 / 399 / 441 / 445 / 447 / 449、185 / 395 / 399 / 441 / 445 / 447、190 / 219 / 257 / 385 / 389 / 441 / 445 / 447 / 449、190 / 219 / 302 / 385 / 399 / 445、190 / 257 / 302 / 385 / 399、190 / 257 / 385 / 389 / 399、190 / 257 / 385 / 389 / 445 / 447、190 / 257 / 385 / 395、190 / 257 / 385 / 441 / 445 / 447 / 449、190 / 257 / 389 / 395 / 441 / 445 / 447、190 / 257 / 399 / 447 / 449、190 / 302 / 385 / 389 / 395 / 399 / 441 / 445 / 447、190 / 389、219 / 257 / 385 / 389 / 395 / 441 / 447 / 449、219 / 257 / 395、219 / 385 / 389 / 399 / 445 / 449、219 / 395、257 / 385 / 389 / 399、257 / 389 / 395 / 399 / 445 / 447、257 / 389 / 395 / 399 / 445 / 449、257 / 389 / 399、302 / 389 / 395 / 445、385 / 389、385 / 395、389 / 395 / 445 / 447、395 / 399、and 399, wherein these positions are numbered with reference to SEQ ID NO: 1216.

[0023] In some additional embodiments, the polypeptide sequence of the engineered glycosyltransferase is 54M, 54M / 185L / 190P, 54M / 185L / 190P / 219L / 257H / 302R / 385P / 389E / 395H / 445K / 447A / 449H, 54M / 185L / 190P / 219L / 385P / 445R / 447A, 54M / 185L / 190P / 219L / 385S, 54M / 185L / 190P / 219L / 385S / 389E / 395D / 399R / 441R / 445R / 447A / 449H ... 90P / 219L / 385S / 395A / 399R / 441R / 445K / 447A / 449H, 54M / 185L / 190P / 219 L / 389E / 395H / 399R / 441S / 445K / 447A / 449H, 54M / 185L / 190P / 302H, 54M / 18 5L / 190P / 302R / 395H / 399R, 54M / 185L / 190P / 385P / 447A / 449H, 54M / 185L / 1 90P / 389E / 395H, 54M / 185L / 190P / 389E / 441R / 445R / 447A / 449H, 54M / 185L / 190P / 389E / 445K, 54M / 185L / 190P / 395D / 399R / 441R / 445K / 447A / 449H, 54 M / 185L / 219L / 389E, 54M / 185L / 257H / 389E / 441S / 445R / 447A / 449H, 54M / 18 5L / 302H / 385S / 399R / 445R / 447A, 54M / 185L / 385S / 389E / 395D / 441R / 445K / 449H, 54M / 185L / 385S / 395D / 399R / 445R / 447A / 449H, 54M / 185L / 389E / 395D / 445K / 447A, 54M / 190P / 219L / 257H / 302H, 54M / 190P / 219L / 257H / 395H / 445 R / 447A / 449H, 54M / 190P / 257H, 54M / 190P / 257H / 302H / 399R, 54M / 190P / 257 H / 309N / 385S / 389E / 395D / 399R / 445K, 54M / 190P / 257H / 385S / 389E, 54M / 19 0P / 257H / 395D / 445K / 449H, 54M / 190P / 302H / 389E / 395D / 399R / 445K / 447S,54M / 190P / 302R / 389E、54M / 190P / 385P / 395D、54M / 190P / 385P / 445R / 447A / 449H、54M / 190P / 385S / 389E / 395H / 441S / 445R、54M / 190P / 395A、54M / 190P / 395H / 445K / 447A、54M / 219L / 302R / 395H / 441S / 445R / 447A、54M / 219L / 385P / 389E / 395D / 441R / 445K / 447A、54M / 257H、54M / 257H / 385S / 449H、54M / 257H / 389E、54M / 257H / 399R、54M / 257H / 441R / 447A、54M / 257H / 441R / 449H、54M / 302H / 385P / 399R / 441S / 445K / 447S、54M / 302H / 385S / 399R / 441S / 445R / 449H 54M / 385P, 54M / 385P / 389E / 441R / 445K / 447A / 449H, 54M / 389E / 395D / 399R / 447A / 449H, 185L / 190P / 219L / 257H / 389E / 395A / 445K / 447A, 185L / 190P / 25 7H / 302R / 395D / 441S / 445R / 447S、185L / 190P / 257H / 385P / 389E / 399R、185L / 190P / 257H / 385P / 399R / 445R / 447A、185L / 190P / 257H / 389E / 395A、185L / 1 90P / 257H / 389E / 395H / 399R / 441S / 447S / 449H、185L / 190P / 385S / 389E / 441 R / 445K / 447S、185L / 190P / 389E / 447S / 449H、185L / 190P / 395D / 399R、185L / 1 90P / 395H / 399R、185L / 219L / 257H / 399R / 445R / 447A、185L / 257H / 385S / 395A / 399R / 445R / 447A、185L / 302R / 395H / 399R / 441R / 445K / 447S / 449H、185L / 395D / 399R / 441R / 445R / 447A、190P / 219L / 257H / 385S / 389E / 441S / 445R / 447A / 449H、190P / 219L / 302H / 385P / 399R / 445R、190P / 257H / 302H / 385P / 399R、190P / 257H / 385P / 389E / 399R, 190P / 257H / 385S / 389E / 445K / 447A, 190P / 257H / 385S / 395D, 190P / 257H / 385S / 441S / 445R / 447S / 449H, 190P / 257H / 389E / 395H / 441R / 445 R / 447A, 190P / 257H / 399R / 447A / 449H, 190P / 302H / 385P / 389E / 395D / 399R / 441S / 44 5K / 447S, 190P / 389E, 219L / 257H / 385S / 389E / 395D / 441R / 447A / 449H, 219L / 257H / 39 5H, 219L / 385S / 389E / 399R / 445R / 449H, 219L / 395H, 257H / 385P / 389E / 399R, 257H / 389E / 395D / 399R / 445K / 447A, 257H / 389E / 395D / 399R / 445K / 449H, 257H / 389E / 399R, 302H / 389E / 395H / 445R, 385S / 389E, 385S / 395D, 389E / 395D / 445R / 447S, 395D / 399R, and 399R, wherein these positions are numbered with reference to SEQ ID NO: 1216.

[0024] In some additional embodiments, the polypeptide sequence of the engineered glycosyltransferase is S54M, S54M / F185L / T190P, S54M / F185L / T190P / C219L / N257H / N302R / V385P / D389E / G395H / N445K / N447A / Y449H, S54M / F185L / T190P / C219L / V385P / N445R / N447A, S54M / F185L / T190P / C219L / V385S, S54M / F185L / T190P / C219L / V385S / D389E / G395D / Q399R / Q441R / N445R / N447A / Y449H, S54M / F185L / T190P / C219L / V385S / G39 5A / Q399R / Q441R / N445K / N447A / Y449H, S54M / F185L / T190P / C219L / D389E / G395H / Q399R / Q441S / N445K / N447A / Y449H, S54M / F185L / T190P / N302H, S54 M / F185L / T190P / N302R / G395H / Q399R, S54M / F185L / T190P / V385P / N447A / Y 449H, S54M / F185L / T190P / D389E / G395H, S54M / F185L / T190P / D389E / Q441R / N445R / N447A / Y449H, S54M / F185L / T190P / D389E / N445K, S54M / F185L / T19 0P / G395D / Q399R / Q441R / N445K / N447A / Y449H, S54M / F185L / C219L / D389E, S54M / F185L / N257H / D389E / Q441S / N445R / N447A / Y449H, S54M / F185L / N302 H / V385S / Q399R / N445R / N447A, S54M / F185L / V385S / D389E / G395D / Q441R / N 445K / Y449H, S54M / F185L / V385S / G395D / Q399R / N445R / N447A / Y449H, S54M / F185L / D389E / G395D / N445K / N447A, S54M / T190P / C219L / N257H / N302H, S5 4M / T190P / C219L / N257H / G395H / N445R / N447A / Y449H, S54M / T190P / N257H,S54M / T190P / N257H / N302H / Q399R、S54M / T190P / N257H / K309N / V385S / D38 9E / G395D / Q399R / N445K、S54M / T190P / N257H / V385S / D389E、S54M / T190P / N 257H / G395D / N445K / Y449H、S54M / T190P / N302H / D389E / G395D / Q399R / N445K / N447S、S54M / T190P / N302R / D389E、S54M / T190P / V385P / G395D、S54M / T19 0P / V385P / N445R / N447A / Y449H、S54M / T190P / V385S / D389E / G395H / Q441S / N445R、S54M / T190P / G395A、S54M / T190P / G395H / N445K / N447A、S54M / C219L / N302R / G395H / Q441S / N445R / N447A、S54M / C219L / V385P / D389E / G395D / Q441R / N445K / N447A、S54M / N257H、S54M / N257H / V385S / Y449H、S54M / N257H / D 389E、S54M / N257H / Q399R、S54M / N257H / Q441R / N447A、S54M / N257H / Q441R / Y449H、S54M / N302H / V385P / Q399R / Q441S / N445K / N447S、S54M / N302H / V38 5S / Q399R / Q441S / N445R / Y449H、S54M / V385P、S54M / V385P / D389E / Q441R / N 445K / N447A / Y449H、S54M / D389E / G395D / Q399R / N447A / Y449H、F185L / T190 P / C219L / N257H / D389E / G395A / N445K / N447A、F185L / T190P / N257H / N302R / G395D / Q441S / N445R / N447S、F185L / T190P / N257H / V385P / D389E / Q399R、F1 85L / T190P / N257H / V385P / Q399R / N445R / N447A、F185L / T190P / N257H / D389E / G395A、F185L / T190P / N257H / D389E / G395H / Q399R / Q441S / N447S / Y449H、F185L / T190P / V385S / D389E / Q441R / N445K / N447S、F185L / T190P / D389E / N 447S / Y449H、F185L / T190P / G395D / Q399R、F185L / T190P / G395H / Q399R、F18 5L / C219L / N257H / Q399R / N445R / N447A、F185L / N257H / V385S / G395A / Q399R / N445R / N447A、F185L / N302R / G395H / Q399R / Q441R / N445K / N447S / Y449H、 F185L / G395D / Q399R / Q441R / N445R / N447A、T190P / C219L / N257H / V385S / D 389E / Q441S / N445R / N447A / Y449H、T190P / C219L / N302H / V385P / Q399R / N44 5R、T190P / N257H / N302H / V385P / Q399R、T190P / N257H / V385P / D389E / Q399R、T190P / N257H / V385S / D389E / N445K / N447A、T190P / N257H / V385S / G395D、 T190P / N257H / V385S / Q441S / N445R / N447S / Y449H、T190P / N257H / D389E / G 395H / Q441R / N445R / N447A、T190P / N257H / Q399R / N447A / Y449H、T190P / N30 2H / V385P / D389E / G395D / Q399R / Q441S / N445K / N447S、T190P / D389E、C219L / N257H / V385S / D389E / G395D / Q441R / N447A / Y449H、C219L / N257H / G395H、 C219L / V385S / D389E / Q399R / N445R / Y449H、C219L / G395H、N257H / V385P / D389E / Q399R、N257H / D389E / G395D / Q399R / N445K / N447A、N257H / D389E / G39 5D / Q399R / N445K / Y449H、N257H / D389E / Q399R、N302H / D389E / G395H / N445R、V385S / D389E、V385S / G395D、D389E / G395D / N445R / N447S、G395D / Q399R、and Q399R, wherein these positions are numbered with reference to SEQ ID NO: 1216. In some additional embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from 5, 14, 96, 108, 157, 181, 188, 278, 293, and 341, wherein these positions are numbered with reference to SEQ ID NO: 1216. In some additional embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations selected from 5S, 14T, 96K, 96P, 108E, 157Q, 181L, 188L, 278L, 293V, and 341L.

[0025] In some additional embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations selected from H5S, R14T, G96K, G96P, N108E, N157Q, M181L, E188L, V278L, A293V and I341L, wherein these positions are numbered with reference to SEQ ID NO: 1216. In some further embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from 54 / 185 / 190 / 219 / 257 / 302 / 385 / 389 / 395 / 445 / 447 / 449, 54 / 185 / 190 / 385 / 447 / 449, 54 / 190 / 257 / 302 / 385 / 395 / 399, 54 / 190 / 302 / 389 / 395 / 399 / 445 / 447, 54 / 257 / 385 / 449, 54 / 257 / 389, and 54 / 389 / 395 / 399 / 447 / 449, wherein these positions are numbered with reference to SEQ ID NO: 1216. In some additional embodiments, the polypeptide sequence of the engineered glycosyltransferase is 54M / 185L / 190P / 219L / 257H / 302R / 385P / 389E / 395H / 445K / 447A / 449H, 54M / 185L / 190P / 385P / 447A / 449H, 54M / 190P / 257H / 302R / 385P / 395A / 399R, and at least one mutation or set of mutations selected from 54M / 190P / 302H / 389E / 395D / 399R / 445K / 447S, 54M / 257H / 385S / 449H, 54M / 257H / 389E, and 54M / 389E / 395D / 399R / 447A / 449H, where these positions are numbered with reference to SEQ ID NO: 1216.In some additional embodiments, the polypeptide sequence of the engineered glycosyltransferase is S54M / F185L / T190P / C219L / N257H / N302R / V385P / D389E / G395H / N445K / N447A / Y449H, S54M / F185L / T190P / V385P / N447A / Y449H, S54M / T190P / N257H / N302R / V385P / G395A / Q399 R, S54M / T190P / N302H / D389E / G395D / Q399R / N445K / N447S, S54M / N257H / V385S / Y449H, S54M / N257H / D389E, and S54M / D389E / G395D / Q399R / N447A / Y449H, wherein these positions are numbered with reference to SEQ ID NO: 1216.

[0026] In some further embodiments, the polypeptide sequence of the engineered glycosyltransferase is selected from the group consisting of 14 / 42 / 51 / 108 / 181, 14 / 42 / 51 / 157 / 341, 14 / 42 / 341, 14 / 51 / 96 / 157, 14 / 51 / 96 / 157 / 341, 14 / 51 / 96 / 341, 14 / 51 / 108, 14 / 51 / 341, 14 / 96, 14 / 96 / 108 / 133, 14 / 96 / 108 / 181 / 341, 14 / 96 / 108 / 188, 14 / 96 / 34 and 293, wherein the positions are numbered with reference to SEQ ID NO: 1488. In some additional embodiments, the engineered glycosyltransferase polypeptide sequence is 14T / 42T / 51V / 108E / 181L, 14T / 42T / 51V / 157Q / 341L, 14T / 42T / 341L, 14T / 51V / 96K / 157Q, 14T / 51V / 96P / 157Q / 341L, 14T / 51V / 96P / 341L, 14T / 51V / 108E, 14T / 51V / 341L, 14T / 96K, 14T / 96K / 108E / 133I, 14T / 96K / 108E / 188V, 14T / 96K / 341L, 14T / 96P / 1 and 293V, wherein these positions are numbered with reference to SEQ ID NO: 1488.In some additional embodiments, the engineered glycosyltransferase polypeptide sequence is R14T / V42T / N51V / N108E / M181L, R14T / V42T / N51V / N157Q / I341L, R14T / V42T / I341L, R14T / N51V / G96K / N157Q, R14T / N51V / G 96P / N157Q / I341L, R14T / N51V / G96P / I341L, R14T / N51V / N108E, R14T / N51V / I341L, R14T / G96K, R14T / G96K / N108E / V133I, R14T / G96K / N108E / E188V, R14T / G96K / I341L, R14T / G9 6P / N108E / M181L / I341L, R14T / N108E / N157Q, R14T / N108E / N157Q / E188L, R14T / N157Q / M181L / V278L, R14T / V278L, V42T / G96P / N157Q / I341L, V42T / E188L / I341L, G96K / E188L, and A293V, G96P / N108E / E188L, G96P / N108E / E188L / I341L, M181L, E188L, and A293V, where these positions are numbered with reference to SEQ ID NO: 1488. In some further embodiments, the engineered glycosyltransferase polypeptide sequence comprises at least one mutation or set of mutations at one or more positions selected from 122, 144, 147, 187, 196, 197, 198, 199, 201, 268, and 324, where these positions are numbered with reference to SEQ ID NO: 1488. In some additional embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations selected from 122V, 144V, 147F, 187K, 196M, 196P, 196V, 197V, 198A, 198F, 199G, 199Q, 199S, 201P, 268A, 324K and 324R, wherein these positions are numbered with reference to SEQ ID NO: 1488.In some additional embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations selected from L122V, L144V, S147F, T187K, A196M, A196P, A196V, P197V, Q198A, Q198F, N199G, N199Q, N199S, G201P, Y268A, H324K and H324R, where these positions are numbered with reference to SEQ ID NO: 1488. In some further embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from 14 / 42 / 341, 14 / 96, 14 / 96 / 108 / 133, 14 / 96 / 108 / 181 / 341, and 188, where these positions are numbered with reference to SEQ ID NO: 1488. In some additional embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations selected from 14T / 42T / 341L, 14T / 96K, 14T / 96K / 108E / 133I, 14T / 96P / 108E / 181L / 341L, and 188L, where these positions are numbered with reference to SEQ ID NO: 1488. In some additional embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations selected from R14T / V42T / I341L, R14T / G96K, R14T / G96K / N108E / V133I, R14T / G96P / N108E / M181L / I341L, and E188L, where these positions are numbered with reference to SEQ ID NO: 1488.

[0027] In yet some additional embodiments, the engineered glycosyltransferase polypeptide sequence is 147 / 188 / 196 / 201, 152 / 187 / 188 / 324, 152 / 188, 152 / 188 / 196 / 198 / 199 / 324, 152 / 188 / 196 / 199, 152 / 188 / 196 / 201 / 324, 152 / 188 / 324, 188, 188 / 196 / 198 / 199 / 201, 188 / 196 / 198 / 199 / 201 / 324, 188 / 196 / 1 and at least one mutation or set of mutations at one or more positions selected from 98 / 201, 188 / 196 / 198 / 324, 188 / 196 / 201, 188 / 198 / 199 / 201 / 324, 188 / 198 / 199 / 268, 188 / 198 / 201 / 324, 188 / 198 / 324, 188 / 199 / 201, 188 / 201, 188 / 201 / 324, and 188 / 324, wherein these positions are numbered with reference to SEQ ID NO: 1516. In some additional embodiments, the polypeptide sequence of the engineered glycosyltransferase is 147F / 188E / 196V / 201P, 152Y / 187K / 188E / 324K, 152Y / 188E, 152Y / 188E / 196V / 198A / 199Q / 324K, 152Y / 188E / 196V / 199Q, 152Y / 188E / 196V / 201P / 324K, 152Y / 188E / 324K, 188E, 188E / 196V / 198A / 199Q / 201P, 188E / 196V / 198A / 324K, 188E / 196V / 198A / 324K, 188E / 196V / 198A / 324K, 188E / 196V / 198 F / 199Q / 201P / 324K, 188E / 196V / 198F / 201P, 188E / 196V / 201P, 188E / 198A / 199Q / 268A, 188E / 198A / 201P / 324K, 188E / 198A / 324K, 188E / 198F / 199Q / 201P / 324K, 188E / 199Q / 201P, 188E / 201P, 188E / 201P / 324K, and 188E / 324K, wherein these positions are numbered with reference to SEQ ID NO: 1516.In some additional embodiments, the engineered glycosyltransferase polypeptide sequence is S147F / L188E / A196V / G201P, F152Y / T187K / L188E / H324K, F152Y / L188E, F152Y / L188E / A196V / Q198A / N199Q / H324K, F15 2Y / L188E / A196V / N199Q, F152Y / L188E / A196V / G201P / H324K, F152Y / L188E / H324K, L1 88E, L188E / A196V / Q198A / N199Q / G201P, L188E / A196V / Q198A / H324K, L188E / A196V / Q1 98F / N199Q / G201P / H324K, L188E / A196V / Q198F / G201P, L188E / A196V / G201P, L188E / Q 198A / N199Q / Y268A, L188E / Q198A / G201P / H324K, L188E / Q198A / H324K, L188E / Q198F / and at least one mutation or set of mutations selected from N199Q / G201P / H324K, L188E / N199Q / G201P, L188E / G201P, L188E / G201P / H324K, and L188E / H324K, where these positions are numbered with reference to SEQ ID NO: 1516. In some further embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations at one or more positions selected from 152 / 188 / 196 / 198 / 199 / 324, 188 / 196 / 198 / 199 / 201, 188 / 196 / 198 / 201, 188 / 196 / 201, 188 / 198 / 199 / 268, 188 / 201, and 188 / 324, where these positions are numbered with reference to SEQ ID NO: 1516.In some additional embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations selected from 152Y / 188E / 196V / 198A / 199Q / 324K, 188E / 196V / 198A / 199Q / 201P, 188E / 196V / 198F / 201P, 188E / 196V / 201P, 188E / 198A / 199Q / 268A, 188E / 201P, and 188E / 324K, wherein these positions are numbered with reference to SEQ ID NO: 1516. In some additional embodiments, the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation or set of mutations selected from F152Y / L188E / A196V / Q198A / N199Q / H324K, L188E / A196V / Q198A / N199Q / G201P, L188E / A196V / Q198F / G201P, L188E / A196V / G201P, L188E / Q198A / N199Q / Y268A, L188E / G201P, and L188E / H324K, wherein these positions are numbered with reference to SEQ ID NO: 1516.

[0028] The present invention also provides engineered glycosyltransferases provided herein, wherein the engineered glycosyltransferase is selected from beta-1,2-glycosyltransferases and beta-1,3-glycosyltransferases. In some embodiments, the engineered glycosyltransferase is an NDP-glycosyltransferase selected from ADP-glucose-dependent glycosyltransferase (AGT), CDP-glucose-dependent glycosyltransferase (CGT), GDP-glucose-dependent glycosyltransferase (GGT), TDP-glucose-dependent glycosyltransferase (TGT), and IDP-glucose-dependent glycosyltransferase (IGT). In some additional embodiments, the engineered glycosyltransferase is an ADP-glucose-dependent glycosyltransferase. In some further embodiments, the engineered glycosyltransferase preferentially uses sugar donors other than uracil diphosphate.

[0029] The present invention also provides engineered polynucleotides encoding at least one engineered glycosyltransferase polypeptide provided herein. The present invention also provides vectors comprising at least one engineered polynucleotide encoding at least one glycosyltransferase provided herein. In some embodiments, the vector further comprises at least one regulatory sequence. The present invention also provides host cells comprising at least one engineered polynucleotide encoding at least one glycosyltransferase provided herein. The present invention further provides host cells comprising at least one vector provided herein. In some embodiments, the host cell is selected from a eukaryote and a prokaryote.

[0030] The present invention also provides methods for producing at least one engineered glycosyltransferase provided herein, comprising culturing a host cell provided herein under conditions such that the engineered glycosyltransferase is produced by the host cell. In some embodiments, the method further comprises recovering the engineered glycosyltransferase. The present invention also provides compositions comprising at least one engineered glycosyltransferase provided herein.

[0031] The present invention also provides engineered sucrose synthases comprising a polypeptide sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 6. In some embodiments, an engineered sucrose synthase comprises a polypeptide sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 22. In some embodiments, the polypeptide sequence of the engineered sucrose synthase comprises at least one mutation or set of mutations at one or more positions selected from 3 / 548, 4, 7, 12, 41, 42, 44, 47, 52, 57, 59, 71, 81, 85, 93, 97, 122, 129, 134, 136, 139, 154, 175, 215, 266, 270, 343, 358, 381, 388, 434, 442, 519, 524, 532, 536, 570, 589, 603, 606, 615, 635, 641, 652, 724, 727, and 738, wherein these positions are numbered with reference to SEQ ID NO:22.In some additional embodiments, the polypeptide sequence of the engineered sucrose synthase is 3G / 548R, 4Q, 4T, 7H, 7L, 12K, 41Q, 41S, 42D, 42E, 42I, 44A, 44I, 44L, 44T, 47A, 47G, 47R, 47T, 52G, 52Q, 52S, 52T, 52V, 57H, 57Y, 59M, 59T, 71Q, 71T, 81H, 81P, 81Q, 85T, 93I, 97S, 97T, 122P, 129Q, 134P, 134Q, 134R, 136G, 139G, 154A, 175S, 215L, 266R, 270L, 343L, and at least one mutation or set of mutations selected from: 358P, 358Q, 381K, 381R, 381T, 381Y, 388A, 388R, 388S, 434G, 434L, 442Y, 519C, 519V, 524R, 524S, 532E, 532T, 532Y, 536T, 570K, 589Q, 603M, 603T, 606A, 606P, 615T, 635G, 635R, 641I, 641L, 652R, 652Y, 724A, 724S, 727H, 738A, and 738K, wherein these positions are numbered with reference to SEQ ID NO:22.In some additional embodiments, the polypeptide sequence of the engineered sucrose synthase is selected from the group consisting of E3G / P548R, E4Q, E4T, Q7H, Q7L, S12K, K41Q, K41S, T42D, T42E, T42I, R44A, R44I, R44L, R44T, P47A, P47G, P47R, P47T, P52G, P52Q, P52 S, P52T, P52V, W57H, W57Y, A59M, A59T, R71Q, R71T, L81H, L81P, L81Q, V85T, V93I, A97S, A9 7T, A122P, E129Q, V134P, V134Q, V134R, Q136G, K139G, H154A, G175S, F215L, N266R, V270L, H343L, E358P, E358Q, S381K, S381R, S381T, S381Y, K388A, K388R, K388S, Y434G, Y434L, H4 42Y, T519C, T519V, A524R, A524S, S532E, S532T, S532Y, E536T, R570K, S589Q, Q603M, Q603 T, M606A, M606P, R615T, S635G, S635R, V641I, V641L, G652R, G652Y, K724A, K724S, E727H, S738A, and S738K, where these positions are numbered with reference to SEQ ID NO: 22. In some embodiments, the engineered sucrose synthase polypeptide sequence comprises at least one mutation or set of mutations at one or more positions selected from 41, 52, 134, 381, 442, 519, 524, and 724, where these positions are numbered with reference to SEQ ID NO: 22. In some additional embodiments, the polypeptide sequence of the engineered sucrose synthase comprises at least one mutation or set of mutations selected from 41S, 52V, 134R, 381R, 442Y, 519V, 524R and 724S, wherein these positions are numbered with reference to SEQ ID NO:22.In some additional embodiments, the polypeptide sequence of the engineered sucrose synthase comprises at least one mutation or set of mutations selected from K41S, P52V, V134R, S381R, H442Y, T519V, A524R and K724S, wherein these positions are numbered with reference to SEQ ID NO:22.

[0032] In some embodiments, the polypeptide sequence of the engineered sucrose synthase is selected from the group consisting of 25 / 44 / 52 / 134 / 434 / 724, 41 / 44 / 52 / 97 / 442 / 719 / 724, 41 / 44 / 52 / 134 / 442, 41 / 44 / 52 / 434 / 442 / 532 / 724, 41 / 44 / 52 / 434 / 724, 41 / 44 / 136 / 329, 41 / 44 / 136 / 442, 41 / 44 / 532, 41 / 52 / 97 / 434 / 442 / 532 / 724, 41 / 52 / 134 / 136 / 434, 41 / 52 / 134 / 442 / 724, 41 / 52 / 13 6, 41 / 52 / 434, 41 / 52 / 434 / 442, 41 / 52 / 434 / 442 / 724, 41 / 52 / 442, 41 / 97 / 134 / 434 / 442 / 532 / 553, 41 / 134 / 442 / 532, 41 / 329 / 442, 41 / 434 / 442 / 532, 41 / 434 / 442 / 532 / 724, 41 / 434 / 532, 41 / 532, 44 / 52 / 97 / 434 / 442 / 724, 44 / 52 / 97 / 442 / 724, 44 / 52 / 134 / 136 / 329 / 434 / 442 / 532, 44 / 136 / 329 / 434 / 532, 44 / 136 / 532, 44 / 434 / 442 / 553, 52, 52 / 97, 52 / 97 / 434 / 442, 52 / 97 / 442, 52 / 97 / 532, 52 / 134, 52 / 134 / 136 / 434, 52 / 134 / 136 / 442, 5 2 / 134 / 329 / 434, 52 / 134 / 329 / 532, 52 / 134 / 434 / 442 / 532 / 553, 52 / 134 / 442 / 724, 52 / 136, 52 / 136 / 434, 52 / 136 / 434 / 442, 52 / 136 / 434 / 442, 52 / 136 / 434 / 442 / 532, 52 / 13 6 / 434 / 724, 52 / 136 / 442, 52 / 434, 52 / 434 / 442 / 532, 52 / 434 / 442 / 724, 52 / 434 / 532, 52 / 442, 52 / 442 / 532 / 724, 52 / 442 / 553 / 724, 52 / 442 / 724, 52 / 532 , 52 / 553, 57 / 97 / 434 / 442 / 724, 97 / 134 / 136 / 442 / 532, 97 / 134 / 136 / 532, 97 / 134 / 442, 97 / 136 / 434 / 442, 97 / 329 / 724, 97 / 442, 134, 134 / 136 / 434 / 442,and at least one mutation or set of mutations at one or more positions selected from 134 / 136 / 434 / 442 / 532 / 553 / 724, 134 / 136 / 434 / 442 / 553 / 724, 134 / 136 / 434 / 532 / 724, 134 / 136 / 442 / 532, 134 / 434 / 442 / 724, 136, 136 / 442, 136 / 442 / 724, 136 / 532 / 724, 434, 434 / 442, 442, 442 / 724, and 532 / 724, wherein these positions are numbered with reference to SEQ ID NO: 1652. In some additional embodiments, the engineered sucrose synthase polypeptide sequence is 25T / 44I / 52G / 134R / 434G / 724S, 41S / 44I / 52G / 97T / 442Y / 719T / 724S, 41S / 44I / 52G / 434G / 442Y / 532Y / 724S, 41S / 44I / 52G / 434G / 724S, 41S / 44I / 52V / 134R / 442Y, 41S / 44I / 136G / 329Q, 41S / 44I / 136G / 442Y, 41S / 44I / 532Y, 41S / 52G / 134R / 442Y / 724S, 41S / 52G / 136G, 41S / 52V / 97T / 434G / 442Y / 532Y / 724S, 41S / 52V / 134R / 136G / 434G, 41S / 52V / 434G, 41S / 52V / 434G / 442Y, 41S / 52V / 434G / 442Y / 724S, 41S / 5 2V / 442Y, 41S / 97T / 134R / 434G / 442Y / 532Y / 553A, 41S / 134R / 442Y / 532Y, 41S / 329Q / 442Y, 41S / 434G / 442Y / 532Y, 41S / 434G / 442Y / 532Y / 724S, 41S / 434G / 532Y, 41S / 532Y, 44I / 52G / 134R / 136G / 329Q / 434G / 442Y / 532Y, 44I / 52V / 97T / 434G / 442Y / 724S, 44I / 52V / 97T / 442Y / 724S, 44I / 52V / 134R / 434G / 532Y, 44I / 136G / 329Q / 434G / 532Y, 44I / 1 36G / 532Y, 44I / 434G / 442Y / 553A, 52G, 52G / 97T, 52G / 97T / 434G / 442Y, 52G / 97T / 442Y, 52G / 97T / 532Y, 52G / 134R,52G / 134R / 136G / 434G, 52G / 134R / 136G / 442Y, 52G / 134R / 329Q / 434G, 52G / 134R / 434G / 442Y / 532Y / 553A, 52G / 136G, 52G / 434G / 4 42Y / 532Y, 52G / 442Y, 52G / 442Y / 553A / 724S, 52G / 442Y / 724S, 52G / 532Y, 52G / 553A, 52V / 134R / 329Q / 532Y, 52V / 134R / 442Y / 724 S, 52V / 136G / 434G, 52V / 136G / 434G / 442Y, 52V / 136G / 434G / 442Y / 532Y, 52V / 136G / 434G / 724S, 52V / 136G / 442Y, 52V / 434G, 52V / 434G / 442Y / 724S, 52V / 434G / 532Y, 52V / 442Y, 52V / 442Y / 532Y / 724S, 52V / 442Y / 553A / 724S, 52V / 442Y / 724S, 52V / 532Y, 57C / 97 T / 434G / 442Y / 724S, 97T / 134R / 136G / 442Y / 532Y, 97T / 134R / 136G / 532Y, 97T / 134R / 442Y, 97T / 136G / 434G / 442Y, 97T / 329Q / 724 S, 97T / 442Y, 134R, 134R / 136G / 434G / 442Y, 134R / 136G / 434G / 442Y / 532Y / 553A / 724S, 134R / 136G / 434G / 442Y / 553A / 724S, 134R / 136G / 434G / 532Y / 724S, 134R / 136G / 442Y / 532Y, 134R / 434G / 442Y / 724S, 136G, 136G / 442Y, 136G / 442Y / 724S, 136G / 532Y / 724S, 434G, 434G / 442Y, 442Y, 442Y / 724S, and 532Y / 724S, wherein these positions are numbered with reference to SEQ ID NO: 1652. In some additional embodiments, the engineered sucrose synthase polypeptide sequence is A25T / R44I / P52G / V134R / Y434G / K724S, K41S / R44I / P52G / A97T / H442Y / A719T / K724S, K41S / R44I / P52G / Y434G / H442Y / S532Y / K724S,K41S / R44I / P52G / Y434G / K724S、K41S / R44I / P52V / V134R / H442Y、K41S / R44I / Q136G / E329Q、K41S / R44I / Q136G / H442Y、K41S / R44I / S532Y、K41S / P52G / V134R / H442Y / K724S、K41S / P52G / Q136G、K41S / P52V / A97T / Y434G / H442Y / S532Y / K724S、K41S / P52V / V134R / Q136G / Y434G、K41S / P52V / Y434G、K41S / P52V / Y434G / H442Y、K41S / P52V / Y434G / H442Y / K724S、K41S / P52V / H442Y、K41S / A97T / V134R / Y434G / H442Y / S532Y / V553A、K41S / V134R / H442Y / S532Y、K41S / E329Q / H442Y、K41S / Y434G / H442Y / S532Y、K41S / Y434G / H442Y / S532Y / K724S、K41S / Y434G / S532Y、K41S / S532Y、R44I / P52G / V134R / Q136G / E329Q / Y434G / H442Y / S532Y、R44I / P52V / A97T / Y434G / H442Y / K724S、R44I / P52V / A97T / H442Y / K724S、R44I / P52V / V134R / Y434G / S532Y、R44I / Q136G / E329Q / Y434G / S532Y、R44I / Q136G / S532Y、R44I / Y434G / H442Y / V553A、P52G、P52G / A97T、P52G / A97T / Y434G / H442Y、P52G / A97T / H442Y、P52G / A97T / S532Y、P52G / V134R、P52G / V134R / Q136G / Y434G、P52G / V134R / Q136G / H442Y、P52G / V134R / E329Q / Y434G、P52G / V134R / Y434G / H442Y / S532Y / V553A、P52G / Q136G、P52G / Y434G / H442Y / S532Y、P52G / H442Y、P52G / H442Y / V553A / K724S、P52G / H442Y / K724S、P52G / S532Y、P52G / V553A、P52V / V134R / E329Q / S532Y、P52V / V134R / H442Y / K724S, P52V / Q136G / Y434G, P52V / Q136G / Y434G / H442Y, P52V / Q136G / Y434G / H442Y / S532Y, P52V / Q136G / Y434G / K724S, P52V / Q136G / H442Y, P52V / Y434G, P52V / Y434G / H442Y / K724S, P52V / Y434G / S532Y, P52V / H442 Y, P52V / H442Y / S532Y / K724S, P52V / H442Y / V553A / K724S, P52V / H442Y / K724S, P52V / S532Y, W57C / A97T / Y434G / H442 Y / K724S, A97T / V134R / Q136G / H442Y / S532Y, A97T / V134R / Q136G / S532Y, A97T / V134R / H442Y, A97T / Q136G / Y434G / H4 42Y, A97T / E329Q / K724S, A97T / H442Y, V134R, V134R / Q136G / Y434G / H442Y, V134R / Q136G / Y434G / H442Y / S532Y / V553 A / K724S, V134R / Q136G / Y434G / H442Y / V553A / K724S, V134R / Q136G / Y434G / S532Y / K724S, V134R / Q136G / H442Y / S532 and at least one mutation or set of mutations selected from Y, V134R / Y434G / H442Y / K724S, Q136G, Q136G / H442Y, Q136G / H442Y / K724S, Q136G / S532Y / K724S, Y434G, Y434G / H442Y, H442Y, H442Y / K724S, and S532Y / K724S, wherein these positions are numbered with reference to SEQ ID NO: 1652. In some additional embodiments, the polypeptide sequence of the engineered sucrose synthase comprises at least one mutation or set of mutations at one or more positions selected from 3, 4, 22, 32, 34, 38, 47 / 488, 51, 51 / 433, 62, 75 / 169, 101, 169, 195 / 213, 708 and 718, which positions are numbered with reference to SEQ ID NO: 1652. In some additional embodiments, the polypeptide sequence of the engineered sucrose synthase comprises at least one mutation or set of mutations at one or more positions selected from 3A, 4V, 22L, 3A, 4V, 22L, 3A, 4V, 22L, 3B, 3C, 3D, 3D, 3E, 3F, 3G, 3H, 3I, 3J, 3J, 3J, 3J, 3J, 3J, 3K ...at least one mutation or set of mutations selected from 22T, 32S, 34E, 34S, 38L, 38N, 38V, 38W, 47S / 488N, 51A, 51H, 51H / 433P, 51T, 62I, 75I / 169A, 101V, 169E, 195K / 213T, 708V and 718H, wherein these positions are numbered with reference to SEQ ID NO: 1652; In some additional embodiments, the polypeptide sequence of the engineered sucrose synthase comprises at least one mutation or set of mutations selected from E3A, E4V, H22L, H22T, L32S, T34E, T34S, R38L, R38N, R38V, R38W, P47S / D488N, Y51A, Y51H, Y51H / L433P, Y51T, V62I, M75I / Q169A, L101V, Q169E, S195K / A213T, T708V, and A718H, wherein these positions are numbered with reference to SEQ ID NO: 1652. In some further embodiments, the polypeptide sequence of the engineered sucrose synthase comprises at least one mutation or set of mutations at one or more positions selected from 44 / 52 / 97 / 442 / 724, 52 / 97 / 442, 97 / 442, and 434 / 442, where these positions are numbered with reference to SEQ ID NO: 1652. In some additional embodiments, the polypeptide sequence of the engineered sucrose synthase comprises at least one mutation or set of mutations selected from 44I / 52V / 97T / 442Y / 724S, 52G / 97T / 442Y, 97T / 442Y, and 434G / 442Y, where these positions are numbered with reference to SEQ ID NO: 1652. In some additional embodiments, the polypeptide sequence of the engineered sucrose synthase comprises at least one mutation or set of mutations selected from R44I / P52V / A97T / H442Y / K724S, P52G / A97T / H442Y, A97T / H442Y, and Y434G / H442Y, wherein these positions are numbered with reference to SEQ ID NO: 1652.

[0033] In still some further embodiments, the engineered sucrose synthase polypeptide sequence is 4 / 22, 4 / 22 / 34, 4 / 22 / 34 / 38, 4 / 22 / 34 / 38 / 169 / 708, 4 / 22 / 34 / 47 / 51 / 169 / 213, 4 / 22 / 51 / 708, 4 / 22 / 101, 4 / 34 / 38 / 101, 4 / 34 / 708, 4 / 62 / 433 / 708, 4 / 169, 4 / 169 / 433, 4 / 169 / 708, 4 / 433, 4 / 708, 22 / 34, 22 22 / 34 / 101 / 169 / 195, 22 / 34 / 169 / 708, 22 / 47 / 169 / 433, 22 / 75, 34 / 38 / 62, 34 / 62 / 169 / 433, 34 / 101, 62 / 708, 75 / 169, 169 / 708, and 195 / 708, wherein these positions are numbered with reference to SEQ ID NO: 1822. In some additional embodiments, the engineered sucrose synthase polypeptide sequence is 4V / 22L / 34E, 4V / 22L / 51A / 708V, 4V / 22L / 101V, 4V / 22T, 4V / 22T / 34E / 38N, 4V / 22T / 34E / 38V / 169A / 708V, 4V / 22T / 34E / 47S / 51H / 169A / 213T, 4V / 34E / 38N / 101V, 4V / 34E / 708V, 4V / 62I / 433P / 708V, 4V / 169A, 4V / 169A / 433P, 4V / 169A / 708V, 4V / 433P, 4V / 708V , 22L / 34E, 22L / 34S / 169A / 708V, 22L / 75I, 22T / 34E / 38V, 22T / 34E / 101V / 169E, 22T / 34E / 101V / 169E / 195K, 22T / 47S / 169A / 433P, 34E / 62I / 169E / 433P, 34E / 101V, 34S / 38L / 62I, 62I / 708V, 75I / 169A, 169A / 708V, and 195K / 708V, wherein these positions are numbered with reference to SEQ ID NO: 1822.In some additional embodiments, the engineered sucrose synthase polypeptide sequence is E4V / H22L / T34E, E4V / H22L / Y51A / T708V, E4V / H22L / L101V, E4V / H22T, E4V / H22T / T34E / R38N, E4V / H22T / T34E / R38V / Q169A / T708V, E4V / H22T / T34E / P47S / Y51H / Q169A / A213T, E4V / T34E / R38N / L101V, E4V / T34E / T708V, E4 V / V62I / L433P / T708V, E4V / Q169A, E4V / Q169A / L433P, E4V / Q169A / T708V, E4V / L433P, E4V / T708V, H22L / T34E, H22L / T34S / Q169A / T708V, H22L / M75I, H22T / T34E / R38V, H22T / T34E / L101V / Q169E, H22T / T34E / L101V / Q169E / S195K, H22T / P47S / Q169A / L433P, T34E / V62I / Q and at least one mutation or set of mutations selected from 169E / L433P, T34E / L101V, T34S / R38L / V62I, V62I / T708V, M75I / Q169A, Q169A / T708V, and S195K / T708V, where these positions are numbered with reference to SEQ ID NO: 1822. In some additional embodiments, the polypeptide sequence of the engineered sucrose synthase comprises at least one mutation or set of mutations at one or more positions selected from 4, 22, 34, 121, 169, 341, 411, 433, 441, 518, 526, 527, 528, 544, 557, 558, 565, 585, 602, 604, 623, 708, 731 and 770, wherein these positions are numbered relative to SEQ ID NO: 1822.In some additional embodiments, the polypeptide sequence of the engineered sucrose synthase comprises at least one mutation or set of mutations selected from 4V, 22L, 22T, 34E, 121D, 169A, 341N, 411I, 433P, 441A, 441L, 518S, 526H, 526V, 527A, 527Q, 528Q, 544H, 557P, 558G, 565V, 585A, 602P, 604A, 623A, 623K, 623Q, 623R, 708V, 731A, 731M, 731Q, 731T, and 770T, wherein these positions are numbered with reference to SEQ ID NO: 1822. In some additional embodiments, the polypeptide sequence of the engineered sucrose synthase comprises at least one mutation or set of mutations selected from E4V, H22L, H22T, T34E, E121D, Q169A, P341N, L411I, L433P, D441A, D441L, R518S, T526H, T526V, E527A, E527Q, E528Q, R544H, R557P, Q558G, M565V, S585A, V602P, N604A, H623A, H623K, H623Q, H623R, T708V, D731A, D731M, D731Q, D731T, and V770T, wherein these positions are numbered with reference to SEQ ID NO: 1822. In some additional embodiments, the polypeptide sequence of the engineered sucrose synthase comprises at least one mutation or set of mutations at one or more positions selected from 4, 4 / 22 / 34 / 38, 4 / 169, 4 / 169 / 433, 4 / 433, 62 / 708, and 169 / 708, where these positions are numbered with reference to SEQ ID NO: 1822. In some additional embodiments, the polypeptide sequence of the engineered sucrose synthase comprises at least one mutation or set of mutations selected from 4V, 4V / 22T / 34E / 38N, 4V / 169A, 4V / 169A / 433P, 4V / 433P, 62I / 708V, and 169A / 708V, where these positions are numbered with reference to SEQ ID NO: 1822.In some additional embodiments, the polypeptide sequence of the engineered sucrose synthase comprises at least one mutation or set of mutations selected from E4V, E4V / H22T / T34E / R38N, E4V / Q169A, E4V / Q169A / L433P, E4V / L433P, V62I / T708V, and Q169A / T708V, wherein these positions are numbered with reference to SEQ ID NO: 1822.

[0034] In yet some additional embodiments, the engineered sucrose synthase polypeptide sequence is 34 / 62 / 411 / 526 / 557, 34 / 62 / 411 / 557 / 602 / 604, 34 / 62 / 441 / 557 / 623, 34 / 62 / 518 / 623, 34 / 62 / 623 / 731, 34 / 121 / 441 / 544 / 604 / 623, 34 / 121 / 526 / 604 / 731, 34 / 411 / 441, 34 / 411 / 441 / 518 / 526 / 557 / 565 / 731, 34 / 411 / 441 / 518 / 544 / 557 / 565 / 708 / 731, 34 / 411 / 441 / 518 / 585 / 604 / 770, 34 / 441 / 518 / 526 / 585 / 604 / 731, 34 / 441 / 526 / 565 / 708 / 770, 34 / 441 / 544 / 557 / 585 / 602 / 623, 34 / 441 / 585 / 623 / 708 / 7 31, 34 / 526 / 585 / 623, 62 / 121 / 329 / 518 / 557 / 565 / 623 / 708, 62 / 121 / 411 / 441 / 518 / 544 / 557 / 585 / 604 / 623, 62 / 121 / 441 / 518 / 526 / 623 / 770, 62 / 121 / 44 1 / 565 / 585, 62 / 121 / 518 / 557 / 585 / 604 / 708 / 770, 62 / 411 / 526 / 565 / 604 / 623, 62 / 411 / 585 / 731, 62 / 441 / 518 / 557 / 604 / 623 / 708 / 731, 62 / 441 / 623 / 708 / 770, 62 / 441 / 770, 121 / 441 / 518 / 526 / 602 / 604, 121 / 441 / 518 / 526 / 623 / 708, 121 / 441 / 526 / 557 / 565 / 708, 121 / 604 / 708 / 731 / 770, 411 / 441 / 518 / 557 / 623, 411 / 441 / 518 / 708, 411 / 441 / 604 / 623 / 708 / 731, 411 / 518 / 526 / 604 / 623 / 731, 411 / 565 / 604 / 623, 411 / 585 / 623, 441 / 518 / 526 / 557 / 565 / 602 / 604 / 623 / 708, 441 / 518 / 526 / 557 / 585 / 604 / 623 / 708, 441 / 518 / 526 / 604 / 623, 441 / 518 / 557 / 565 / 585, 441 / 518 / 565 / 623 / 731 / 770, 441 / 518 / 585, 441 / 585,At least one mutation or set of mutations at one or more positions selected from 441 / 585 / 602 / 604 / 623 / 708 / 731, 441 / 708 / 731, 557 / 602 / 604, 557 / 604, 585 / 623 / 708, and 623, where these positions are numbered with reference to SEQ ID NO: 2092.

[0035] In some additional embodiments, the engineered sucrose synthase polypeptide sequence is 34E / 62I / 411I / 526H / 557P, 34E / 62I / 411I / 557P / 602P / 604A, 34E / 62I / 441L / 557P / 623K, 34E / 62I / 518S / 623K, 34E / 62I / 623K / 731Q, 34E / 121D / 441L / 544H / 604A / 623K, 34E / 121D / 526H / 604A / 731Q, 34E / 411I / 441L, 34E / 411I / 441L / 518S / 526H / 557P / 565V / 731Q, 34E / 411I / 441L / 518S / 544H / 557P / 565V / 708V / 731Q, 34E / 41 1I / 441L / 518S / 585A / 604A / 770T, 34E / 441L / 518S / 526H / 585A / 604A / 731Q , 34E / 441L / 526H / 565V / 708V / 770T, 34E / 441L / 544H / 557P / 585A / 602P / 62 3K, 34E / 441L / 585A / 623K / 708V / 731Q, 34E / 526H / 585A / 623K, 62I / 121D / 32 9Q / 518S / 557P / 565V / 623R / 708V, 62I / 121D / 411I / 441L / 518S / 544H / 557P / 585A / 604A / 623K, 62I / 121D / 441L / 518S / 526H / 623R / 770T, 62I / 121D / 44 1L / 565V / 585A, 62I / 121D / 518S / 557P / 585A / 604A / 708V / 770T, 62I / 411I / 526H / 565V / 604A / 623K, 62I / 411I / 585A / 731Q, 62I / 441L / 518S / 557P / 604 A / 623K / 708V / 731Q, 62I / 441L / 623R / 708V / 770T, 62I / 441L / 770T, 121D / 4 41L / 518S / 526H / 602P / 604A, 121D / 441L / 518S / 526H / 623K / 708V, 121D / 44 1L / 526H / 557P / 565V / 708V, 121D / 604A / 708V / 731Q / 770T, 411I / 441L / 518 S / 557P / 623K, 411I / 441L / 518S / 708V, 411I / 441L / 604A / 623K / 708V / 731Q,411I / 518S / 526H / 604A / 623K / 731Q, 411I / 565V / 604A / 623R, 411I / 585A / 623K, 441L / 518S / 526H / 557P / 565V / 602P / 604A / 623 K / 708V, 441L / 518S / 526H / 557P / 585A / 604A / 623R / 708V, 441L / 518S / 526H / 604A / 623R, 441L / 518S / 557P / 565V / 585A, 441L / 51 and at least one mutation or set of mutations selected from 8S / 565V / 623R / 731Q / 770T, 441L / 518S / 585A, 441L / 585A, 441L / 585A / 602P / 604A / 623R / 708V / 731Q, 441L / 708V / 731Q, 557P / 602P / 604A, 557P / 604A, 585A / 623R / 708V, and 623R, wherein these positions are numbered with reference to SEQ ID NO: 2092. In some additional embodiments, the engineered sucrose synthase polypeptide sequence is selected from the group consisting of T34E / V62I / L411I / T526H / R557P, T34E / V62I / L411I / R557P / V602P / N604A, T34E / V62I / D441L / R557P / H623K, T34E / V62I / R51 8S / H623K, T34E / V62I / H623K / D731Q, T34E / E121D / D441L / R544H / N604A / H623K, T34E / E121D / T526H / N604A / D731Q, T34E / L411I / D441L, T34E / L411I / D441L / R518S / T526H / R5 57P / M565V / D731Q, T34E / L411I / D441L / R518S / R544H / R557P / M565V / T708V / D731Q, T3 4E / L411I / D441L / R518S / S585A / N604A / V770T, T34E / D441L / R518S / T526H / S585A / N60 4A / D731Q, T34E / D441L / T526H / M565V / T708V / V770T, T34E / D441L / R544H / R557P / S585 A / V602P / H623K, T34E / D441L / S585A / H623K / T708V / D731Q, T34E / T526H / S585A / H623K,V62I / E121D / E329Q / R518S / R557P / M565V / H623R / T708V、V62I / E121D / L411I / D441L / R518S / R544H / R557P / S585A / N604A / H623K、V62I / E121D / D441L / R518S / T526H / H623R / V770T、V62I / E121D / D441L / M565V / S585A、V62I / E121D / R518S / R557P / S585A / N604A / T708V / V770T、V62I / L411I / T526H / M565V / N604A / H623K、V62I / L411I / S585A / D731Q、V62I / D441L / R518S / R557P / N604A / H623K / T708V / D731Q、V62I / D441L / H623R / T708V / V770T、V62I / D441L / V770T、E121D / D441L / R518S / T526H / V602P / N604A、E121D / D441L / R518S / T526H / H623K / T708V、E121D / D441L / T526H / R557P / M565V / T708V、E121D / N604A / T708V / D731Q / V770T、L411I / D441L / R518S / R557P / H623K、L411I / D441L / R518S / T708V、L411I / D441L / N604A / H623K / T708V / D731Q、L411I / R518S / T526H / N604A / H623K / D731Q、L411I / M565V / N604A / H623R、L411I / S585A / H623K、D441L / R518S / T526H / R557P / M565V / V602P / N604A / H623K / T708V、D441L / R518S / T526H / R557P / S585A / N604A / H623R / T708V、D441L / R518S / T526H / N604A / H623R、D441L / R518S / R557P / M565V / S585A、D441L / R518S / M565V / H623R / D731Q / V770T、D441L / R518S / S585A、D441L / S585A、D441L / S585A / V602P / N604A / H623R / T708V / D731Q、D441L / T708V / D731Q、R557P / V602P / N604A、R557P / N604A、and S585A / H623R / T708V, and H623R, wherein these positions are numbered with reference to SEQ ID NO: 2092. In still some further embodiments, the engineered sucrose synthase polypeptide sequence comprises at least one mutation or set of mutations at one or more positions selected from 63, 65, 269, 323, 406, 416, 469, 511 and 640, wherein these positions are numbered with reference to SEQ ID NO: 2092. In some additional embodiments, the polypeptide sequence of the engineered sucrose synthase comprises at least one mutation or set of mutations selected from 63G, 63S, 63T, 65C, 65L, 269V, 323G, 323S, 323T, 406G, 416F, 469S, 511L, 640A, 640E, 640H, 640N, 640R, 640V and 640W, wherein these positions are numbered with reference to SEQ ID NO: 2092. In some additional embodiments, the polypeptide sequence of the engineered sucrose synthase comprises at least one mutation or set of mutations selected from A63G, A63S, A63T, T65C, T65L, I269V, A323G, A323S, A323T, N406G, L416F, T469S, V511L, T640A, T640E, T640H, T640N, T640R, T640V and T640W, wherein these positions are numbered with reference to SEQ ID NO: 2092. In some further embodiments, the polypeptide sequence of the engineered sucrose synthase comprises at least one mutation or set of mutations at one or more positions selected from 34 / 62 / 441 / 557 / 623, 34 / 441 / 585 / 623 / 708 / 731, 62 / 441 / 623 / 708 / 770, 411 / 441 / 518 / 557 / 623, 411 / 441 / 604 / 623 / 708 / 731, 441 / 518 / 526 / 557 / 585 / 604 / 623 / 708, 441 / 518 / 557 / 565 / 585, and 441 / 585 / 602 / 604 / 623 / 708 / 731, wherein these positions are numbered with reference to SEQ ID NO:2092. In some additional embodiments, the polypeptide sequence of the engineered sucrose synthase is34E / 62I / 441L / 557P / 623K, 34E / 441L / 585A / 623K / 708V / 731Q, 62I / 441L / 623R / 708V / 770 T, 411I / 441L / 518S / 557P / 623K, 411I / 441L / 604A / 623K / 708V / 731Q, 441L / 518S / 526H / 55 and at least one mutation or set of mutations selected from 7P / 585A / 604A / 623R / 708V, 441L / 518S / 557P / 565V / 585A, and 441L / 585A / 602P / 604A / 623R / 708V / 731Q, where these positions are numbered with reference to SEQ ID NO: 2092. In some additional embodiments, the engineered sucrose synthase polypeptide sequence is selected from the group consisting of T34E / V62I / D441L / R557P / H623K, T34E / D441L / S585A / H623K / T708V / D731Q, V62I / D441L / H623R / T708V / V770T, L411I / D441L / R518S / R557P / H623K, L411I / D441L / N604A / H623K / T708V / and at least one mutation or set of mutations selected from D731Q, D441L / R518S / T526H / R557P / S585A / N604A / H623R / T708V, D441L / R518S / R557P / M565V / S585A, and D441L / S585A / V602P / N604A / H623R / T708V / D731Q, where these positions are numbered with reference to SEQ ID NO: 2092.

[0036] In some further embodiments, the polypeptide sequence of the engineered sucrose synthase is 34, 34 / 62, 34 / 62 / 65 / 640, 34 / 62 / 323, 34 / 63 / 65 / 323 / 528 / 640, 34 / 63 / 65 / 406 / 528 / 640 / 713, 34 / 63 / 323 / 526 / 528 / 640, 34 / 63 / 406 / 528 / 640 / 731, 34 / 65, 34 / 65 / 528 / 640, 34 / 323 / 406 / 640, 34 / 323 / 640, 34 / 640, 38 / 640, 62 / 63, 62 / 63 / 65 / 528 / 640, 62 / 63 / 69 / 323 / 406 / 640, 62 / 63 / 526 / 640 / 731, 62 / 323 / 640, 63 / 6 5 / 323 / 406 / 526 / 528 / 640 / 731, 63 / 65 / 406 / 731, 63 / 65 / 528 / 640 / 731, 63 / 65 / 640, 63 / 323 / 406 / 640, 63 / 406, 63 / 406 / 640, 63 / 526 / 528 / 640 / 731, 63 / 731, 323 / 406 / 640, 323 / 406 / 64 and at least one mutation or set of mutations at one or more positions selected from 0 / 731, 323 / 526 / 528 / 640, 323 / 526 / 640, 323 / 640 / 731, 406 / 640, 526 / 528 / 640 / 731, and 731, where these positions are numbered with reference to SEQ ID NO: 2182.In some additional embodiments, the engineered sucrose synthase polypeptide sequence is 34E, 34E / 62I, 34E / 62I / 65C / 640R, 34E / 62I / 323G, 34E / 63S / 65C / 406G / 528D / 640R / 713V, 34E / 63S / 323G / 526T / 528D / 640R, 34E / 63S / 406G / 528D / 640N / 731Q, 34E / 63T / 65C ...323G, 34E / 63S / 65C / 323G, 34E / 63S / 65C / 323G, 34E / 63S / 65C / 323G, 34E / 63S / 65C / 323G, 34E / 63S / 65C / 323G, 34E / 63S / 65C / 323G, 34E / 63S / 65C / 323G, 34E / 63S / 65C / 323G, 34E / 63S / 65C / 323G, 34E / 63S / 65C / 323G, 34E / 63S / 65C / 323G, 34E / 63S / 65C / 23G / 528D / 640R, 34E / 65C, 34E / 65C / 528D / 640R, 34E / 323G / 406G / 640A, 34E / 323G / 640A, 34E / 640A, 34E / 640R, 38H / 640R, 62I / 63S / 65C / 528D / 640A, 62I / 63S / 526T / 640R / 731Q, 62I / 63T, 62I / 63T / 69F / 323G / 406G / 640R, 62 I / 323G / 640R, 63S / 65C / 640R, 63S / 323G / 406G / 640A, 63S / 406G, 63S / 526T / 528D / 640R / 731Q, 63S / 731Q, 63T / 6 5C / 323G / 406G / 526T / 528D / 640N / 731Q, 63T / 65C / 406G / 731Q, 63T / 65C / 528D / 640A / 731Q, 63T / 406G / 640A, 323 and at least one mutation or set of mutations selected from G / 406G / 640N, 323G / 406G / 640R / 731Q, 323G / 526T / 528D / 640R, 323G / 526T / 640R, 323G / 640A / 731Q, 406G / 640R, 526T / 528D / 640A / 731Q, and 731Q, where these positions are numbered with reference to SEQ ID NO: 2182.In some additional embodiments, the engineered sucrose synthase polypeptide sequence is T34E, T34E / V62I, T34E / V62I / T65C / T640R, T34E / V62I / A323G, T34E / A63S / T65C / N406G / E528D / T640R / A713V, T34E / A63S / A323G / H526T / E528D / T640R, T34E / A63S / N406G / E528D / T640N / D731Q, T34E / A63T / T65C / A3 23G / E528D / T640R, T34E / T65C, T34E / T65C / E528D / T640R, T34E / A323G / N406G / T640A, T34E / A323G / T640A, T34E / T640A, T34E / T640 R, R38H / T640R, V62I / A63S / T65C / E528D / T640A, V62I / A63S / H526T / T640R / D731Q, V62I / A63T, V62I / A63T / I69F / A323G / N406G / T64 0R, V62I / A323G / T640R, A63S / T65C / T640R, A63S / A323G / N406G / T640A, A63S / N406G, A63S / H526T / E528D / T640R / D731Q, A63S / D731 Q, A63T / T65C / A323G / N406G / H526T / E528D / T640N / D731Q, A63T / T65C / N406G / D731Q, A63T / T65C / E528D / T640A / D731Q, A63T / N406G / T640A, A323G / N406G / T640N, A323G / N406G / T640R / D731Q, A323G / H526T / E528D / T640R, A323G / H526T / T640R, A323G / T640A / D731Q, N406G / T640R, H526T / E528D / T640A / D731Q, and D731Q, wherein these positions are numbered with reference to SEQ ID NO: 2182.In some further embodiments, the polypeptide sequence of the engineered sucrose synthase comprises at least one mutation or set of mutations at one or more positions selected from 28, 30, 30 / 158, 37, 59, 102, 108, 158, 164, 183, 191, 206, 235, 307, 311, 409, 419, 533, 543, 546, 559, 683, 710, 752 and 793, which positions are numbered relative to SEQ ID NO: 2182. In some additional embodiments, the polypeptide sequence of the engineered sucrose synthase is 28H, 30A, 30H / 158H, 30M, 30Q, 37L, 37M, 59T, 102N, 102T, 108R, 158A, 158K, 164G, 164Q, 164S, 164T, 183P, 191L, 206I, 235A, 307E, 307H, 311L, 31 1S, 409S, 419L, 419V, 533K, 533R, 543A, 546N, 546Q, 546T, 559R, 683L, 683V, 710A, 710G, 710S, 710V, 752R, and 793G, wherein these positions are numbered with reference to SEQ ID NO: 2182. In some additional embodiments, the polypeptide sequence of the engineered sucrose synthase is R28H, S30A, S30H / R158H, S30M, S30Q, Q37L, Q37M, A59T, S102N, S102T, Q108R, R158A, R158K, A164G, A164Q, A164S, A164T, N183P, T191L, L206I, V235A, N307E, N307H, Q311L , Q311S, A409S, T419L, T419V, L533K, L533R, G543A, P546N, P546Q, P546T, K559R, R683L, R683V, E710A, E710G, E710S, E710V, T752R, and E793G, wherein these positions are numbered with reference to SEQ ID NO: 2182.In some further embodiments, the polypeptide sequence of the engineered sucrose synthase comprises at least one mutation or set of mutations at one or more positions selected from 34 / 62, 34 / 65, 34 / 323 / 640, 34 / 640, 38 / 640, and 63 / 65 / 406 / 731, where these positions are numbered with reference to SEQ ID NO: 2182. In some additional embodiments, the polypeptide sequence of the engineered sucrose synthase comprises at least one mutation or set of mutations selected from 34E / 62I, 34E / 65C, 34E / 323G / 640A, 34E / 640A, 38H / 640R, and 63T / 65C / 406G / 731Q, where these positions are numbered with reference to SEQ ID NO: 2182. In some additional embodiments, the polypeptide sequence of the engineered sucrose synthase comprises at least one mutation or set of mutations selected from T34E / V62I, T34E / T65C, T34E / A323G / T640A, T34E / T640A, R38H / T640R, and A63T / T65C / N406G / D731Q, wherein these positions are numbered with reference to SEQ ID NO: 2182.

[0037] In still some further embodiments, the polypeptide sequence of the engineered sucrose synthase is 34 / 65 / 323 / 406 / 411 / 565, 34 / 323 / 406 / 411 / 565, 34 / 323 / 406 / 565 / 731, 62 / 65 / 323 / 406 / 565, 62 / 65 / 323 / 406 / 565 / 731, 62 / 65 / 323 / 411 / 565, 62 / 65 / 406 / 411 / 565 / 731, 62 / 323 / 406 / 411 , 62 / 323 / 406 / 411 / 565, 62 / 323 / 411 / 565, 63 / 65 / 323 / 406 / 565 / 731, 63 / 65 / 406 / 411 / 565, 65 / 323 / 406 / 565, 323 / 406 / 411 / 565, 323 / 411 / 565, and 636, where these positions are numbered with reference to SEQ ID NO:2322. In some additional embodiments, the engineered sucrose synthase polypeptide sequence is 34E / 65C / 323G / 406G / 411I / 565V, 34E / 323G / 406G / 411I / 565V, 34E / 323G / 406G / 565V / 731Q, 62I / 65C / 323G / 406G / 565V, 62I / 65C / 323G / 406G / 565V / 731Q, 62I / 65C / 323G / 411I / 565V, 62I / 65C / 406G / 411I / 565V, 62I / 65C / 406G / 411I / 565V / 731Q, 62I / 323G / 406G / 4 and at least one mutation or set of mutations selected from 11I, 62I / 323G / 406G / 411I / 565V, 62I / 323G / 411I / 565V, 63T / 65C / 323G / 406G / 565V / 731Q, 63T / 65C / 406G / 411I / 565V, 65C / 323G / 406G / 565V, 323G / 406G / 411I / 565V, 323G / 411I / 565V, 636A, 636H, and 636N, wherein these positions are numbered with reference to SEQ ID NO: 2322.In some additional embodiments, the engineered sucrose synthase polypeptide sequence is T34E / T65C / A323G / N406G / L411I / M565V, T34E / A323G / N406G / L411I / M565V, T34E / A323G / N406G / M565V / D731Q, V62I / T65C / A323G / N406G / M565V, V62I / T65C / A323G / N406G / M565V / D731Q, V62I / T65C / A323G / L411I / M565V, V62I / T65C / N406G / L411I / M565V / D731Q, V62I / A323G / N406 and at least one mutation or set of mutations selected from G / L411I, V62I / A323G / N406G / L411I / M565V, V62I / A323G / L411I / M565V, A63T / T65C / A323G / N406G / M565V / D731Q, A63T / T65C / N406G / L411I / M565V, T65C / A323G / N406G / M565V, A323G / N406G / L411I / M565V, A323G / N406G / L411I / M565V, Q636A, Q636H, and Q636N, wherein these positions are numbered with reference to SEQ ID NO: 2322. In some further embodiments, the polypeptide sequence of the engineered sucrose synthase comprises at least one mutation or set of mutations at one or more positions selected from 34 / 65 / 323 / 406 / 411 / 565, 34 / 323 / 406 / 411 / 565, 62 / 65 / 323 / 406 / 565, 62 / 65 / 406 / 411 / 565 / 636 / 731, 62 / 65 / 406 / 411 / 565 / 731, 62 / 323 / 406 / 411, 62 / 323 / 406 / 411 / 565, and 62 / 323 / 411 / 565, wherein these positions are numbered with reference to SEQ ID NO:2322.In some additional embodiments, the polypeptide sequence of the engineered sucrose synthase comprises at least one mutation or set of mutations selected from 34E / 65C / 323G / 406G / 411I / 565V, 34E / 323G / 406G / 411I / 565V, 62I / 65C / 323G / 406G / 565V, 62I / 65C / 406G / 411I / 565V / 636H / 731Q, 62I / 65C / 406G / 411I / 565V / 731Q, 62I / 323G / 406G / 411I, 62I / 323G / 406G / 411I / 565V, and 62I / 323G / 411I / 565V, wherein these positions are numbered with reference to SEQ ID NO: 2322. In some additional embodiments, the engineered sucrose synthase polypeptide sequence is T34E / T65C / A323G / N406G / L411I / M565V, T34E / A323G / N406G / L411I / M565V, V62I / T65C / A323G / N406G / M565V, V62I / T65C / N406G / L411I / M565V / Q636H / D731Q, V6 and V62I / A323G / N406G / L411I / M565V, and V62I / A323G / L411I / M565V, wherein these positions are numbered with reference to SEQ ID NO: 2322.

[0038] The present invention also provides engineered polynucleotides encoding at least one engineered sucrose synthase polypeptide provided herein. The present invention further provides vectors comprising at least one engineered polynucleotide encoding at least one engineered sucrose synthase provided herein. In some embodiments, the vector further comprises at least one regulatory sequence. The present invention also provides host cells comprising at least one engineered polynucleotide encoding at least one sucrose synthase. In some embodiments, the host cell comprises at least one vector comprising at least one polynucleotide encoding at least one sucrose synthase. In some embodiments, the host cell is selected from eukaryotes and prokaryotes. The present invention also provides methods for producing at least one engineered sucrose synthase variant provided herein, the method comprising culturing a host cell provided herein under conditions such that the engineered sucrose synthase variant is produced by the host cell. In some embodiments, the method further comprises recovering the engineered sucrose synthase variant. The present invention also provides compositions comprising at least one engineered sucrose synthase variant provided herein.

[0039] The present invention also provides methods for glycosylation of a substrate, the methods comprising providing at least one substrate, at least one engineered glycosyltransferase provided herein, and contacting the substrate with the glycosyltransferase under conditions such that the substrate is glycosylated to produce at least one glycosylated product. In some embodiments, the substrate comprises at least one steviol glycoside. In some additional embodiments, the glycosylated product comprises at least one mono- and / or poly-glycosylated product.

[0040] The present invention also provides methods for producing rebaudioside M, the method including providing rebaudioside D and / or rebaudioside I substrates, NDP-glucose, and at least one engineered glycosyltransferase provided herein, combining the rebaudioside D and rebaudioside I substrates, NDP-glucose, and glycosyltransferase under conditions such that rebaudioside M is produced.

[0041] The present invention also provides methods for producing rebaudioside A and / or rebaudioside I, the method including providing a stevioside substrate, NDP-glucose, and at least one engineered glycosyltransferase provided herein, combining the stevioside substrate, NDP-glucose, and glycosyltransferase under conditions such that rebaudioside A and / or rebaudioside I is produced.

[0042] The present invention also provides a method for producing rebaudioside D, the method including providing a stevioside substrate, NDP-glucose, and at least one engineered glycosyltransferase provided herein, combining the stevioside substrate, NDP-glucose, and glycosyltransferase under conditions such that rebaudioside D is produced.

[0043] In some embodiments of the methods provided herein, the NDP-glucose is selected from ADP-glucose, CDP-glucose, TDP-glucose, GDP-glucose, and / or IDT-glucose. In some further embodiments, the NDP-glucose is not UDP-glucose.

[0044] The present invention also provides methods for producing rebaudioside M, the method including providing a rebaudioside D and / or rebaudioside I substrate, ADP-glucose, and at least one engineered glycosyltransferase provided herein, combining the rebaudioside D and / or rebaudioside I substrate, ADP-glucose, and glycosyltransferase under conditions such that rebaudioside M is produced.

[0045] The present invention also provides methods for producing rebaudioside A and / or rebaudioside I, the method including providing a stevioside substrate, ADP-glucose, and at least one engineered ADP-glycosyltransferase provided herein, combining the stevioside substrate, ADP-glucose, and glycosyltransferase under conditions such that rebaudioside A and / or rebaudioside I is produced.

[0046] The present invention also provides a method for producing rebaudioside D, the method including providing a stevioside substrate, ADP-glucose, and at least one engineered glycosyltransferase provided herein, combining the stevioside substrate, ADP-glucose, and glycosyltransferase under conditions such that rebaudioside D is produced.

[0047] The present invention also provides methods for producing rebaudioside M, the method including providing a rebaudioside D and / or rebaudioside I substrate, NDP, sucrose, sucrose synthase, and at least one engineered glycosyltransferase provided herein, combining the rebaudioside D substrate, NDP, sucrose, sucrose synthase, and glycosyltransferase under conditions such that rebaudioside M is produced.

[0048] The present invention also provides methods for producing rebaudioside A and / or rebaudioside I, the method including providing a stevioside substrate, NDP, sucrose, sucrose synthase, and at least one engineered glycosyltransferase provided herein, combining the stevioside substrate, NDP, sucrose, sucrose synthase, and glycosyltransferase under conditions such that rebaudioside A and / or rebaudioside I is produced.

[0049] The present invention also provides a method for producing rebaudioside D, the method including providing a stevioside substrate, NDP, sucrose, sucrose synthase, and at least one engineered glycosyltransferase provided herein, combining the stevioside substrate, NDP, sucrose, sucrose synthase, and glycosyltransferase under conditions such that rebaudioside D is produced.

[0050] The present invention also provides methods for producing rebaudioside M, the method comprising providing a stevioside substrate comprising at least one stevioside and / or a mixture of stevioside and rebA, NDP, sucrose, sucrose synthase, and at least one engineered glycosyltransferase provided herein, and combining the stevioside substrate, NDP, sucrose, sucrose synthase, and glycosyltransferase under conditions such that rebaudioside M is produced.

[0051] The present invention also provides a method for producing rebaudioside M, the method including the steps of providing a stevioside substrate, an NDP, sucrose, at least one sucrose synthase, and at least one engineered glycosyltransferase provided herein, combining the stevioside substrate, the NDP, and the glycosyltransferase under conditions such that rebaudioside A is produced first, followed by rebaudioside D and / or rebaudioside I, and finally by rebaudioside M.

[0052] In some embodiments of the methods provided herein, the sucrose synthase is an engineered sucrose synthase provided herein. In some further embodiments of the methods provided herein, the method is performed as a one-pot reaction. In some alternative embodiments, the method is performed sequentially. In yet some additional embodiments, the method further comprises repeating the steps of the method. In some further embodiments, sucrose is recycled throughout the repeated steps. In some additional embodiments, the engineered glycosyltransferase and / or other reaction components are recycled. In yet some further embodiments, the stevioside substrate is extracted from Stevia rebaudiana. In some additional embodiments, the stevioside substrate is synthetically produced. In yet some further embodiments, the glycosyltransferase and / or sucrose synthase is immobilized. In some further embodiments, the method produces a reaction product comprising fructose. In yet some further embodiments, fructose is removed from the reaction product. In some embodiments, the method further comprises a washing step. In some additional embodiments, the method further comprises at least one column chromatography step. In yet some additional embodiments of the method, the at least one engineered glycosyltransferase is a beta-1,2-glycosyltransferase selected from the glycosyltransferases provided herein. In some additional embodiments of the method, the at least one engineered glycosyltransferase is a beta-1,3-glycosyltransferase selected from the glycosyltransferases provided herein. In some embodiments of the method, the at least one engineered glycosyltransferase is a beta-1,2-glycosyltransferase selected from the glycosyltransferases provided herein, further comprising a beta-1,3-glycosyltransferase selected from the glycosyltransferases provided herein. In some embodiments, the method further comprises at least one engineered sucrose synthase provided herein.

[0053] The present invention also provides at least one rebaudioside produced according to the methods provided herein. The present invention also provides compositions comprising a rebaudioside produced according to the methods provided herein. In some embodiments, rebaudioside M is produced according to the methods provided herein. The present invention also provides compositions comprising rebaudioside M produced according to the methods provided herein.

[0054] In some embodiments, rebaudioside A is produced according to the methods provided herein. The present invention also provides compositions comprising rebaudioside A produced according to the methods provided herein. In some embodiments, rebaudioside I is produced according to the methods provided herein. The present invention also provides compositions comprising rebaudioside I produced according to the methods provided herein. In some embodiments, rebaudioside D is produced according to the methods provided herein. The present invention also provides compositions comprising rebaudioside D produced according to the methods provided herein. In some embodiments, a mixture of rebaudiosides is produced according to the methods provided herein. The present invention also provides compositions comprising a mixture of rebaudiosides produced according to the methods provided herein. In some embodiments, the mixture comprises at least two compositions comprising at least one rebaudioside produced according to the methods provided herein. The present invention provides compositions comprising a mixture of at least two rebaudiosides provided herein. [Brief explanation of the drawings]

[0055] [Figure 1]1 provides an enzymatic reaction scheme in which a glycosyltransferase catalyzes the transfer of a glucosyl group from a nucleoside diphosphoglucose (NDP-glucose), e.g., ADP-glucose, to an acceptor, e.g., R—OH, where R is any glycosyl, alkoxy, carboxy, aminocarbonyl, heteroalkyl, heteroalkenyl, heteroalkynyl, carboxyalkyl, aminoalkyl, haloalkyl, alkylthioalkyl, heterocycloalkyl, heteroaryl, or heteroarylalkyl group. In a further embodiment, R—OH is stevioside or rebaudioside D, and the product is rebaudioside A, rebaudioside I, or rebaudioside M. A nucleoside diphosphate-dependent synthase catalyzes the transfer of a glucosyl group from a glucose donor (e.g., sucrose) to a nucleoside diphosphate, regenerating NDP-glucose and releasing a byproduct (e.g., fructose).

[0056] [Figure 2] FIG. 2 provides the structure of rebaudioside M with carbon numbering.

[0057] [Figure 3] FIG. 3 provides the structure of rebaudioside I with the carbons numbered. DETAILED DESCRIPTION OF THE INVENTION

[0058] The present invention provides engineered glycosyltransferase (GT) enzymes, polypeptides having GT activity, and polynucleotides encoding these enzymes, as well as vectors and host cells comprising these polynucleotides and polypeptides. The present invention provides engineered sucrose synthase (SuS) enzymes, polypeptides having SuS activity, and polynucleotides encoding these enzymes, as well as vectors and host cells comprising these polynucleotides and polypeptides. The present invention further provides compositions comprising GT enzymes and methods of using engineered GT enzymes to generate products with β-glucose linkages. The present invention further provides compositions and methods for producing rebaudiosides (e.g., rebaudioside M, rebaudioside A, rebaudioside I, and rebaudioside D). The present invention also provides compositions comprising SuS enzymes and methods of using them. Methods for producing GT and SuS enzymes are also provided.

[0059] Unless otherwise defined, all technical and scientific terms used herein generally have the same meaning as commonly understood by those skilled in the art to which this invention belongs. Generally, the nomenclature used herein and the laboratory procedures of cell culture, molecular genetics, microbiology, organic chemistry, analytical chemistry, and nucleic acid chemistry described below are well known and commonly employed in the art. Such techniques are well known and described in numerous textbooks and references well known to those skilled in the art. Standard techniques, or modifications thereof, are used for chemical synthesis and chemical analysis. All patents, patent applications, articles, and publications mentioned herein, both above and below, are hereby expressly incorporated by reference.

[0060] Although any suitable methods and materials similar or equivalent to those described herein can be used in practicing the present invention, some methods and materials are described herein. It should be understood that the present invention is not limited to the specific methodologies, protocols, and reagents described, as these may vary depending on the context in which they are used by those skilled in the art. Accordingly, the terms defined immediately below are more fully described by referring to the present invention as a whole.

[0061] It is to be understood that both the foregoing general description and the following detailed description are exemplary and explanatory only and are not restrictive of the present invention. The section headings used herein are for organizational purposes only and should not be construed as limiting the subject matter described. Numerical ranges are inclusive of the numbers defining the range. Accordingly, every numerical range disclosed herein is intended to include every narrower numerical range that falls within such broader numerical range, as if such narrower numerical ranges were all expressly written herein. Every maximum (or minimum) numerical limit disclosed herein is also intended to include every lower (upper) numerical limit, as if such lower (upper) numerical limit were expressly written herein.

[0062] Abbreviations and Definitions Abbreviations used for genetically encoded amino acids are conventional and are as follows: alanine (Ala or A), arginine (Are or R), asparagine (Asn or N), aspartic acid (Asp or D), cysteine ​​(Cys or C), glutamic acid (Glu or E), glutamine (Gln or Q), histidine (His or H), isoleucine (Ile or I), leucine (Leu or L), lysine (Lys or K), methionine (Met or M), phenylalanine (Phe or F), proline (Pro or P), serine (Ser or S), threonine (Thr or T), tryptophan (Trp or W), tyrosine (Tyr or Y), and valine (Val or V). When three-letter abbreviations are used, the amino acid may be in the L- or D-configuration about the alpha carbon (Cα), unless specifically preceded by "L" or "D" or otherwise clear from the context in which the abbreviation is used. For example, "Ala" refers to alanine with no configuration specified about the alpha carbon, while "D-Ala" and "L-Ala" refer to D-alanine and L-alanine, respectively. When one-letter abbreviations are used, uppercase letters refer to amino acids in the L-configuration about the alpha carbon, and lowercase letters refer to amino acids in the D-configuration about the alpha carbon. For example, "A" refers to L-alanine and "a" refers to D-alanine. When a polypeptide sequence is presented as a series of one-letter or three-letter abbreviations (or mixtures thereof), the sequence is presented in the amino (N) to carboxy (C) direction, according to common convention.

[0063] The abbreviations used for genetically encoded nucleosides are conventional and are as follows: adenosine (A), guanosine (G), cytidine (C), thymidine (T), and uridine (U). Unless otherwise specified, the abbreviated nucleosides may be ribonucleosides or 2'-deoxyribonucleosides. Nucleosides may be designated individually or collectively as either ribonucleosides or 2'-deoxyribonucleosides. When a nucleic acid sequence is presented as a series of one-letter abbreviations, the sequence is presented in the 5' to 3' direction, according to common convention, and the phosphate is not indicated.

[0064] With respect to the present invention, technical and scientific terms used in the description herein shall have the meanings commonly understood by those skilled in the art unless otherwise defined. Accordingly, the following terms are intended to have the following meanings:

[0065] As used herein, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise. Thus, for example, "a polypeptide" includes more than one polypeptide.

[0066] Similarly, the terms "comprise," "comprises," "comprising," "include," "includes," and "including" are interchangeable and are not intended to be limiting. Accordingly, as used herein, the term "comprising" and its cognates are used in their inclusive sense (i.e., equivalent to the term "including" and its corresponding cognates).

[0067] Those skilled in the art will understand that where the description of various embodiments uses the term "comprising," in some specific instances, the embodiments may instead be described using the words "consisting essentially of" or "consisting of."

[0068] As used herein, the term "about" refers to an acceptable error for a particular value. In some cases, "about" refers to within 0.05%, 0.5%, 1.0%, or 2.0% of a given value range. In some cases, "about" refers to within 1 standard deviation, 2 standard deviations, 3 standard deviations, or 4 standard deviations of a given value.

[0069] As used herein, "EC" numbers refer to the Nomenclature Committee of the International Union of Biochemistry and Molecular Biology (NC-IUBMB) enzyme nomenclature. The IUBMB biochemical classification is a numerical classification system for enzymes based on the chemical reactions they catalyze.

[0070] As used herein, "ATCC" refers to the American Type Culture Collection, whose biorepository collection includes genes and strains.

[0071] As used herein, "NCBI" refers to the National Center for Biological Information and the sequence databases provided therein.

[0072] "Protein," "polypeptide," and "peptide" are used interchangeably herein to refer to a polymer of at least two amino acids covalently linked by amide bonds, regardless of length or post-translational modification (e.g., glycosylation or phosphorylation). This definition includes D-amino acids, L-amino acids, mixtures of D- and L-amino acids, polymers comprising D-amino acids, polymers comprising L-amino acids, and polymers comprising mixtures of D- and L-amino acids.

[0073] "Amino acids" are referred to herein by either their commonly known three letter symbols or by the one-letter symbols recommended by the IUPAC-IUB Biochemical Nomenclature Commission. Nucleotides, likewise, may be referred to by their commonly accepted single-letter codes.

[0074] As used herein, "polynucleotide" and "nucleic acid" refer to two or more nucleotides covalently linked together. A polynucleotide can be composed entirely of ribonucleotides (i.e., RNA), entirely of 2' deoxyribonucleotides (i.e., DNA), or a mixture of ribonucleotides and 2' deoxyribonucleotides. Nucleosides are typically linked to each other by standard phosphodiester linkages, although a polynucleotide can also contain one or more non-standard linkages. A polynucleotide can be single-stranded or double-stranded, or can contain both single- and double-stranded regions. Furthermore, a polynucleotide is typically composed of naturally occurring coding nucleobases (i.e., adenine, guanine, uracil, thymine, and cytosine), but can also contain one or more modified and / or synthetic nucleobases, such as inosine, xanthine, hypoxanthine, etc. In some embodiments, such modified or synthetic nucleobases are nucleobases that encode an amino acid sequence.

[0075] As used herein, "nucleoside" refers to a glycosylamine comprising a nucleobase (i.e., a nitrogenous base) and a five-carbon sugar (e.g., ribose or deoxyribose). Non-limiting examples of nucleosides include cytidine, uridine, adenosine, guanosine, thymidine, and inosine. In contrast, the term "nucleotide" refers to a glycosylamine comprising a nucleobase, a five-carbon sugar, and one or more phosphate groups. In some embodiments, a nucleoside can be phosphorylated by a kinase to produce a nucleotide.

[0076] As used herein, "nucleoside diphosphate" refers to a glycosylamine containing a nucleobase (i.e., a nitrogenous base), a five-carbon sugar (e.g., ribose or deoxyribose), and a diphosphate (i.e., pyrophosphate) moiety. In some embodiments herein, "nucleoside diphosphate" is abbreviated as "NDP." Non-limiting examples of nucleoside diphosphates include cytidine diphosphate (CDP), uridine diphosphate (UDP), adenosine diphosphate (ADP), guanosine diphosphate (GDP), thymidine diphosphate (TDP), and inosine diphosphate. The terms "nucleoside" and "nucleotide" may be used interchangeably in some contexts.

[0077] As used herein, "coding sequence" refers to that portion of a nucleic acid (eg, a gene) that codes for the amino acid sequence of a protein.

[0078] As used herein, the terms "biocatalysis," "biocatalysis," "biotransformation," and "biosynthesis" refer to the use of enzymes to carry out chemical reactions on organic compounds.

[0079] As used herein, "glycosyltransferase" (GT) refers to a polypeptide capable of enzymatically transferring glycosyl residues from an activated sugar donor to monomeric and multimeric acceptor molecules. In some embodiments, glycosyltransferases are referred to as "glycosyltransferase variants" or "glycosyltransferase combination variants." In some embodiments, "glycosyltransferase" refers to a UDP-glucuronosyltransferase enzyme in classification EC 2.4.1.17, which catalyzes the transfer of glucose (also known as UDP-glucuronoside) from UDP-α-D-glucuronic acid to an acceptor, releasing UDP to form an acceptor β-D-glucuronoside. The Carbohydrate-Associated Enzymes Database (CAZy) provides a continuously updated list of glycosyltransferase families. In some embodiments, glycosyltransferases include, but are not limited to, enzymes classified as the GT1 family. In some preferred embodiments, the glycosyltransferase variants of the present invention preferentially utilize ADP-glucose. In some additional embodiments, the glycosyltransferase enzymes of the present invention do not utilize UDP-glucose. In some further embodiments, the glycosyltransferase variants of the present invention utilize ADP-glucose, CDP-glucose, TDP-glucose, GDP-glucose, and / or IDT-glucose, but do not utilize UDP-glucose. Thus, in some preferred embodiments, the present invention provides ADP-glucose-dependent glycosyltransferases (ADP-glycosyltransferases; AGT), CDP-glucose-dependent glycosyltransferases (CDP-glycosyltransferases; CGT), GDP-glucose-dependent glycosyltransferases (GDP-glycosyltransferases; GGT), TDP-glucose-dependent glycosyltransferases (TDP-glycosyltransferases; TGT), and IDP-glucose-dependent glycosyltransferases (IDP-glycosyltransferases; IGT).

[0080] As used herein, "NDP-glycosyltransferase" (NDP-GT) refers to a polypeptide that is enzymatically capable of transferring glycosyl residues from an activated sugar donor that is an NDP to monomeric and polymeric acceptor molecules. In some embodiments, NDP-glycosyltransferases are generally referred to as "glycosyltransferases." Indeed, the term "glycosyltransferase" as used herein encompasses NDP-glycosyltransferases, including, but not limited to, ADP-glucose-dependent glycosyltransferase (ADP-glycosyltransferase; AGT), CDP-glucose-dependent glycosyltransferase (CDP-glycosyltransferase; CGT), GDP-glucose-dependent glycosyltransferase (GDP-glycosyltransferase; GGT), TDP-glucose-dependent glycosyltransferase (TDP-glycosyltransferase; TGT), and IDP-glucose-dependent glycosyltransferase (IDP-glycosyltransferase; IGT). In some embodiments, glycosyltransferase enzymes of the invention utilize ADP-glucose, CDP-glucose, TDP-glucose, GDP-glucose, and / or IDT-glucose, but not UDP-glucose. In some additional embodiments, these enzymes are referred to as "variants" or "combination variants" (e.g., ADP-glycosyltransferase variants).

[0081] As used herein, "transglycosylation" refers to a reaction in which a glycosyl residue is transferred from a di-, tri-, or oligosaccharide donor to an unglycosylated or glycosylated donor molecule.

[0082] As used herein, "transglucosylation" refers to a transglycosylation reaction in which the transferred glycosyl residue is glucose and the disaccharide, trisaccharide, or oligosaccharide donor contains glucose.

[0083] As used herein, "glycosylation" refers to the formation of a glycosidic bond between a glycosyl residue and an acceptor molecule.

[0084] As used herein, "glycosylation" refers to the formation of a glycosidic bond between a glucose residue and an acceptor molecule.

[0085] As used herein, "glycosyl" refers to an organic group that is a monovalent free radical or substituent structure obtained by removal of the hemiacetal hydroxyl group from a cyclic monosaccharide, lower oligosaccharide, or oligosaccharide derivative. Glycosyl groups react with inorganic acids (e.g., phosphoric acid) to form esters (e.g., glucose 1-phosphate).

[0086] As used herein, "glycoside" refers to a molecule in which a carbohydrate (e.g., a sugar) is linked to another functional group by a glycosidic bond. Glycosides can be hydrolyzed to yield sugar and non-sugar (i.e., aglycone) components.

[0087] As used herein, the term "steviol glycoside" refers to naturally occurring steviol glycosides (e.g., stevioside, steviolmonoside, steviolbioside, rubusoside, dulcoside B, dulcoside A, rebaudioside B, rebaudioside G, rebaudioside C, rebaudioside F, rebaudioside A, rebaudioside I, rebaudioside E, rebaudioside F, rebaudioside I ... Rebaudioside H, rebaudioside L, rebaudioside K, rebaudioside J, rebaudioside M (also called rebaudioside X), rebaudioside D, rebaudioside N, rebaudioside O), and synthetic steviol glycosides (e.g., enzymatically glucosylated steviol glycosides), and combinations thereof. The chemical structures of steviol and its glycosides are provided below (see WO2013 / 176738).

[0088] As used herein, "stevioside substrate" refers to any suitable substance that contains at least one steviol glycoside. [Table A-1] [Table A-2]

[0089] As used herein, "sucrose synthase" refers to a glycosyltransferase enzyme (EC 2.4.1.1.13) that reversibly catalyzes the chemical reaction of NDP-glucose and D-fructose to NDP and sucrose. In some embodiments, the present invention provides variants of Acidithiobacillus caldus sucrose synthase ("AcSuS"). In some embodiments, these enzymes are referred to as "sucrose synthase variants," "SuS," "SUS," "SuS variants," "SUS variants," "sucrose synthase combination variants," or "SuS combination variants," or "SUS combination variants." In some embodiments, these variants preferentially utilize an NDP other than uridine (i.e., ADP-glucose, CDP-glucose, TDP-glucose, GDP-glucose, and / or IDP-glucose are utilized rather than UDP-glucose). In some embodiments, these variants do not utilize UDP-glucose.

[0090] As used herein, the term "one-pot reaction" refers to the production of a desired rebaudioside in a single reaction vessel. In some embodiments, the term is used in reference to the production of rebM from starting materials, including, but not limited to, rebA and / or stevioside, with the intermediate production of other rebaudiosides (e.g., rebD and / or rebI). In some embodiments, the conversion of stevioside to RebA, the conversion of RebA to RebD and / or RebI, and the conversion of RebD and / or RebI to RebM are carried out as a multiple enzyme cascade in a single reaction vessel.

[0091] As used herein, "wild-type" and "naturally occurring" refer to forms found in nature. For example, a wild-type polypeptide or polynucleotide sequence is a sequence present in an organism, which can be isolated from a source in nature and which has not been intentionally modified by human manipulation.

[0092] As used herein, "recombinant," "engineered," and "non-naturally occurring" when used with respect to a cell, nucleic acid, or polypeptide refer to a material that has been modified in a way that does not otherwise occur in nature, or a material that corresponds to the natural or native form of the material. In some embodiments, the cell, nucleic acid, or polypeptide is identical to a naturally occurring cell, nucleic acid, or polypeptide, but is produced or derived from synthetic material and / or by manipulation using recombinant technology. Non-limiting examples include recombinant cells that express genes not found in the native (non-recombinant) form of the cell, or that express native genes that are otherwise expressed at different levels, among others.

[0093] The term "percent (%) sequence identity" is used herein to refer to a comparison between polynucleotides or polypeptides and is determined by comparing two optimally aligned sequences over a comparison window, where the portion of the polynucleotide or polypeptide sequence within the comparison window may contain additions or deletions (i.e., gaps) compared to the reference sequence due to optimal alignment of the two sequences. The percentage can be calculated by determining the number of positions where the same nucleic acid base or amino acid residue appears in both sequences to obtain the number of matched positions, dividing the number of matched positions by the total number of positions in the comparison window, and multiplying the result by 100 to obtain the percentage sequence identity. Alternatively, the percentage can be calculated by determining the number of positions where either the same nucleic acid base or amino acid residue appears in both sequences, or the number of positions where the nucleic acid base or amino acid residue is aligned with a gap, to obtain the number of matched positions, dividing the number of matched positions by the total number of positions in the comparison window, and multiplying the result by 100 to obtain the percentage sequence identity. Those skilled in the art will appreciate that there are many established algorithms available for aligning two sequences. Optimal alignment of sequences for comparison can be performed by any suitable method known in the art, including, but not limited to, the local homology algorithm of Smith and Waterman (Smith and Waterman, Adv. Appl. Math., 2:482

[1981] ), by the homology alignment algorithm of Needleman and Wunsch (Needleman and Wunsch, J. Mol. Biol., 48:443

[1970] ), by the similarity search method of Pearson and Lipman (Pearson and Lipman, Proc. Natl. Acad. Sci. USA 85:2444

[1988] ), by computer implementations of these algorithms (e.g., GAP, BESTFIT, FASTA, and TFASTA in the GCG Wisconsin Software Package), or by visual inspection.Examples of algorithms suitable for determining percent sequence identity and percent sequence similarity include, but are not limited to, the BLAST and BLAST 2.0 algorithms described by Altschul et al. (See Altschul et al., J. Mol. Biol., 215:403-410

[1990] ; and Altschul et al., Nucl. Acids Res., 3389-3402

[1977] , respectively). Software for performing BLAST analyses is publicly available through the website of the National Center for Biotechnology Information. This algorithm involves first identifying high-scoring sequence pairs (HSPs) by identifying short words of length W in a query sequence that match or meet some positive threshold score T when aligned with words of the same length in a database sequence. T is referred to as the neighborhood word score threshold (see Altschul et al., supra). These initial neighborhood word hits act as seeds for initiating searches to find longer HSPs containing them. The word hits are then extended in both directions along each sequence for as far as possible to increase the cumulative alignment score. For nucleotide sequences, the cumulative score is calculated using the parameters M (reward score for a matching residue pair, always >0) and N (penalty score for mismatching residues, always <0). For amino acid sequences, a scoring matrix is ​​used to calculate the cumulative score. Extension of the word hits in each direction is halted when the cumulative alignment score falls by an amount X from its maximum achieved value; when the cumulative score becomes zero or less due to the accumulation of one or more negative-scoring residue alignments; or when the end of either sequence is reached. The BLAST algorithm parameters W, T, and X determine the sensitivity and speed of the alignment.The BLASTN program (for nucleotide sequences) uses as defaults a word length (W) of 11, an expectation (E) of 10, M=5, N=-4, and a comparison of both strands. The BLASTP program for amino acid sequences uses as defaults a word length (W) of 3, an expectation (E) of 10, and the BLOSUM62 scoring matrix (see Henikoff and Henikoff, Proc. Natl. Acad. Sci. USA 89:10915

[1989] ). Exemplary sequence alignments and determination of percent sequence identity can utilize the BESTFIT or GAP programs in the GCG Wisconsin Software package (Accelrys, Madison, WI) using the default parameters provided.

[0094] As used herein, a "reference sequence" refers to a defined sequence used as a basis for sequence and / or activity comparison. A reference sequence can also be a subset of a larger sequence, e.g., a segment of a full-length gene or polypeptide sequence. Generally, a reference sequence is at least 20 nucleotides or amino acid residues long, at least 25 residues long, at least 50 residues long, at least 100 residues long, or the full length of a nucleic acid or polypeptide. Because two polynucleotides or polypeptides can each contain (1) similar sequences (i.e., portions of the complete sequence) between the two sequences and (2) additional sequences that differ between the two sequences, sequence comparison between two (or more) polynucleotides or polypeptides is typically performed by comparing the sequences of the two polynucleotides or polypeptides over a "comparison window" to identify and compare local regions of sequence similarity. In some embodiments, a "reference sequence" can be based on a primary amino acid sequence, in which case the reference sequence can have one or more changes in the primary sequence.

[0095] As used herein, a "comparison window" refers to a conceptual segment of at least about 20 contiguous nucleotide positions or amino acid residues within which a sequence can be compared to a reference sequence of at least 20 contiguous nucleotides or amino acids, and the portion of the sequence within the comparison window may contain 20 percent or less additions or deletions (i.e., gaps) compared to the reference sequence (which contains no additions or deletions) for optimal alignment of the two sequences. The comparison window may be longer than 20 contiguous residues, including windows of 30, 40, 50, 100, or longer, as appropriate.

[0096] As used herein, "corresponding to," "to," and "compared to" when used in the context of the numbering of a given amino acid or polynucleotide sequence refer to the numbering of residues in a specified reference sequence when the given amino acid or polynucleotide sequence is compared to the reference sequence. In other words, the residue numbers or residue positions in a given polymer are indicated relative to the reference sequence, rather than by the actual numbered positions of the residues in the given amino acid or polynucleotide sequence. For example, a given amino acid sequence, such as the amino acid sequence of an engineered glycosyltransferase, can be aligned with a reference sequence by introducing gaps to optimize residue matches between the two sequences. In these cases, despite the presence of gaps, the numbering of residues in a given amino acid or polynucleotide sequence is performed relative to the reference sequence to which it is aligned.

[0097] As used herein, "substantial identity" refers to a polynucleotide or polypeptide sequence that has at least 80 percent sequence identity, at least 85 percent identity, at least 89-95 percent sequence identity, or more usually at least 99 percent sequence identity relative to a reference sequence over a comparison window of at least 20 residue positions, often over a window of at least 30-50 residues, where this sequence identity percentage is calculated by comparing the reference sequence over the comparison window to a sequence that contains deletions or additions totaling 20 percent or less of the reference sequence. In some specific embodiments, as applied to polypeptides, the term "substantial identity" means that two polypeptide sequences, when optimally aligned, e.g., optimally aligned using the programs GAP or BESTFIT with default gap weights, share at least 80 percent sequence identity, preferably at least 89 percent sequence identity, at least 95 percent sequence identity, or even higher sequence identity (e.g., 99 percent sequence identity). In some embodiments, residue positions in the compared sequences that are not identical differ by conservative amino acid substitutions.

[0098] As used herein, "amino acid difference" and "residue difference" refer to the difference in an amino acid residue at a position in a polypeptide sequence compared to the amino acid residue at the corresponding position in a reference sequence. In some cases, the reference sequence has a histidine tag, but the numbering is maintained relative to an equivalent reference sequence without the histidine tag. The position of an amino acid difference is generally referred to herein as "Xn," where n refers to the corresponding position in the reference sequence that the residue difference is based on. For example, "a residue difference at position X93 compared to SEQ ID NO:4" refers to the difference in the amino acid residue at the polypeptide position corresponding to position 93 of SEQ ID NO:4. Thus, if the reference polypeptide of SEQ ID NO:4 has a serine at position 93, then "a residue difference at position X93 compared to SEQ ID NO:4" refers to an amino acid substitution of any residue other than serine at the polypeptide position corresponding to position 93 of SEQ ID NO:4. In most cases herein, a specific amino acid residue difference at a position is designated as "XnY," where "Xn" designates the corresponding position as described above, and "Y" is the single-letter identifier of the amino acid found in the engineered polypeptide (i.e., the residue that differs from that in the reference polypeptide). In some cases (e.g., in the tables presented in the Examples), the present invention also provides specific amino acid differences, designated by the conventional designation "AnB," where A is the single-letter identifier of the residue in the reference sequence, "n" is the number of the residue position in the reference sequence, and B is the single-letter identifier of the residue substitution in the sequence of the engineered polypeptide. In some cases, the polypeptides of the present invention contain one or more amino acid residue differences compared to the reference sequence, as indicated by a list of the specific positions at which the residue difference exists compared to the reference sequence. In some embodiments, when more than one amino acid can be used at a particular residue position in a polypeptide, the various amino acid residues that can be used are separated by a " / " (e.g., X307H / X307P or X307H / P). A slash can also be used to indicate multiple substitutions within a given variant (i.e., more than one substitution is present in a given sequence, e.g., in a combination variant).In some embodiments, the invention includes engineered polypeptide sequences that contain one or more amino acid differences, including conservative or non-conservative amino acid substitutions. In some additional embodiments, the invention provides engineered polypeptide sequences that contain both conservative and non-conservative amino acid substitutions.

[0099] As used herein, " conservative amino acid substitution " refers to the substitution of a residue with a different residue that has a similar side chain, and thus typically includes the substitution of an amino acid in a polypeptide with the amino acid of the same or similar defined class of amino acid.For example, but not limited to, in some embodiments, the amino acid with an aliphatic side chain is substituted with another aliphatic amino acid (for example, alanine, valine, leucine and isoleucine); the amino acid with a hydroxyl side chain is substituted with another amino acid with a hydroxyl side chain (for example, serine and threonine); the amino acid with an aromatic side chain is substituted with another amino acid with an aromatic side chain (for example, phenylalanine, tyrosine, tryptophan and histidine); the amino acid with a basic side chain is substituted with another amino acid with a basic side chain (for example, lysine and arginine); the amino acid with an acidic side chain is substituted with another amino acid with an acidic side chain (for example, aspartic acid or glutamic acid); and / or the hydrophobic or hydrophilic amino acid is substituted with another hydrophobic or hydrophilic amino acid, respectively.

[0100] As used herein, "non-conservative substitution" refers to the substitution of an amino acid in a polypeptide with an amino acid having significantly different side chain properties. Non-conservative substitutions may use amino acids between defined groups rather than within a defined group, and affect (a) the structure of the peptide backbone in the area of ​​substitution (e.g., substitution of glycine with proline), (b) the charge or hydrophobicity, or (c) the bulk of the side chain. By way of example, and not limitation, exemplary non-conservative substitutions may be an acidic amino acid substituted with a basic or aliphatic amino acid; an aromatic amino acid substituted with a small amino acid; and a hydrophilic amino acid substituted with a hydrophobic amino acid.

[0101] As used herein, "deletion" refers to the modification of a polypeptide by the removal of one or more amino acids from a reference polypeptide. Deletions can include the removal of one or more amino acids, two or more amino acids, five or more amino acids, ten or more amino acids, fifteen or more amino acids, or twenty or more amino acids, up to 10% of the total number of amino acids, or up to 20% of the total number of amino acids comprising the reference enzyme, while retaining the enzymatic activity and / or improved properties of the engineered glycosyltransferase enzyme. Deletions can involve internal and / or terminal portions of the polypeptide. In various embodiments, deletions can include contiguous segments or can be discontinuous. Deletions are typically indicated by a "-" in the amino acid sequence.

[0102] As used herein, "insertion" refers to the modification of a polypeptide by the addition of one or more amino acids from a reference polypeptide.The insertion may be in the internal portion of the polypeptide or at the carboxy or amino terminus.As used herein, insertion includes fusion proteins, as known in the art.The insertion may be a continuous segment of amino acids in a naturally occurring polypeptide, or may be separated by one or more amino acids.

[0103] "Functional fragment" and "biologically active fragment" are used interchangeably herein to refer to a polypeptide that has an amino-terminal and / or carboxy-terminal deletion and / or an internal deletion, but where the remaining amino acid sequence is identical to the corresponding positions in the sequence to which it is compared (e.g., a full-length engineered glycosyltransferase of the invention), and which retains substantially all of the activity of the full-length polypeptide.

[0104] As used herein, an "isolated polypeptide" refers to a polypeptide that has been substantially separated from other contaminants that naturally accompany it (e.g., proteins, lipids, and polynucleotides). The term encompasses polypeptides that have been removed or purified from their naturally occurring environment or expression system (e.g., within a host cell or by in vitro synthesis). Recombinant glycosyltransferase polypeptides may be present intracellularly, in cell culture medium, or prepared in various forms, such as a lysate or isolated preparation. Thus, in some embodiments, a recombinant glycosyltransferase polypeptide may be an isolated polypeptide.

[0105] As used herein, "substantially pure polypeptide" or "purified protein" refers to a composition in which the polypeptide species is the predominant species present (i.e., it is more abundant, on a molar or weight basis, than any other individual macromolecular species in the composition); generally, a composition is substantially purified when the target species constitutes at least about 50 percent, by molar or weight percent, of the macromolecular species present. However, in some embodiments, a composition comprising a glycosyltransferase comprises a glycosyltransferase that is less than 50% pure (e.g., about 10%, about 20%, about 30%, about 40%, or about 50%). Generally, a substantially pure glycosyltransferase composition comprises about 60% or more, about 70% or more, about 80% or more, about 90% or more, about 95% or more, and about 98% or more, by molar or weight percent, of the total macromolecular species present in the composition. In some embodiments, the target species is purified to essential homogeneity, such that the composition consists essentially of a single macromolecular species (i.e., contaminant species cannot be detected in the composition by conventional detection methods). Solvent species, small molecules (<500 Daltons), and elemental ion species are not considered macromolecular species. In some embodiments, the isolated recombinant glycosyltransferase polypeptide is a substantially pure polypeptide composition.

[0106] As used herein, "improved enzymatic property" refers to at least one improved property of an enzyme. In some embodiments, the present invention provides engineered glycosyltransferase polypeptides that exhibit an improved enzymatic property compared to a reference glycosyltransferase polypeptide and / or a wild-type glycosyltransferase polypeptide and / or another engineered glycosyltransferase polypeptide. Thus, the level of "improvement" can be determined and compared among various glycosyltransferase polypeptides, including wild-type as well as engineered glycosyltransferases. Improved properties include, but are not limited to, properties such as increased protein expression, increased thermal activity, increased thermostability, increased pH activity, increased stability, increased enzymatic activity, increased substrate specificity or affinity, increased specific activity, increased resistance to substrate or end-product inhibition, increased chemical stability, improved chemoselectivity, improved solvent stability, increased tolerance to acidic pH, increased resistance to proteolytic activity (i.e., decreased susceptibility to proteolysis), reduced aggregation, increased solubility, and altered temperature profile. In additional embodiments, the term is used in reference to at least one improved property of a sucrose synthase enzyme. In some embodiments, the present invention provides engineered sucrose synthase polypeptides that exhibit an improvement in any enzymatic property compared to a reference sucrose synthase polypeptide and / or a wild-type sucrose synthase polypeptide and / or another engineered sucrose synthase polypeptide. Thus, the level of "improvement" can be determined and compared among various sucrose synthase polypeptides, including wild-type as well as engineered sucrose synthases.

[0107] As used herein, "increased enzymatic activity" and "enhanced catalytic activity" refer to improved properties of an engineered polypeptide, which may be represented by an increase in specific activity (e.g., product produced / time / weight of protein) or an increase in the percent conversion of substrate to product (e.g., the percent conversion of a starting amount of substrate to product within a specified period of time using a specified amount of enzyme) compared to a reference enzyme. In some embodiments, these terms refer to improved properties of an engineered glycosyltransferase polypeptide provided herein, which may be represented by an increase in specific activity (e.g., product produced / time / weight of protein) or an increase in the percent conversion of substrate to product (e.g., the percent conversion of a starting amount of substrate to product within a specified period of time using a specified amount of glycosyltransferase) compared to a reference glycosyltransferase enzyme. In some embodiments, these terms are used in reference to the improved sucrose synthase enzymes provided herein. Exemplary methods for determining the enzymatic activity of engineered glycosyltransferases and sucrose synthases of the invention are provided in the Examples. m , V max or k cat Any property related to enzyme activity can be affected, including classical enzyme properties (these changes can lead to increased enzyme activity). For example, improved enzyme activity can be from about 1.1-fold the enzyme activity of the corresponding wild-type enzyme to as much as 2-fold, 5-fold, 10-fold, 20-fold, 25-fold, 50-fold, 75-fold, 100-fold, 150-fold, 200-fold or more higher enzyme activity than the naturally occurring glycosyltransferase or another engineered glycosyltransferase from which the glycosyltransferase polypeptide is derived.

[0108] As used herein, "conversion" refers to the enzymatic conversion (or biotransformation) of a substrate to a corresponding product. "Percent conversion" refers to the percent of a substrate that is converted to a product under specified conditions within a period of time. Thus, the "enzyme activity" or "activity" of a glycosyltransferase polypeptide can be expressed as the "percent conversion" of a substrate to a product within a particular period of time.

[0109] An enzyme with "generalist properties" (or "generalist enzyme") refers to an enzyme that exhibits improved activity against a wide range of substrates compared to the parent sequence. A generalist enzyme does not necessarily demonstrate improved activity against every possible substrate. In some embodiments, the present invention provides glycosyltransferase variants that have generalist properties because they exhibit similar or improved activity against a wide range of sterically and electronically diverse substrates compared to the parent gene. Additionally, the generalist enzymes provided herein have been engineered to be improved across a wide variety of molecules to increase production of metabolites / products.

[0110] The term "stringent hybridization conditions" is used herein to refer to conditions under which nucleic acid hybrids are stable. As known to those skilled in the art, hybrid stability is determined by the melting temperature (T m ) Generally, hybrid stability is a function of ionic strength, temperature, G / C content, and the presence of chaotropic agents. mValues ​​can be calculated using known methods for predicting melting temperatures (e.g., Baldino et al., Meth. Enzymol., 168:761-777

[1989] ; Bolton et al., Proc. Natl. Acad. Sci. USA 48:1390

[1962] ; Bresslauer et al., Proc. Natl. Acad. Sci. USA 83:8893-8897

[1986] ; Freier et al., Proc. Natl. Acad. Sci. USA 83:9373-9377

[1986] ; Kierzek et al., Biochem., 25:7840-7846

[1986] ; Rychlik et al., Nucl. Acids Res., 18:6409-6412

[1990] (err. Nucl. Acids Res. Res., 19:698 (1991); Sambrook et al., supra; Suggs et al., 1981, in Developmental Biology Using Purified Genes, Brown et al. [eds.], pp. 683-693, Academic Press, Cambridge, MA (1981); and Wetmur, Crit. Rev. Biochem. Mol. Biol. 26:227-259 (1991). In some embodiments, the polynucleotide encodes a polypeptide disclosed herein and hybridizes under defined conditions, such as moderately stringent or highly stringent conditions, to the complement of a sequence encoding an engineered glycosyltransferase enzyme of the invention.

[0111] As used herein, "hybridization stringency" refers to hybridization conditions, such as washing conditions, during nucleic acid hybridization. Generally, hybridization reactions are carried out under conditions of lower stringency, followed by washing with various but higher stringency. The term "moderately stringent hybridization" refers to conditions that allow target DNA to bind to complementary nucleic acids that have about 60% identity with target DNA, preferably about 75% identity, about 85% identity, and about 90% or more identity with target polynucleotide. Exemplary moderately stringent conditions are those that correspond to hybridization in 50% formamide, 5x Denhardt's solution, 5x SSPE, 0.2% SDS at 42°C, followed by washing in 0.2x SSPE, 0.2% SDS at 42°C. "High stringency hybridization" refers to hybridization that achieves a thermal melting temperature, T, determined under solution conditions for a defined polynucleotide sequence. m Generally, high stringency conditions refer to conditions at or below about 10°C. In some embodiments, high stringency conditions refer to conditions that allow hybridization of only nucleic acid sequences that form stable hybrids in 0.018M NaCl at 65°C (i.e., if a hybrid is not stable in 0.018M NaCl at 65°C, it will not be stable under high stringency conditions as contemplated herein). High stringency conditions can be provided, for example, by hybridization under conditions equivalent to 50% formamide, 5x Denhardt's solution, 5x SSPE, 0.2% SDS at 42°C, followed by washing in 0.1x SSPE and 0.1% SDS at 65°C. Another high stringency condition is hybridization under conditions equivalent to hybridization in 5x SSC containing 0.1% (w / v) SDS at 65°C and washing in 0.1x SSC containing 0.1% SDS at 65°C. Other high stringency hybridization conditions, and moderately stringent conditions, are described in the references above.

[0112] As used herein, "codon-optimized" refers to changing the codons of a polynucleotide encoding a protein to those preferentially used in that particular organism, so that the encoded protein is efficiently expressed in that organism. Although the genetic code is degenerate because most amino acids are represented by several codons called "synonymous" or "synonymous" codons, it is well known that the codon usage frequency by a particular organism is not random but is biased toward certain codon triplets. This codon usage bias may be more severe for a given gene, genes of common function or ancestral origin, highly expressed proteins relative to low copy number proteins, and aggregated protein-coding regions of an organism's genome. In some embodiments, a polynucleotide encoding a glycosyltransferase enzyme may be codon-optimized for optimal production in the host organism selected for expression.

[0113] As used herein, "preferred" codons, "optimal" codons, and "high codon usage bias" codons, when used alone or in combination, refer synonymously to codons that are used more frequently in protein-coding regions than other codons that encode the same amino acid. Preferred codons may be determined with respect to codon usage frequency in a single gene, a set of genes of common function or origin, highly expressed genes, codon frequency in aggregate protein-coding regions across organisms, codon frequency in aggregate protein-coding regions of related organisms, or a combination thereof. Codons whose frequency increases with gene expression levels are typically optimal codons for expression. Various methods are known for determining codon frequencies (e.g., codon usage, relative synonymous codon usage) and codon preferences in a particular organism, including multivariate analysis, for example, using cluster analysis or correspondence analysis, as well as for determining the effective number of codons used in a gene (see, e.g., GCG CodonPreference, Genetics Computer Group Wisconsin Package; CodonW, Peden, University of Nottingham; McInerney, Bioinform., 14:372-73

[1998] ; Stenico et al., Nucl. Acids Res., 222437-46

[1994] ; and Wright, Gene 87:23-29

[1990] ).Codon usage tables are available for many different organisms (see, e.g., Wada et al., Nucl. Acids Res., 20:2111-2118

[1992] ; Nakamura et al., Nucl. Acids Res., 28:292

[2000] ; Duret, et al., supra; Henaut and Danchin, in Escherichia coli and Salmonella, Neidhardt, et al. (eds.), ASM Press, Washington DC, pp. 2047-2066

[1996] ). The data source for obtaining codon usage can be based on any available nucleotide sequence capable of encoding a protein. These datasets include nucleic acid sequences that are actually known to encode expressed proteins (e.g., complete protein coding sequences - CDS), to encode expressed sequence tags (ESTS), or to encode predicted coding regions of genomic sequences (see, e.g., Mount, Bioinformatics: Sequence and Genome Analysis, Chapter 8, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY

[2001] ; Uberbacher, Meth. Enzymol., 266:259-281

[1996] ; and Tiwari et al., Comput. Appl. Biosci., 13:263-270

[1997] ).

[0114] As used herein, "control sequences" includes all components necessary or advantageous for expression of polynucleotides and / or polypeptides of the present invention. Each control sequence may be native or foreign to the nucleic acid sequence encoding the polypeptide. Such control sequences include, but are not limited to, a leader, polyadenylation sequence, propeptide sequence, promoter sequence, signal peptide sequence, initiation sequence, and transcription terminator. At a minimum, control sequences include a promoter, and transcriptional and translational stop signals. Control sequences may also be provided with linkers to introduce specific restriction sites facilitating ligation of the control sequences with the coding region of the nucleic acid sequence encoding the polypeptide.

[0115] "Operably linked" is defined herein as a configuration in which the control sequences are positioned relative to the polynucleotide of interest such that the control sequences are suitable (i.e., in a functional relationship) to direct or regulate expression of the polynucleotide and / or polypeptide of interest.

[0116] A "promoter sequence" refers to a nucleic acid sequence, e.g., a coding sequence, that is recognized by a host cell for expression of a polynucleotide of interest. The promoter sequence contains transcriptional control sequences that mediate expression of the polynucleotide of interest. The promoter can be any nucleic acid sequence that exhibits transcriptional activity in the host cell of choice, including mutant, truncated, and hybrid promoters, and can be derived from genes encoding extracellular or intracellular polypeptides either homologous or heterologous to the host cell.

[0117] The phrase "suitable reaction conditions" refers to conditions in an enzymatic conversion reaction solution (e.g., ranges of enzyme loading, substrate loading, temperature, pH, buffers, cosolvents, etc.) under which a glycosyltransferase polypeptide of the invention can convert a substrate into a desired product compound. Some exemplary "suitable reaction conditions" are provided herein.

[0118] As used herein, "loading amount," such as in "compound loading amount" or "enzyme loading amount," refers to the concentration or amount of a component in the reaction mixture at the start of the reaction.

[0119] As used herein, a "substrate," in the context of an enzymatic conversion reaction process, refers to a compound or molecule that is acted upon by an engineered enzyme (e.g., an engineered glycosyltransferase polypeptide) provided herein.

[0120] As used herein, the terms "biomass," "biomass substrate," "cellulosic biomass," "cellulosic feedstock," and "cellulosic substrate" refer to any material that contains cellulose. Biomass can be derived from plants, animals, or microorganisms and can include, but is not limited to, agricultural, industrial, and forestry residues, industrial and municipal waste, and terrestrial and aquatic crops grown for energy purposes. Examples of cellulosic substrates include, but are not limited to, wood, wood pulp, paper pulp, corn fiber, corn kernels, corn cobs, crop residues such as corn husks, corn stover, grasses, wheat, straw, barley, barley straw, hay, rice, rice straw, switchgrass, waste paper, paper processing and pulping waste, woody or herbaceous plants, fruit or vegetable pulp, corn cobs, brewer's grains, grasses, rice husks, cotton, hemp, flax, sisal, sugarcane pomace, sorghum, soybeans, switchgrass; ingredients obtained from grinding grains, trees, branches, roots, leaves, wood chips, sawdust, shrubs, bushes, vegetables, fruits and flowers; and any suitable mixtures thereof. In some embodiments, cellulosic biomass includes, but is not limited to, cultivated crops (e.g., grasses, including C4 grasses such as switchgrass, cordgrass, ryegrass, miscanthus, reed canary grass, or any combination thereof), sugar mill residues, such as, but not limited to, marc (e.g., sugarcane marc, beet pulp [e.g., sugar beet], or combinations thereof), agricultural residues (e.g., soybean stover, corn stover, corn fiber, rice straw, sugarcane straw, rice, rice husks, barley straw, corn cob, wheat straw, canola straw, oat straw, oat husks, corn fiber, hemp, flax, sisal, cotton, or any combinations thereof), fruit pulp, vegetable pulp, brewer's grains, forestry biomass (e.g., wood, wood pulp, paper pulp, recycled wood pulp fiber, sawdust, hardwoods such as poplar, softwoods, or combinations thereof). Additionally, in some embodiments, cellulosic biomass comprises cellulosic and / or forestry waste, including, but not limited to, paper processing and pulp processing waste, newsprint, cardboard, and the like.In some embodiments, the cellulosic biomass comprises one type of fiber, while in some alternative embodiments, the cellulosic biomass comprises a mixture of fibers derived from different cellulosic biomass. In some embodiments, the biomass may also comprise transgenic plants expressing ligninase and / or cellulase enzymes (see, e.g., U.S. Patent Application Publication No. 2008 / 0104724, incorporated herein by reference).

[0121] As used herein, the term "slurry" refers to an aqueous solution in which one or more solid components, such as a cellulosic substrate, are dispersed.

[0122] As used herein, an "increase" in the yield of a product (e.g., steviol glycoside) from a reaction occurs when a particular component (e.g., a GH enzyme) present in the reaction causes more product to be produced compared to a reaction carried out under the same conditions in the absence of the component of interest but with the same substrate and other substituents.

[0123] As used herein, "hydrolysis" of cellulose or other polysaccharides occurs when at least a portion of the glycosidic bonds between two monosaccharides present in the substrate are hydrolyzed, thereby dissociating them from the two previously linked monomers.

[0124] A reaction is "substantially free" of a particular enzyme if the amount of that enzyme is less than about 2%, about 1%, or about 0.1% (wt / wt) relative to the other enzymes involved in catalyzing the reaction.

[0125] As used herein, "fractionating" a liquid (e.g., a culture broth) means applying a separation process (e.g., salting out precipitation, column chromatography, size exclusion, filtration) or a combination of such processes to obtain a solution in which the desired protein (e.g., rebaudioside) comprises a higher percentage of total protein in solution than in the initial liquid product.

[0126] As used herein, "starting composition" refers to any composition comprising at least one substrate. In some embodiments, the starting composition comprises any cellulosic substrate.

[0127] In some alternative embodiments, the term "starting composition" refers to any composition comprising at least one steviol glycoside, where one or more of the steviol glycosides act as a substrate for biotransformation. In some embodiments, the starting composition is provided as an aqueous solution. In some embodiments, the starting composition comprises at least one steviol glycoside selected from stevioside, steviolmonoside, steviolbioside, rubusoside, dulcoside B, dulcoside A, rebaudioside B, rebaudioside G, rebaudioside C, rebaudioside F, rebaudioside A, rebaudioside I, rebaudioside E, rebaudioside H, rebaudioside L, rebaudioside K, rebaudioside J, rebaudioside M (also known as rebaudioside X), rebaudioside D, rebaudioside N, rebaudioside O, and a synthetic steviol glycoside (e.g., an enzymatically glucosylated steviol glycoside). In some embodiments, the starting composition comprises two or more steviol glycosides. In some embodiments, the starting composition is an extract obtained from the purification of Stevia rebaudiana plant material (e.g., leaves). In some alternative embodiments, the starting composition comprises a commercially available stevia extract. Additional starting compositions include by-products of processes used to isolate and purify steviol glycosides. In some embodiments, the starting composition comprises a purified or partially purified steviol glycoside substrate. In some embodiments, the starting composition comprises greater than about 99% by weight of a particular steviol glycoside.

[0128] In some embodiments, the starting composition includes at least one glycoside and a cellulosic component as substrates for producing at least one steviol glycoside (e.g., rebaudioside A, D, etc.).

[0129] As used herein, "product" in the context of an enzymatic conversion process refers to a compound or molecule that results from the action of an enzyme polypeptide on a substrate. As used herein, in some embodiments, the term refers to a compound or molecule that results from the action of a glycosyltransferase polypeptide on a substrate. In some embodiments, the products provided by the present invention are steviol glycosides. In some embodiments, the product comprises at least one steviol glycoside selected from stevioside, steviolmonoside, steviolbioside, rubusoside, dulcoside B, dulcoside A, rebaudioside B, rebaudioside G, rebaudioside C, rebaudioside F, rebaudioside A, rebaudioside I, rebaudioside E, rebaudioside H, rebaudioside L, rebaudioside K, rebaudioside J, rebaudioside M (also called rebaudioside X), rebaudioside D, rebaudioside N, rebaudioside O, and synthetic steviol glycosides (e.g., enzymatically glucosylated steviol glycosides).

[0130] As used herein, the term "culturing" refers to growing a population of microbial cells under any suitable conditions (e.g., using liquid, gel, or solid media).

[0131] Recombinant polypeptides can be produced using any suitable method known in the art. A gene encoding a wild-type polypeptide of interest can be cloned into a vector such as a plasmid and expressed in a desired host, such as E. coli. Variants of recombinant polypeptides can be generated by various methods known in the art. Indeed, there are a wide variety of different mutagenesis techniques known to those of skill in the art. In addition, mutagenesis kits are also available from many commercial molecular biology suppliers. Methods are available for specific substitutions at defined amino acids (site-directed), specific or random mutations in local regions of a gene (position-directed), or random mutagenesis throughout the gene (e.g., saturation mutagenesis). Numerous suitable methods for generating enzyme variants are known to those of skill in the art, including, but not limited to, site-directed mutagenesis of single- or double-stranded DNA using PCR, cassette mutagenesis, gene synthesis, error-prone PCR, shuffling, and chemical saturation mutagenesis, or any other suitable method known in the art. Mutagenesis and directed evolution methods can be readily applied to enzyme-encoding polynucleotides to generate libraries of variants that can be expressed, screened, and assayed. Any suitable mutagenesis and directed evolution method finds use in the present invention and is well known in the art (e.g., U.S. Patents 5,605,793, 5,811,238, 5,830,721, 5,834,252, 5,837,458, 5,928,905, 6,096,548, 6,117,679, 6,132,970, 6,165,793, 6,180,406, 6,251,674, 6,265,201, 6,277,638, 6,287 ,861, 6,287,862, 6,291,242, 6,297,053, 6,303,344, 6,309,883, 6,319,713, 6,319,714, 6,323,030, 6,326,204, 6,335,160, 6,335,198, 6,344,356, 6,352,859, 6,355,484, 6,358,740, 6,358,742, 6,365,377, 6,365,408, 6,368,861, 6,372,497, 6,337,186, 6,376,246, 6,379,964, 6,387,702, 6,391,552, 6,391,640, 6,395,547, 6,406,855, 6,406,910, 6,413,745, 6,413,774, 6,420,175 , 6,423,542, 6,426,224, 6,436,675, 6,444,468, 6,455,253, 6,479,652, 6,482,647, 6,483,011, 6,484,105, 6,489,146, 6,500,617, 6,500,639, 6,5 06,602, 6,506,603, 6,518,065, 6,519,065, 6,521,453, 6,528,311, 6,537,746, 6,573,098, 6,576,467, 6,579,678, 6,586,182, 6,602,986, 6,605, 430, 6,613,514, 6,653,072, 6,686,515, 6,703,240, 6,716,631, 6,825,001, 6,902,922, 6,917,882, 6,946,296, 6,961,664, 6,995,017, 7,024,312, 7,058,515, 7,105,297, 7,148,054, 7,220,566, 7,288,375, 7,384,387, 7,421,347, 7,430,477, 7,462,469, 7,534,564, 7,620,500, 7,620,502, 7,6 29,170, 7,702,464, 7,747,391, 7,747,393, 7,751,986, 7,776,598, 7,783,428, 7,795,030, 7,853,410, 7,868,138, 7,783,428, 7,873,477, 7,873,4 99, 7,904,249, 7,957,912, 7,981,614, 8,014,961, 8,029,988, 8,048,674, 8,058,001, 8,076,138, 8,108,150, 8,170,806, 8,224,580, 8,377,681, 8,383,346, 8,457,903, 8,504,498, 8,589,085, 8,762,066, 8,768,871, 9,593,326, 9,665,694, 9,684,771, and all related U.S. patents, as well as PCT and non-U.S. counterparts; Ling et al.Anal. Biochem., 254(2):157-78

[1997] ;Dale et al., Meth. Mol. Biol., 57:369-74

[1996] ;Smith, Ann. Rev. Genet., 19:423-462

[1985] ;Botstein et al., Science, 229:1193-1201

[1985] ;Carter, Biochem. J., 237:1-7

[1986] ;Kramer et al., Cell, 38:879-887

[1984] ;Wells et al., Gene, 34:315-323

[1985] ;Minshull et al., Curr. Op. Chem. Biol., 3:284-290

[1999] ;Christians et al., Nat. Biotechnol., 17:259-264

[1999] ;Crameri et al., Nature, 391:288-291

[1998] ;Crameri, et al., Nat. Biotechnol., 15:436-438

[1997] ;Zhang et al., Proc. Nat. Acad. Sci. USA, 94:4504-4509

[1997] ;Crameri et al., Nat. Biotechnol., 14:315-319

[1996] ;Stemmer, Nature, 370:389-391

[1994] ;Stemmer, Proc. Nat. Acad. Sci. USA, 91:10747-10751

[1994] ; WO95 / 22625; WO97 / 0078; WO97 / 35966; WO98 / 27230; WO00 / 42651; WO01 / 75767; and WO2009 / 152336, all of which are incorporated herein by reference.

[0132] In some embodiments, the enzyme clones obtained after the mutagenesis treatment are screened by subjecting the enzyme preparation to a predetermined temperature (or other assay conditions) and measuring the amount of enzyme activity remaining after the heat treatment or other suitable assay conditions. Clones containing polynucleotides encoding the polypeptides are then isolated from the gene, sequenced to identify nucleotide sequence changes (if any), and used to express the enzyme in host cells. Measurement of enzyme activity from the expression library can be performed using any suitable method known in the art (e.g., standard biochemical techniques such as HPLC analysis).

[0133] After the variants are produced, they can be screened for any desired properties (e.g., high or increased activity, or low or decreased activity, increased thermal activity, increased thermostability, and / or acidic pH stability, etc.). In some embodiments, "recombinant glycosyltransferase polypeptides" (also referred to herein as "engineered glycosyltransferase polypeptides," "variant glycosyltransferase enzymes," "glycosyltransferase variants," and "glycosyltransferase combination variants") are used. In some embodiments, "recombinant sucrose synthase polypeptides" (also referred to herein as "engineered sucrose synthase polypeptides," "variant sucrose synthase enzymes," "sucrose synthase variants," and "sucrose synthase combination variants") are used.

[0134] As used herein, a "vector" is a DNA construct for introducing a DNA sequence into a cell. In some embodiments, the vector is an expression vector operably linked to a suitable control sequence that can effect the expression of a polypeptide encoded by the DNA sequence in a suitable host. In some embodiments, an "expression vector" has a promoter sequence operably linked to a DNA sequence (e.g., a transgene) to drive expression in a host cell, and in some embodiments, also includes a transcription terminator sequence.

[0135] As used herein, the term "expression" includes any step involved in producing a polypeptide, including, but not limited to, transcription, post-transcriptional modification, translation, and post-translational modification. In some embodiments, the term also encompasses secretion of the polypeptide from the cell.

[0136] As used herein, the term "producing" refers to the production of a protein and / or other compound by a cell. The term is intended to encompass any step involved in producing a polypeptide, including, but not limited to, transcription, post-transcriptional modification, translation, and post-translational modification. In some embodiments, the term also encompasses the secretion of a polypeptide from the cell.

[0137] As used herein, an amino acid or nucleotide sequence (e.g., a promoter sequence, signal peptide, terminator sequence, etc.) is "heterologous" to another sequence to which it is operably linked if the two sequences are not naturally associated. For example, a "heterologous polynucleotide" is any polynucleotide that is introduced into a host cell by laboratory techniques, including polynucleotides that are removed from the host cell, subjected to laboratory manipulation, and then reintroduced into the host cell.

[0138] As used herein, the terms "host cell" and "host strain" refer to a suitable host for an expression vector containing DNA (e.g., a polynucleotide encoding a glycosyltransferase variant) provided herein. In some embodiments, a host cell is a eukaryotic or prokaryotic cell that has been transformed or transfected with a vector constructed using recombinant DNA techniques known in the art.

[0139] The term "analog" refers to a polypeptide having greater than 70% sequence identity but less than 100% sequence identity (e.g., greater than 75%, 78%, 80%, 83%, 85%, 88%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% sequence identity) to a reference polypeptide. In some embodiments, an analog refers to a polypeptide that contains not only naturally occurring amino acids, but also one or more non-naturally occurring amino acids, including, but not limited to, homoarginine, ornithine, and norvaline. In some embodiments, an analog also includes one or more D-amino acid residues and a non-peptide linkage between two or more amino acid residues.

[0140] The term "effective amount" means an amount sufficient to produce a desired result. One of ordinary skill in the art can determine what an effective amount is by using routine experimentation.

[0141] The terms "isolated" and "purified" are used to refer to a molecule (e.g., an isolated nucleic acid, polypeptide, etc.) or other component that has been removed from at least one other component with which it is naturally associated. The term "purified" does not require absolute purity, but rather is intended as a relative definition.

[0142] As used herein, "stereoselectivity" refers to the preferential formation of one stereoisomer over another in a chemical or enzymatic reaction. Stereoselectivity can be partial, where one stereoisomer is preferred over the other, or complete, where only one stereoisomer is formed. When the stereoisomers are enantiomers, the stereoselectivity is referred to as enantioselectivity, which is the fraction (typically reported as a percentage) of one enantiomer in the sum of both enantiomers. This is generally instead reported in the art as enantiomeric excess ("ee") (typically as a percentage), calculated therefrom according to the formula [major enantiomer - minor enantiomer] / [major enantiomer + minor enantiomer]. When the stereoisomers are diastereoisomers, the stereoselectivity is called diastereoselectivity, which is the fraction (typically reported as a percentage) of one diastereomer in a mixture of two diastereomers, and is commonly reported instead as diastereomeric excess ("de"). Enantiomeric excess and diastereomeric excess are types of stereoisomeric excess.

[0143] As used herein, "regioselectivity" and "regioselective reaction" refer to a reaction in which one direction of bond formation or cleavage occurs in preference to all other possible directions. A reaction can be completely (100%) regioselective, where discrimination is complete and substantially regioselective (at least 75%), or partially regioselective (x%, where the percentage is set depending on the reaction of interest), where the product of the reaction at one site predominates over the product of the reaction at the other site.

[0144] As used herein, "thermostable" refers to a glycosyltransferase polypeptide that, after exposure to elevated temperatures (e.g., 40-80°C) for a period of time (e.g., 0.5-24 hours), maintains similar activity (e.g., 60%-80% greater) compared to the wild-type enzyme exposed to the same elevated temperature.

[0145] As used herein, "solvent-stable" refers to a glycosyltransferase polypeptide that, after exposure to various concentrations (e.g., 5-99%) of a solvent (e.g., ethanol, isopropyl alcohol, dimethyl sulfoxide [DMSO], tetrahydrofuran, 2-methyltetrahydrofuran, acetone, toluene, butyl acetate, methyl tert-butyl ether, etc.) for a period of time (e.g., 0.5-24 hours), maintains similar activity (e.g., 60%-80% greater) compared to the wild-type enzyme exposed to the same solvent at the same concentration.

[0146] As used herein, "thermo- and solvent-stable" refers to a glycosyltransferase polypeptide that is both thermostable and solvent-stable.

[0147] As used herein, a "reducing agent" refers to Fe +3 Fe +2 An exemplary reducing agent is ascorbic acid, which is generally in the form of L-ascorbic acid.

[0148] As used herein, "optionally" and "optionally" mean that the subsequently described event or circumstance may or may not occur, and that the description includes instances in which the event or circumstance occurs and instances in which it does not occur. It will be understood by those of skill in the art that with respect to any molecule described as containing one or more optional substituents, only sterically realistic and / or synthetically feasible compounds are intended to be included. "Optionally substituted" refers to all subsequent modifiers in a chemical group or series of chemical groups.

[0149] Glycosylation Glycosylation can alter many properties of natural and synthetic products, including stability, pharmacodynamics, solubility, and membrane transport. The present invention provides compositions, methods, and enzymes suitable for the production of new glycosylated compounds from various aglycones and glycosylated substrates. In some embodiments, the present invention provides a means for efficiently producing known glycosylated compounds from readily available precursors. In some cases, glycosylation is accomplished by chemical synthesis methods. However, these methods generally require undesirable chemicals and processes and can result in mixed products (e.g., with bonds in the wrong position and / or with undesired anomeric configurations). Furthermore, carbohydrate chemistry requires multiple protection and deprotection steps.

[0150] In contrast, glycosylation enzymes can be active under mild conditions and can confer high regioselectivity and stereospecificity in a single step. Many naturally occurring glycosylated metabolites are produced in vivo using glycosyltransferases, which transfer sugar moieties from various sugar nucleosides. Many molecules, including many secondary metabolites with antibacterial, antitumor, and naturally sweet properties, contain nonribosomal peptide, polyketide, or terpenoid backbones modified with β-glycosidic bonds. Many diterpene glycosides extracted from the plant Stevia rebaudiana Bertoni contain β-linked glucose molecules. Naturally, these molecules are glycosylated in vivo using UDP-glucose-dependent glycosyltransferase enzymes. The present invention provides methods (see FIG. 1 ) that use novel engineered glycosyltransferases to transfer a glucose moiety from a nucleoside diphosphoglucose to a substrate (e.g., rebaudioside D or stevioside) to produce one or more β-glucose-linked products (e.g., rebaudioside M, rebaudioside A, or rebaudioside I). However, when used in vitro, UDP-glucose can be prohibitively expensive and / or unavailable. In some additional embodiments, a synthase (e.g., sucrose synthase or trehalose synthase) acts in the reverse direction to form a nucleoside diphosphoglucose compound from a nucleoside diphosphate and a glucose donor (e.g., sucrose, trehalose, or starch).

[0151] Glycosylation is therefore used to produce natural sweeteners, such as those derived from the aromatic herb Stevia rebaudiana Bertoni. As noted above, this plant produces several diterpene glycosides characterized by high-intensity sweetness and sensory properties superior to many other potent sweeteners. The sweet glycosides described above share a common aglycone (i.e., steviol) but differ in the number and type of carbohydrate residues at the C13 and C19 positions. Steviol glycosides differ from each other not only in their molecular structure but also in their taste characteristics. Typically, stevioside is 89 to 143 times sweeter than sucrose, while rebaudioside A has been reported to be between 85 and 242 times sweeter than sucrose (see, e.g., Kasai et al., Nippon Kagaku Kaishi, 1981:726-735

[1981] ). Of these common compounds, rebaudioside A is the least astringent, least bitter, and has the shortest lingering aftertaste. Therefore, rebaudioside A has the most favorable sensory attributes of the major steviol glycosides, and rebaudioside A has been commercialized. However, rebaudioside A constitutes only a small fraction (approximately 20%) of the total glycosides isolated from Stevia rebaudiana Bertoni, with stevioside (approximately 70%) and minor steviol glycosides making up the remainder (e.g., FAO, Chemical and Technical Assessment, 63 rd (See JECFA, Steviol Glycosides

[2004] .) A naturally occurring but even less abundant compound, rebaudioside M, also known as rebaudioside X, is 200-350 times sweeter than sucrose and has a reduced aftertaste compared to rebaudioside A (see, e.g., Prakash et al., Food, 3:162-175

[2014] ). Thus, there is interest in commercializing rebaudioside M, for example, as a natural sweetener, but there is currently no viable commercial synthetic route for this compound.

[0152] Engineered glycosyltransferase polypeptides The present invention provides glycosyltransferase polypeptides, polynucleotides encoding the polypeptides, methods of preparing the polypeptides, and methods of using the polypeptides. It is understood that where a description refers to a polypeptide, the description also describes the polynucleotide encoding the polypeptide. In some embodiments, the present invention provides engineered, non-naturally occurring GT enzymes with improved properties compared to wild-type GT enzymes. Any suitable reaction conditions can be used in the present invention. In some embodiments, methods are used to analyze the improved properties of engineered polypeptides for performing transferase reactions. In some embodiments, the reaction conditions are improved with respect to conditions including the concentration or amount of polypeptide, substrate, cosubstrate, buffer, cosolvent, pH, temperature, and reaction time, and / or conditions associated with the polypeptide immobilized on a solid support, as further described below and in the Examples.

[0153] In some embodiments, the engineered GT polypeptides described herein have improved properties compared to wild-type GT enzymes, e.g., improved properties in terms of conversion of steviol glycosides to further glycosylated steviol glycosides (e.g., stevioside to rebaudioside A or rebaudioside D to rebaudioside M) and in terms of adenine diphosphoglucose or other nucleoside diphosphate usage.

[0154] In some embodiments, additional reaction components or techniques are utilized to supplement the reaction conditions, including taking measures to stabilize or prevent enzyme inactivation, to reduce product inhibition, or to shift the equilibrium of the reaction toward glycosylated product formation.

[0155] In some further embodiments, any of the above processes for converting substrate compounds into product compounds may further comprise one or more steps selected from the following: extraction of the product compound; isolation; purification; and crystallization, filtration, or lyophilization. Methods, techniques, and protocols for extracting, isolating, purifying, and / or crystallizing the glycosylated product from the biocatalytic reaction mixture produced by the above-disclosed process are known to those skilled in the art and / or can be obtained by routine experimentation. In addition, illustrative methods are provided in the following examples.

[0156] Engineered sucrose synthase polypeptides The present invention provides engineered sucrose synthase (SuS) polypeptides, polynucleotides encoding the polypeptides, methods of preparing the polypeptides, and methods of using the polypeptides. It is understood that where a description refers to a polypeptide, the description also describes the polynucleotide encoding the polypeptide. In some embodiments, the present invention provides engineered, non-naturally occurring SuS enzymes with improved properties compared to wild-type SuS enzymes. Any suitable reaction conditions can be used in the present invention. In some embodiments, methods are used to analyze the improved properties of engineered polypeptides for performing synthase reactions. In some embodiments, the reaction conditions are improved with respect to conditions including the concentration or amount of engineered SuS, substrate, buffer, solvent, pH, temperature, and reaction time, and / or conditions involving engineered SuS polypeptides immobilized on a solid support, as further described below and in the Examples.

[0157] In some embodiments, the engineered SuS polypeptides described herein have improved properties compared to wild-type SuS enzymes, for example, improved properties with respect to the reactions described herein.

[0158] In some embodiments, additional reaction components or techniques are utilized to supplement the reaction conditions, including taking measures to stabilize or prevent enzyme inactivation, to reduce product inhibition, or to shift the equilibrium of the reaction toward glycosylated product formation.

[0159] In some further embodiments, any of the above processes for converting substrate compounds to product compounds may further comprise one or more steps selected from extraction, isolation, purification, crystallization, filtration, and / or lyophilization of the product compound. Methods, techniques, and protocols for extracting, isolating, purifying, and / or crystallizing products (e.g., rebaudioside) from biocatalytic reaction mixtures produced by the processes provided herein are known to those of skill in the art and / or obtained by routine experimentation. Additionally, illustrative methods are provided in the Examples below.

[0160] Polynucleotides encoding engineered polypeptides, expression vectors and host cells The present invention provides polynucleotides encoding the engineered enzyme polypeptides described herein. In some embodiments, the polynucleotides are operably linked to one or more heterologous regulatory sequences that control gene expression to produce recombinant polynucleotides capable of expressing the polypeptides. In some embodiments, an expression construct containing at least one heterologous polynucleotide encoding an engineered enzyme polypeptide is introduced into a suitable host cell to express the corresponding enzyme polypeptide.

[0161] As will be apparent to those skilled in the art, the availability of a protein sequence and knowledge of the codons corresponding to various amino acids provides a description of all polynucleotides capable of encoding a subject polypeptide. The degeneracy of the genetic code, in which the same amino acids are coded for by alternative or synonymous codons, makes it possible to generate a vast number of nucleic acids, all of which encode an engineered enzyme (e.g., GT or SuS) polypeptide. Thus, the present invention provides methods and compositions for the production of any and all possible variations of enzyme polynucleotides that can be made to encode the enzyme polypeptides described herein by selecting combinations based on possible codon choices; all such variations are contemplated and specifically disclosed for any polypeptide described herein, including the amino acid sequences presented in the Examples (e.g., in the various Tables).

[0162] In some embodiments, codons are preferably optimized for use by a selected host cell for protein production. For example, preferred codons used in bacteria are typically used for expression in bacteria. Thus, a codon-optimized polynucleotide encoding an engineered enzyme polypeptide contains preferred codons at about 40%, 50%, 60%, 70%, 80%, 90%, or more than 90% of the codon positions in the full-length coding region.

[0163] In some embodiments, the enzyme polynucleotide encodes an engineered polypeptide having the enzymatic activity and properties disclosed herein, wherein the engineered polypeptide has an amino acid sequence that is at least 60%, 65%, 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identity to a reference sequence selected from the SEQ ID NOs provided herein, or the amino acid sequence of any variant (e.g., those provided in the Examples), and includes one or more residue differences (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more amino acid residue positions) compared to the amino acid sequence of the reference polynucleotide or any variant disclosed in the Examples.

[0164] In some embodiments, a polynucleotide can hybridize under highly stringent conditions to a reference polynucleotide sequence selected from any of the polynucleotide sequences provided herein, or its complementary sequence, or to a polynucleotide sequence encoding any of the variant enzyme polypeptides provided herein. In some embodiments, a polynucleotide capable of hybridizing under highly stringent conditions encodes an enzyme polypeptide comprising an amino acid sequence having one or more residue differences compared to the reference sequence.

[0165] In some embodiments, an isolated polynucleotide encoding any of the engineered enzyme polypeptides herein is engineered in various ways to facilitate expression of the enzyme polypeptide. In some embodiments, the polynucleotide encoding the enzyme polypeptide comprises an expression vector in which one or more regulatory sequences are present to regulate expression of the enzyme polynucleotide and / or polypeptide. Manipulation of the isolated polynucleotide prior to its insertion into a vector may be desirable or necessary depending on the expression vector used. Techniques for modifying polynucleotides and nucleic acid sequences using recombinant DNA methods are well known in the art. In some embodiments, regulatory sequences include, among others, promoters, leader sequences, polyadenylation sequences, propeptide sequences, signal peptide sequences, and transcription terminators. In some embodiments, a suitable promoter is selected based on the host cell selection. For bacterial host cells, suitable promoters for directing transcription of the nucleic acid constructs of the present disclosure include, but are not limited to, promoters obtained from the E. coli lac operon, Streptomyces coelicolor agarase gene (dagA), Bacillus subtilis levansucrase gene (sacB), Bacillus licheniformis alpha-amylase gene (amyL), Bacillus stearothermophilus maltogenic amylase gene (amyM), Bacillus amyloliquefaciens alpha-amylase gene (amyQ), Bacillus licheniformis penicillinase gene (penP), Bacillus subtilis xylA and xylB genes, and prokaryotic beta-lactamase genes (e.g., Villa-Kamaroff et al., Proc. Natl. Acad. Sci. USA 75: 3727-3731).

[1978] ), as well as the tac promoter (see, e.g., DeBoer et al., Proc. Natl. Acad. Sci. USA 80: 21-25

[1983] ).Exemplary promoters for filamentous fungal host cells include, but are not limited to, promoters obtained from the genes for Aspergillus oryzae TAKA amylase, Rhizomucor miehei aspartic proteinase, Aspergillus niger neutral alpha-amylase, Aspergillus niger acid-stable alpha-amylase, Aspergillus niger or Aspergillus awamori glucoamylase (glaA), Rhizomucor miehei lipase, Aspergillus oryzae alkaline protease, Aspergillus oryzae triosephosphate isomerase, Aspergillus nidulans acetamidase, and Fusarium oxysporum trypsin-like protease (see, e.g., WO 96 / 00787), as well as the NA2-tpi promoter (a promoter from the gene for Aspergillus niger neutral alpha-amylase and Aspergillus Examples of useful promoters for yeast host cells include promoters from the Saccharomyces cerevisiae enolase (ENO-1), Saccharomyces cerevisiae galactokinase (GAL1), Saccharomyces cerevisiae alcohol dehydrogenase / glyceraldehyde-3-phosphate dehydrogenase (ADH2 / GAP), and Saccharomyces cerevisiae 3-phosphoglycerate kinase genes. Other useful promoters for yeast host cells are known in the art (see, e.g., Romanos et al., Yeast 8:423-488

[1992] ).

[0166] In some embodiments, the control sequence is also a suitable transcription terminator sequence (i.e., a sequence recognized by a host cell to terminate transcription). In some embodiments, the terminator sequence is operably linked to the 3' end of the nucleic acid sequence encoding the enzyme polypeptide. Any suitable terminator that is functional in the host cell of choice finds use in the present invention. Exemplary transcription terminators for filamentous fungal host cells can be obtained from the genes for Aspergillus oryzae TAKA amylase, Aspergillus niger glucoamylase, Aspergillus nidulans anthranilate synthase, Aspergillus niger alpha-glucosidase, and Fusarium oxysporum trypsin-like protease. Exemplary terminators for yeast host cells can be obtained from the genes for Saccharomyces cerevisiae enolase, Saccharomyces cerevisiae cytochrome C (CYC1), and Saccharomyces cerevisiae glyceraldehyde-3-phosphate dehydrogenase. Other useful terminators for yeast host cells are known in the art (see, e.g., Romanos et al., supra).

[0167] In some embodiments, the control sequence is also a suitable leader sequence (i.e., a nontranslated region of an mRNA that is important for translation by the host cell). In some embodiments, the leader sequence is operably linked to the 5' end of the nucleic acid sequence encoding the enzyme polypeptide. Any suitable leader sequence that is functional in the host cell of choice finds use in the present invention. Exemplary leaders for filamentous fungal host cells are obtained from the genes for Aspergillus oryzae TAKA amylase and Aspergillus nidulans triosephosphate isomerase. Suitable leaders for yeast host cells are obtained from the genes for Saccharomyces cerevisiae enolase (ENO-1), Saccharomyces cerevisiae 3-phosphoglycerate kinase, Saccharomyces cerevisiae alpha factor, and Saccharomyces cerevisiae alcohol dehydrogenase / glyceraldehyde-3-phosphate dehydrogenase (ADH2 / GAP).

[0168] In some embodiments, the control sequence is also a polyadenylation sequence (i.e., a sequence operably linked to the 3' end of a nucleic acid sequence which, when transcribed, is recognized by a host cell as a signal for the addition of polyadenosine residues to the transcribed mRNA). Any suitable polyadenylation sequence that is functional in the host cell of choice finds use in the present invention. Exemplary polyadenylation sequences for filamentous fungal host cells include, but are not limited to, the genes for Aspergillus oryzae TAKA amylase, Aspergillus niger glucoamylase, Aspergillus nidulans anthranilate synthase, Fusarium oxysporum trypsin-like protease, and Aspergillus niger alpha-glucosidase. Useful polyadenylation sequences for yeast host cells are known (see, e.g., Guo and Sherman, Mol. Cell. Biol., 15:5983-5990

[1995] ).

[0169] In some embodiments, a control sequence is also a signal peptide (i.e., a coding region that encodes an amino acid sequence linked to the amino terminus of a polypeptide that directs the encoded polypeptide into the secretory pathway of a cell). In some embodiments, the 5' end of the coding sequence of the nucleic acid sequence inherently contains a signal peptide coding region that is naturally linked in translation reading frame with the segment of the coding region that encodes the secreted polypeptide. Alternatively, in some embodiments, the 5' end of the coding sequence contains a signal peptide coding region that is foreign to the coding sequence. Any suitable signal peptide coding region that directs the expressed polypeptide into the secretory pathway of a chosen host cell is used to express the engineered polypeptide. Useful signal peptide coding regions for bacterial host cells include, but are not limited to, those from the genes for Bacillus NCIB 11837 maltogenic amylase, Bacillus stearothermophilus alpha-amylase, Bacillus licheniformis subtilisin, Bacillus licheniformis beta-lactamase, Bacillus stearothermophilus neutral protease (nprT, nprS, nprM), and Bacillus subtilis prsA. Additional signal peptides are known in the art (see, e.g., Simonen and Palva, Microbiol. Rev., 57:109-137

[1993] ). In some embodiments, effective signal peptide coding regions for filamentous fungal host cells include, but are not limited to, signal peptide coding regions obtained from the genes for Aspergillus oryzae TAKA amylase, Aspergillus niger neutral amylase, Aspergillus niger glucoamylase, Rhizomucor miehei aspartic proteinase, Humicola insolens cellulase, and Humicola lanuginosa lipase.Useful signal peptides for yeast host cells include, but are not limited to, those from the genes for Saccharomyces cerevisiae alpha factor and Saccharomyces cerevisiae invertase.

[0170] In some embodiments, the control sequence is also a propeptide-coding region that encodes an amino acid sequence located at the amino terminus of a polypeptide. The resulting polypeptide is referred to as a "proenzyme," "propolypeptide," or "zymogen." A propolypeptide can be converted to a mature, active polypeptide by catalytic or autocatalytic cleavage of the propeptide from the propolypeptide. The propeptide-coding region can be obtained from any suitable source, including, but not limited to, the genes for Bacillus subtilis alkaline protease (aprE), Bacillus subtilis neutral protease (nprT), Saccharomyces cerevisiae alpha-factor, Rhizomucor miehei aspartic proteinase, and Myceliophthora thermophila lactase (see, e.g., WO 95 / 33836). When both a signal peptide region and a propeptide region are present at the amino terminus of a polypeptide, the propeptide region is located adjacent to the amino terminus of the polypeptide, and the signal peptide region is located adjacent to the amino terminus of the propeptide region.

[0171] In some embodiments, regulatory sequences are also utilized. These sequences facilitate regulation of polypeptide expression relative to the growth of the host cell. Examples of regulatory systems are those that turn gene expression on or off in response to chemical or physical stimuli, including the presence of a regulatory compound. In prokaryotic host cells, suitable regulatory sequences include, but are not limited to, the lac, tac, and trp operator systems. In yeast host cells, suitable regulatory sequences include, but are not limited to, the ADH2 system or the GAL1 system. In filamentous fungi, suitable regulatory sequences include, but are not limited to, the TAKA alpha-amylase promoter, the Aspergillus niger glucoamylase promoter, and the Aspergillus oryzae glucoamylase promoter.

[0172] In another aspect, the present invention relates to a recombinant expression vector comprising a polynucleotide encoding an engineered enzyme polypeptide and, depending on the type of host to be introduced, one or more expression control regions, such as a promoter and terminator, an origin of replication, etc. In some embodiments, the various nucleic acids and control sequences described herein are ligated together to generate a recombinant expression vector that contains one or more convenient restriction sites to allow for insertion or substitution of the nucleic acid sequence encoding the enzyme polypeptide at such sites. Alternatively, in some embodiments, the nucleic acid sequences of the present invention are expressed by inserting the nucleic acid sequence or a nucleic acid construct comprising the sequence into an appropriate vector for expression. In some embodiments involving the creation of an expression vector, the coding sequence is positioned within the vector such that the coding sequence is operably linked to appropriate control sequences for expression.

[0173] The recombinant expression vector can be any suitable vector (e.g., a plasmid or a virus) that can be conveniently subjected to recombinant DNA procedures and can cause the expression of the enzyme polynucleotide sequence. The selection of the vector typically depends on the compatibility of the vector with the host cell into which the vector will be introduced. The vector can be a linear plasmid or a closed circular plasmid.

[0174] In some embodiments, the expression vector is a self-replicating vector (i.e., a vector that exists as an extrachromosomal entity and whose replication is independent of chromosomal replication, e.g., a plasmid, extrachromosomal element, minichromosome, or artificial chromosome). The vector may contain any means for ensuring self-replication. In some alternative embodiments, the vector may be one that, when introduced into a host cell, integrates into the genome and is replicated along with the chromosome into which it has been integrated. Furthermore, in some embodiments, a single vector or plasmid, or two or more vectors or plasmids that together contain the total DNA to be introduced into the genome of the host cell and / or into a transposon, are utilized.

[0175] In some embodiments, the expression vector contains one or more selectable markers that allow for easy selection of transformed cells. A "selectable marker" is a gene whose product confers biocide or viral resistance, resistance to heavy metals, prototrophy to auxotrophs, and the like. Examples of bacterial selectable markers include, but are not limited to, the dal genes from Bacillus subtilis or Bacillus licheniformis, or markers that confer antibiotic resistance such as ampicillin, kanamycin, chloramphenicol, or tetracycline resistance. Suitable markers for yeast host cells include, but are not limited to, ADE2, HIS3, LEU2, LYS2, MET3, TRP1, and URA3. Selectable markers for use in filamentous fungal host cells include, but are not limited to, amdS (acetamidase; e.g., from A. nidulans or A. orzyae), argB (ornithine carbamoyltransferase), bar (phosphinothricin acetyltransferase; e.g., from S. hygroscopicus), hph (hygromycin phosphotransferase), niaD (nitrate reductase), pyrG (orotidine-5'-phosphate decarboxylase; e.g., from A. nidulans or A. orzyae), sC (sulfate adenyltransferase), and trpC (anthranilate synthase), and equivalents thereof. In another aspect, the invention provides a host cell comprising at least one polynucleotide encoding at least one engineered enzyme polypeptide of the invention, wherein the polynucleotide is operably linked to one or more control sequences for expression of the engineered enzyme(s) in the host cell.Host cells suitable for use in expressing the polypeptides encoded by the expression vectors of the invention are well known in the art and include, but are not limited to, bacterial cells, such as E. coli, Vibrio fluvialis, Streptomyces, and Salmonella typhimurium cells; fungal cells, such as yeast cells (e.g., Saccharomyces cerevisiae or Pichia pastoris (ATCC Accession No. 201178)); insect cells, such as Drosophila S2 and Spodoptera Sf9 cells; animal cells, such as CHO, COS, BHK, 293, and Bowes melanoma cells; and plant cells. Exemplary host cells also include various Escherichia coli strains (e.g., W3110(ΔfhuA) and BL21).

[0176] Thus, in another aspect, the invention provides methods for producing an engineered enzyme polypeptide, the method comprising culturing a host cell capable of expressing a polynucleotide encoding the engineered enzyme polypeptide under conditions suitable for expression of the polypeptide. In some embodiments, the method further comprises isolating and / or purifying the enzyme polypeptide as described herein.

[0177] Suitable culture medium and growth conditions for host cells are well known in the art.Any suitable method for introducing polynucleotide into cells for the expression of enzyme polypeptides is contemplated to be used in the present invention.Suitable techniques include, but are not limited to, electroporation, particle bombardment by biolistic bombardment, liposome-mediated transfection, calcium chloride transfection, and protoplast fusion.

[0178] Various features and embodiments of the present invention are illustrated in the following representative examples, which are intended to be illustrative and not limiting. [Example]

[0179] experiment The following examples, including the experiments performed and the results, are provided for illustrative purposes only and should not be construed as limiting the invention. Indeed, there are a variety of suitable sources for many of the reagents and equipment listed below. It is not intended that the invention be limited to any particular source for any reagent or item of equipment.

[0180] In the experiments disclosed below, the following abbreviations apply: M (molar); mM (millimolar), uM and μM (micromolar); nM (nanomolar); mol (mole); gm and g (grams); mg (milligrams); ug and μg (micrograms); L and l (liters); ml and mL (milliliters); cm (centimeters); mm (millimeters); um and μm (micrometers); sec. (seconds); min (minutes); h and hr (hours); U (units); MW (molecular weight); rpm (revolutions per minute) ); psi and PSI (pounds per square inch); °C (degrees Celsius); RT and rt (room temperature); CV (coefficient of variation); CAM and cam (chloramphenicol); PMBS (polymyxin B sulfate); IPTG (isopropyl β-D-1-thiogalactopyranoside); LB (Luria Broth); TB (Terrific Broth); SFP (Shake Flask Powder); CDS (coding sequence); DNA (deoxyribonucleic acid); RNA (ribonucleic acid); nt (nucleotide; polynucleotide); aa (amino acid; polypeptide); E. coli W3110 (a commonly used laboratory strain of E. coli available from the Coli Genetic Stock Center [CGSC], New Haven, CT).coli strains); AcSus (Acidithiobacillus caldus sucrose synthase); SUS, SuS, and SuSy (sucrose synthases, also known as sucrose synthetases); NDP (nucleoside diphosphate); adenosine diphosphate (ADP); cytidine diphosphate (CDP); guanosine diphosphate (GDP); thymidine diphosphate (TDP); uridine diphosphate (UDP); inosine diphosphate (IDP); GT (glycosyltransferase); UGT (UDP-glucose-dependent glycosyltransferase); NGT (NDP-nucleoside diphosphate-dependent glycosyltransferase); AGT (AD P-glucose-dependent glycosyltransferase; CGT (CDP-glucose-dependent glycosyltransferase); GGT (GDP-glucose-dependent glycosyltransferase); TGT (TDP-glucose-dependent glycosyltransferase); IGT (IDP-glucose-dependent glycosyltransferase); UGT (UDP-glucose-dependent glycosyltransferase); reb (rebaudioside); rebA (rebaudioside A); rebD (rebaudioside D); rebI (rebaudioside I); rebM (rebaudioside M); "Reb A 60" is an approximately 1:2 mixture of stevioside and rebaudioside A, respectively; HTP (high throughput); HPLC (high pressure liquid chromatography); HPLC-UV (HPLC-ultraviolet-visible detector); 1H NMR (proton nuclear magnetic resonance spectroscopy); HSQC NMR (heteronuclear single quantum coherence spectroscopy NMR); COSY NMR (homonuclear correlation spectroscopy NMR); Acorn (Acorn NMR, Livermore, CA); FIOPC (fold improvement over positive control); Sigma and Sigma-Aldrich (Sigma-Aldrich, St.Louis, MO; Difco (Difco Laboratories, BD Diagnostic Systems, Detroit, MI); Microfluidics (Microfluidics, Westwood, MA); ChromaDex (ChromaDex, Inc., Irvine, CA); Life Technologies (Life Technologies, Fisher Amresco (Amresco, LLC, Solon, OH); Carbosynth (Carbosynth, Ltd., Berkshire, UK); Varian (Varian Medical Systems, Palo Alto, CA); Agilent (Agilent Technologies, Inc., Santa Clara, CA); and Thermotron (Thermotron, Inc., Holland, MI). .

[0181] Example 1 Synthesis, optimization and assay This example describes the methods used to synthesize, optimize, and assay UGT enzymes with glucosylation activity.

[0182] Gene synthesis and optimization: A polynucleotide sequence (SEQ ID NO: 1) encoding a wild-type Stevia rebaudiana polypeptide (SEQ ID NO: 2), which has been reported to glucosylate steviolbioside to rebaudioside B and stevioside to rebaudioside A (see, e.g., Richman et al., Plant J., 41:56-67

[2005] ), was codon-optimized and synthesized as the gene set forth in SEQ ID NO: 3. This synthetic gene (SEQ ID NO: 3) was cloned into the pCK110900 vector system (see, e.g., U.S. Patent Application Publication No. 2006 / 0195947, hereby incorporated by reference) and subsequently expressed in E. coli W3110(ΔfhuA). The E. coli strain W3110 expressed UGT enzymes under the control of a lac promoter. Evolutionary rounds were performed as described in the Examples below.

[0183] Production of shake flask powder (SFP): A shake flask procedure was used to generate glycosyltransferase polypeptide shake flask powders (SFPs) for characterization assays used in the biocatalytic processes described herein. Shake flask powder (SFP) enzyme preparation yields more purified preparations of enzymes (e.g., up to >30% total protein) compared to the cell lysates used in HTP assays and also allows for the use of more concentrated enzyme solutions. A single colony of E. coli containing a plasmid encoding the engineered polypeptide of interest was inoculated into 5 mL of Luria-Bertani broth containing 30 μg / mL chloramphenicol and 1% glucose. Cells were grown overnight (at least 16 hours) in a 30°C incubator with shaking at 250 rpm. The culture was diluted to an optical density at 600 nm (OD600) of 0.2 in 250 mL of Terrific Broth (12 g / L Bacto-tryptone, 24 g / L yeast extract, 4 mL / L glycerol, 65 mM potassium phosphate, pH 7.0, 1 mM MgSO4) containing 30 μg / ml CAM in a 1 L flask and grown at 30°C.

[0184] When the culture reached an OD600 of 0.6-0.8, expression of the glycosyltransferase genes was induced by adding IPTG to a final concentration of 1 mM. Incubation was then continued overnight (at least 16 hours). Cells were harvested by centrifugation (5000 rpm, 15 minutes, 4°C), and the supernatant was discarded. The cell pellet was resuspended in two volumes of 25 mM triethanolamine buffer, pH 7.5, and passed through a MICROFLUIDIZER® high-pressure homogenizer (Microfluidics) set for standard E. coli lysis and maintained at 4°C. Cell debris was removed by centrifugation (10,000 rpm, 45 minutes, 4°C). The clarified lysate supernatant was collected, frozen at -80°C, and then either His affinity purified and dialyzed to produce purified protein or lyophilized to produce a dry shake-flask powder of crude protein.

[0185] Assay of SFP for stevioside glucosylation: SFP was reconstituted to a 20 g / L powder. 50 μL of these stocks were then diluted in a total reaction volume of 200 μL of 50 mM Tris-HCl buffer, pH 7.5, with 3 mM MgSO4, 1 mM stevioside (ChromaDex, purity >94%), and 2 mM uridine diphosphoglucose. The reaction was carried out at 30°C for 16–18 hours with shaking at 300 RPM in a THERMOTRON® titer plate shaker.

[0186] HPLC-MS / MS analysis: The reaction was quenched with 0.5 vol / vol acetonitrile with 0.2% formic acid and precipitated by centrifugation. The glycosylated stevioside product in the supernatant was detected by LC-MS / MS using the following instrument and parameters: [Table 1]

[0187] Activity was detected for SEQ ID NO: 4. A high degree of conversion of stevioside to rebaudioside A (i.e., >95%) was observed in LC-MS / MS analysis of the assay samples described above.

[0188] Example 2 GT variant of SEQ ID NO: 4 This example describes experiments in evolving and screening GT polypeptides derived from SEQ ID NO:4 for improved glucosylation of steviol glycosides using ADP-glucose. Directed evolution of GT, encoded by SEQ ID NO:3 (i.e., SEQ ID NO:4), was performed by constructing libraries of variant genes with mutagenesis at positions related to certain structural features of the enzyme. These libraries were then plated, grown, and screened using the high-throughput (HTP) assay described below to obtain first-round ("Round 1") engineered GT variant polypeptides with glucosyltransferase activity toward ADP-glucose and steviol glycosides. Many additional rounds of evolution were performed by constructing libraries of variant genes that recombined mutations associated with improved activity in Round 1 and then with mutations associated with improved activity in subsequent evolutionary rounds. These libraries were then plated, grown, and screened using the high-throughput (HTP) growth, expression, lysate preparation, and assay described below.

[0189] HTP growth, expression and lysate preparation Cells were harvested into 96-well plates and grown overnight at 30°C, 200 rpm, and 85% humidity in LB medium containing 1% glucose and 30 μg / mL CAM. 20 μL of the overnight growth was then transferred to a deep-well plate containing 380 μL of TB growth medium containing 30 μg / mL CAM, induced with 1 mM IPTG, and incubated for 18 hours at 30°C, 200 rpm, and 85% humidity. The cell culture was centrifuged at 4000 rpm for 10 minutes at 4°C, and the medium was discarded. The resulting cell pellet was frozen at -80°C and lysed in 250 μL of lysis buffer (0.5 g / L lysozyme and 0.5 g / L PMBS in 20 mM Tris-HCl buffer, pH 7.5) with slow shaking at room temperature for 2 hours on a titer plate shaker. The plates were then centrifuged at 4000 rpm and 4° C. for 20 minutes and the clarified lysate supernatant was used in the HTP assay reaction described below.

[0190] HTP assay for glucose transfer from ADP-glucose to stevioside Assays were performed using 96-well plates of clarified E. coli culture lysates expressing SEQ ID NO:3 variants, with a lysate load of 50 μL lysate in 200 μL reactions, and a substrate load of 1 mM stevioside (ChromaDex, purity >94%) from a 20 mM stock solution in 50% ethanol, and a cosubstrate load of 0.5 mM ADP-glucose (Sigma, purity >93%). The following reaction conditions were used: 50 mM Tris-HCl buffer, pH 7.5, 3 mM MgCl, 30°C, shaking at 300 RPM in a THERMOTRON® titer plate shaker for 18 hours. Reactions were quenched with 100 μL / well of acetonitrile with 0.2% formic acid, centrifuged for 10 minutes at 4°C, and the supernatants were analyzed by HPLC-MS / MS as described in Example 1, Table 1.1.

[0191] The formation of rebaudioside A from stevioside in the presence of wild-type UGT76G1 (SEQ ID NO: 4) and ADP-glucose was indistinguishable from the no-enzyme control. In contrast to the wild-type enzyme of SEQ ID NO: 4, glycosyltransferase variant polypeptides were identified that produced rebaudioside A from stevioside and ADP-glucose. These engineered polypeptides are listed in Table 2.1. The parent and variant constructs contained an N-terminal histidine tag for affinity purification; for clarity, mutations are numbered relative to the untagged reference sequence. Shake-flask-scale cultures of variants produced during multiple evolutionary rounds were grown for protein purification as described in Example 1.

[0192] Example 3 Synthesis, optimization, and assay of glycosyltransferase enzymes with glucosylation activity This example describes the methods used to synthesize, optimize, and assay UGT enzymes with glucosylation activity.

[0193] Gene synthesis and optimization A polynucleotide sequence encoding the beta-1,2-glycosyltransferase Solanum tuberosum was codon-optimized and synthesized as the gene set forth in SEQ ID NO: 11. These synthetic genes were cloned into the pCK110900 vector system (see, e.g., U.S. Pat. No. 9,714,437, hereby incorporated by reference) and then expressed in E. coli W3110 (ΔfhuA). The E. coli strain W3110 expressed the UGT enzyme under the control of the lac promoter.

[0194] Production of shake flask powder (SFP) A shake flask procedure was used to generate glycosyltransferase polypeptide shake flask powders (SFPs) for characterization assays used in the biocatalytic processes described herein. Shake flask powder (SFP) enzyme preparation yields more purified preparations of enzymes (e.g., up to >30% total protein) compared to the cell lysates used in HTP assays and also allows for the use of more concentrated enzyme solutions. A single colony of E. coli containing a plasmid encoding the engineered polypeptide of interest was inoculated into 5 mL of Luria-Bertani broth containing 30 μg / ml chloramphenicol and 1% glucose. Cells were grown overnight (at least 16 hours) in a 30°C incubator with shaking at 250 rpm. The culture was diluted to an optical density at 600 nm (OD600) of 0.2 in 250 mL of Terrific Broth (12 g / L Bacto-tryptone, 24 g / L yeast extract, 4 mL / L glycerol, 65 mM potassium phosphate, pH 7.0, 1 mM MgSO4) containing 30 μg / ml CAM in a 1 L flask and grown at 30°C.

[0195] When the culture reached an OD600 of 0.6-0.8, expression of the glycosyltransferase genes was induced by adding IPTG to a final concentration of 1 mM. Incubation was then continued overnight (at least 16 hours). Cells were harvested by centrifugation (5000 rpm, 15 minutes, 4°C), and the supernatant was discarded. The cell pellet was resuspended in two volumes of 25 mM triethanolamine buffer, pH 7.5, and passed through a MICROFLUIDIZER® high-pressure homogenizer (Microfluidics) set for standard E. coli lysis and maintained at 4°C. Cell debris was removed by centrifugation (10,000 rpm, 45 minutes, 4°C). The clarified lysate supernatant was collected, frozen at -80°C, and then either His affinity purified and dialyzed to produce purified protein or lyophilized to produce a dry shake-flask powder of crude protein.

[0196] Assay for rebaudioside A glucosylation in purified proteins First, 50 μL of purified protein was diluted in a 200 μL total reaction volume consisting of 50 mM Tris-HCl buffer pH 7.5, 3 mM magnesium chloride, 1 mM rebaudioside A, and 0.5 mM uridine diphosphoglucose. The reaction was carried out at 30°C for 18 hours with shaking at 300 RPM in a THERMOTRON® titer plate shaker. A boiled enzyme reaction was used as a negative control. 10 μL of the reaction was quenched with 90 μL of acetonitrile with 0.2% formic acid and precipitated by centrifugation. The glycosylated rebaudioside A product was detected in the supernatant by LC-MS / MS as described in Example 1, Table 1.1. Despite poor soluble expression, SEQ ID NO: 12 demonstrated high specific activity and good selectivity for the production of β-1,2-glucose linkages in steviol glycoside substrates.

[0197] Assay for rebaudioside A glucosylation in shake flask powder Lyophilized shake flask powders were reconstituted to 20 mg / mL. 10 μL of these stocks were then diluted in a 100 μL total reaction volume of 50 mM potassium phosphate (KPhos) buffer, pH 7, with 3 mM MgCl, 1 mM rebaudioside A (purity >97%), and 2 mM uridine diphosphoglucose (UDP-glucose). The reaction was carried out at 40°C for 16-18 hours with shaking at 300 RPM in a THERMOTRON® titer plate shaker. Higher activity than the negative control was detected for SEQ ID NO: 12. Low conversion of rebaudioside A to rebaudioside D (i.e., <10%) was observed by LC-MS / MS analysis.

[0198] Example 4 GT variant of SEQ ID NO: 12 This example describes experiments in evolving and screening GT polypeptides derived from SEQ ID NO:12 for improved glucosylation of steviol glycosides. Directed evolution of the GT encoded by SEQ ID NO:11 (i.e., SEQ ID NO:12) was performed by constructing combinatorial libraries of variant genes in which mutagenesis was performed at positions relevant to the surface residues of the enzyme. These libraries were then plated, grown, and screened using the high-throughput (HTP) assay described below to obtain a first-round ("Round 1") engineered GT variant polypeptide with β-1,2-glucosyltransferase activity to steviol glycosides. Many additional rounds of evolution were performed by constructing libraries of variant genes that recombined the mutations associated with improved activity in Round 1 and then with mutations associated with improved activity in subsequent evolutionary rounds. These libraries were then plated, grown, and screened using the high-throughput (HTP) growth, expression, lysate preparation, and assay described below.

[0199] HTP growth, expression and lysate preparation Cells were harvested into 96-well plates and grown overnight at 30°C, 200 rpm, and 85% humidity in LB medium containing 1% glucose and 30 μg / mL CAM. 20 μL of the overnight growth was then transferred to a deep-well plate containing 380 μL of TB growth medium containing 30 μg / mL CAM, induced with 1 mM IPTG, and incubated for 18 hours at 30°C, 200 rpm, and 85% humidity. The cell culture was centrifuged at 4000 rpm for 10 minutes at 4°C, and the medium was discarded. The resulting cell pellet was frozen at -80°C and lysed in 250 μL of lysis buffer (0.5 g / L lysozyme and 0.5 g / L PMBS in 20 mM Tris-HCl buffer, pH 7.5) with slow shaking at room temperature for 2 hours on a titer plate shaker. The plates were then centrifuged at 4000 rpm and 4° C. for 20 minutes and the clarified lysate supernatant was used in the HTP assay reaction described below.

[0200] HTP assay for rebaudioside A glucosylation Assays were performed using 96-well plates of clarified E. coli culture lysates expressing the enzyme variants, with a lysate load of 25 μL lysate in 100 μL reactions, a substrate load of 1 mM rebaudioside A (Sigma, purity >96%) from a 20 mM stock solution in 50% ethanol, and a cosubstrate load of 0.5 mM UDP-glucose (Sigma, purity >98%). The following reaction conditions were used: 50 mM Tris-HCl buffer, pH 7.5, 3 mM MgCl, 30°C, shaking at 300 RPM in a THERMOTRON® titer plate shaker for 4 hours. Reactions were quenched with 0.5 v / v acetonitrile with 0.2% formic acid and precipitated by centrifugation for 10 minutes at 4°C. After a 1:20 dilution with water, glycosylated products were detected in the supernatant by LC-MS / MS using the instrumentation and parameters described in Example 1, Table 1.1. Glycosyltransferase variant polypeptides that produced rebaudioside D from rebaudioside A in greater amounts than the reference backbone sequence were identified and used in subsequent rounds of evolution. For analysis of the variants, shake flask-scale cultures for lyophilized powder production were grown as described in Example 1.

[0201] Shake flask lysate characterization assay and analysis of rebaudioside A glucosylation First, 250 mL shake flask cultures were grown, induced, and lysed. Cell debris was removed by centrifugation as described in Example 1, and the clarified lysate supernatant was collected. Next, 10 μL of the lysate was diluted in a total reaction volume of 100 μL with 50 mM Tris-HCl buffer, pH 7.5, 3 mM MgCl2, 1 mM rebaudioside A (Sigma, purity >96%), and 2 mM UDP-glucose (Sigma, purity >98%). The reaction was carried out for 0-18 hours at 30°C with shaking at 300 RPM in a THERMOTRON® titer plate shaker. The reaction was quenched with 0.5 v / v acetonitrile with 0.2% formic acid and precipitated by centrifugation. After a 1:20 dilution with water, glycosylated products in the supernatant were detected by LC-MS / MS using the instrumentation and parameters described in Example 1, Table 1.1.

[0202] Example 5 Sucrose synthase variant of SEQ ID NO: 6 This example describes experiments in the evolution and screening of sucrose synthase (SuS) polypeptides derived from the codon-optimized Acidothiobacillus caldus sucrose synthase polynucleotide (SEQ ID NO: 5) for improved production of ADP-glucose from sucrose and ADP. Directed evolution of SuS (i.e., SEQ ID NO: 6), encoded by SEQ ID NO: 5, was performed by constructing libraries of variant genes that underwent saturation mutagenesis at positions related to certain structural features of the enzyme and recombined diversity from homologs in public databases. These libraries were then plated, grown, and screened using the high-throughput (HTP) assay described below to obtain first-round ("Round 1") engineered SuS variant polypeptides with improved activity toward the synthesis of ADP-glucose. Many additional rounds of evolution were performed by constructing libraries of variant genes that recombined mutations associated with improved activity in Round 1 and then with mutations associated with improved activity in subsequent evolutionary rounds. These libraries were then plated, grown, and screened using the high-throughput (HTP) growth, expression, lysate preparation, and assay described below.

[0203] HTP assay for glucose transfer from sucrose to ADP Assays were performed using 96-well plates of clarified E. coli culture lysates expressing SEQ ID NO:5 variants (i.e., variants of SEQ ID NO:6), with a lysate load of 25 μL lysate in 100 μL reactions, and a substrate load of 30% w / v sucrose (Sigma) from a 60% stock solution in water, and a co-substrate load of 2 mM ADP (Sigma, purity >95%). The following reaction conditions were used: 2 hours in a thermocycler, 50 mM Tris-HCl buffer, pH 7.5, 3 mM MgCl, 30°C. Reactions were heat quenched at 95°C for 10 minutes and then analyzed by a colorimetric D-fructose dehydrogenase assay adapted from the literature (see, e.g., Ameyama et al., J. Bacteriol., 145:814-823

[1981] ; and Ameyama, Meth. Enzymol., 89:20-29

[1982] ). Briefly, overnight enzyme-linked assays were performed in 96-well plates using 20 μL of sample diluted to a fructose concentration of <1 g / L, 20 μL of 100 mM potassium ferricyanide (Sigma P-8131), and 160 μL of 0.8 units / mL fructose dehydrogenase (Sigma F4892) dissolved in pH 4.6 McIlvaine buffer with 0.1% Triton® X-100. This reaction quantitatively converts fructose to KFe(CN), and therefore KFe(CN) is quantified colorimetrically by adding 67 μL of the overnight reaction to 33 μL of stop solution (0.3 w / v% sodium dodecyl sulfate, Sigma L-4509, 8.1 v / v% phosphoric acid, Sigma P-6560, and 0.5 w / v% ferric sulfate, Sigma F-1135), shaking for 20 minutes to allow complete conversion of KFe(CN) to Prussian blue, and reading the absorbance at 690 nm using a plate reader.After the primary assay, engineered sucrose synthase (SuS) variant polypeptides with higher fructose-forming activity, and therefore higher stoichiometric ADP-glucose-forming activity, than SEQ ID NO: 6 were screened in triplicate at a lower substrate load of 2 w / v% sucrose (Sigma) and a co-substrate load of 1 mM ADP (Sigma, >95%).

[0204] HTP binding assay for glucose transfer from sucrose to ADP and then to rebaudioside D The library was screened using the following HTP enzyme-linked assay. Pelleted E. coli culture was lysed in 250 μL of Tris-HCl, pH 7.5, with 1 mM magnesium sulfate, 0.5 mg / mL lysozyme, and polymyxin B sulfate (PMBS) and clarified by centrifugation. The lysate was diluted 20-fold by adding Tris-HCl, pH 7.5. 10 μL of the diluted SuS lysate and 2 g / L of GT SEQ ID NO:8 were then combined in a 100 μL reaction volume with a substrate load of approximately 1 mM rebaudioside D and a co-substrate load of 1 mM ADP (Sigma, >95%) and 10 mM sucrose (Sigma). The following reaction conditions were used: 50 mM potassium phosphate buffer, pH 7, 3 mM MgCl, 50°C, shaking at 300 RPM in a THERMOTRON® titer plate shaker for 2 hours. The reaction was quenched by adding 10 μL of assay mixture to 90 μL of acetonitrile with 0.2% formic acid and precipitated by centrifugation. The supernatant was diluted 10-fold with water, and steviol glycoside products were detected by RapidFire SPE-MS / MS using the instrument and parameters listed in Table 5.1. [Table 5]

[0205] Production of shake flask powder (SFP) A shake flask procedure was used to generate glycosyltransferase polypeptide shake flask powders (SFPs) for characterization assays used in the biocatalytic processes described herein. Shake flask powder (SFP) enzyme preparation yields more purified preparations of enzymes (e.g., up to >30% total protein) compared to the cell lysates used in HTP assays and also allows for the use of more concentrated enzyme solutions. A single colony of E. coli containing a plasmid encoding the engineered polypeptide of interest was inoculated into 5 mL of Luria-Bertani broth containing 30 μg / ml chloramphenicol and 1% glucose. Cells were grown overnight (at least 16 hours) in a 30°C incubator with shaking at 250 rpm. The culture was diluted to an optical density at 600 nm (OD600) of 0.2 in 250 mL of Terrific Broth (12 g / L Bacto-tryptone, 24 g / L yeast extract, 4 mL / L glycerol, 65 mM potassium phosphate, pH 7.0, 1 mM MgSO4) containing 30 μg / ml CAM in a 1 L flask and grown at 30°C.

[0206] Shake flask powder characterization assay and analysis of glucosyl transfer from sucrose to rebaudioside D Experiments were conducted to characterize the activity of engineered SuS variants toward sucrose and ADP to promote the formation of rebaudioside M from rebaudioside D. Shake flask powder (SFP) was added at a concentration of 0.125 g / L to a 100 μL total reaction volume containing 50 mM potassium phosphate buffer, pH 7, 3 mM magnesium chloride, 1 g / L rebaudioside D, 10 mM sucrose, 1 mM ADP, and 2 g / L GT SEQ ID NO: 10. The reaction was carried out at 50°C for 1 hour with shaking at 300 RPM in a THERMOTRON® titer plate shaker. The reaction was quenched by adding 10 μL of the reaction mixture to 90 μL acetonitrile with 0.2% formic acid and precipitated by centrifugation. The supernatant was diluted 10-fold with water and analyzed for steviol glycosides by RapidFire SPE-MS / MS using the instrument and parameters listed in Table 5.1. Based on these results, additional rounds of evolution were performed to optimize the enzyme.

[0207] Example 6 Sucrose synthase variants We continued directed evolution of the sucrose synthase enzyme by constructing libraries of variant genes that recombined the mutations associated with the activity improvements in previous evolutionary rounds. These libraries were then plated, grown, and screened using the high-throughput (HTP) assay described below to obtain additional iterative rounds of engineered SuS variant polypeptides with activity toward the production of ADP-glucose.

[0208] HTP binding assay for glucose transfer from sucrose to ADP and then to rebaudioside A The combinatorial library was screened using the following HTP enzyme-linked assay. Pelleted E. coli culture was lysed in 400 μL of Tris-HCl, pH 7.5, with 1 mM magnesium sulfate, 0.5 mg / mL lysozyme, and polymyxin B sulfate (PMBS) and clarified by centrifugation. The lysate was diluted approximately 90-fold by adding Tris-HCl, pH 7.5. 10 μL of the diluted SuS lysate and 1 g / L GT SEQ ID NO:14 were then combined in a 100 μL reaction volume with a substrate load of 4.5-7.5 mM rebaudioside A97 and a co-substrate load of 0.2-0.25 mM ADP (Sigma, >95%) and 30 mM sucrose (Sigma). The following reaction conditions were used: 50 mM potassium phosphate buffer, pH 6, 55°C, 2 hours with shaking at 300 RPM in a THERMOTRON® titer plate shaker. The above reactions were solubilized by adding 10 μL of assay to 90-190 μL of water, quenched by adding 10 μL of solubilized assay to 90 μL of acetonitrile with 0.2% formic acid, and precipitated by centrifugation. The supernatant was diluted 4.4-6.7 times with water, and the steviol glycoside products were detected by RapidFire SPE-MS / MS using the instrument and parameters listed in Table 5.1. After analysis, engineered SuS variant polypeptides were identified that conjugated with GT and showed improved activity against rebaudioside A.

[0209] Shake flask powder characterization assay and analysis of glucosyl transfer from sucrose to rebaudioside A Experiments were conducted to characterize the activity of engineered SuS variants toward sucrose and ADP to promote the formation of rebaudioside D from rebaudioside A. Shake flask powder (SFP) was added at a concentration of 0.02 g / L to a 100 μL total reaction volume containing 50 mM potassium phosphate buffer, pH 6, 7.5 mM rebaudioside A97, 30 mM sucrose, 0.2 mM ADP, and 1 g / L GT SEQ ID NO:14. The reaction was carried out at 50°C for 1 hour with shaking at 300 RPM in a THERMOTRON® titer plate shaker. The reaction was solubilized by 20-fold dilution into water, quenched by adding 10 μL of the diluted reaction to 90 μL acetonitrile with 0.2% formic acid, and precipitated by centrifugation. The supernatant was diluted 4.4-fold with water and analyzed for steviol glycosides by RapidFire SPE-MS / MS using the instrument and parameters listed in Table 5.1. Variants with higher activity than the reference sequence and higher levels of rebaudioside D produced from rebaudioside A were selected for further directed evolution to catalyze the recycling reaction transferring glucose from sucrose to ADP.

[0210] Example 7 Beta-1,3-ADP-glycosyltransferase variant of SEQ ID NO: 20 This example describes an evolution and screening experiment of β1,3-glycosyltransferase (β1,3GT) polypeptides derived from SEQ ID NO:8598 for improved glucosylation of steviol glycosides using in situ synthesized ADP-glucose. Directed evolution of GT encoded by SEQ ID NO:19 (i.e., SEQ ID NO:20) was performed by constructing libraries of variant genes that incorporated mutations associated with improved production identified during development of the present invention and subjected certain structural features to saturation mutagenesis. These libraries were then plated, grown, and screened using the high-throughput (HTP) assay described below to obtain another round of 72 engineered GT variant polypeptides with glucosyltransferase activity toward ADP-glucose and steviol glycosides.

[0211] HTP assay for glucose transfer from sucrose to ADP, followed by glucose transfer from ADP-glucose to rebaudioside A60 Assays were performed using 96-well plates of clarified E. coli culture lysates expressing SEQ ID NO: 19 variants (i.e., variants of SEQ ID NO: 20). Pellets were lysed and lysates were clarified as described in Example 6 and then diluted 10-fold into 50 mM potassium phosphate buffer, pH 6. To heat challenge the lysates, they were preincubated at 75°C for 1 hour with shaking at 300 RPM in a Thermotron® titer plate shaker. Assays were performed using 10 μL of preincubated lysate in a 100 μL reaction with 20 g / L rebaudioside A 60% substrate, 0.025 g / L ADP (Amresco, Ultra Pure Grade) cosubstrate, 0.05 g / L SUS SFP SEQ ID NO: 18, 0.12 g / L β-1,2-glycosyltransferase (β12GT) SEQ ID NO: 16, and 40 g / L sucrose. The following reaction conditions were used: 50 mM potassium phosphate buffer, pH 6, 60°C, 16 hours with shaking at 300 RPM in a THERMOTRON® titer plate shaker. Reactions were solubilized by 20-fold dilution with water, quenched by 5-fold dilution with acetonitrile with 0.2% formic acid, and diluted 20-fold with water for analysis. Samples were analyzed by RapidFire-MS / MS as described in Example 5, Table 5.1. Glycosyltransferase variant polypeptides were identified that produce higher amounts of rebaudioside M from rebaudioside A60 using in situ synthesized ADP-glucose than SEQ ID NO: 20. These engineered polypeptides are listed in Tables 7.1 and 7.2. For analysis of the variants shown in Table 7.3 compared to SEQ ID NO: 20, shake flask scale cultures were grown, lysed, clarified, and lyophilized to a powder as described in Example 1. [Table 7-1] [Table 7-2] [Table 7-3] [Table 7-4]

[0212] SFP characterization assay and analysis of glucosyl transfer from sucrose to ADP, followed by glucosyl transfer from ADP-glucose to stevioside and rebaudioside D Shake flask powder (SFP) was reconstituted to a concentration of 20 g / L and diluted to 0.005–0.15 g / L of SFP in a 100 μL total reaction volume with 50 mM potassium phosphate buffer, pH 6, 15 mM stevioside (purity >95%) or rebaudioside D, 0.02 g / L ADP (Amresco, Ultra Pure Grade) cosubstrate, 0.05 g / L SUS SFP SEQ ID NO: 18, and 37.5 mM sucrose. Reactions were incubated at 60°C for 4 hours with shaking at 300 RPM in a Thermotron® titer plate shaker. Reactions were solubilized by a 20-fold dilution with water, quenched by a 5-fold dilution with acetonitrile with 0.2% formic acid, clarified by centrifugation, and diluted 15-fold with water for analysis. Glycosylation products were detected by SPE-QQQ as described in Example 5, Table 5.1. One-pot reactions were performed using 0.01-0.3 g / L of SFP in a total reaction volume of 100 μL with 50 mM potassium phosphate buffer, pH 6, 20 g / L RebA60, 0.02 g / L ADP (Amresco, Ultra Pure Grade) cosubstrate, 0.05 g / L SUS SFP SEQ ID NO:18, 0.12 g / L β1,2GT SFP SEQ ID NO:16, and 30 g / L sucrose. The reactions were incubated at 60°C for 16 hours with shaking at 300 RPM in a THERMOTRON® titer plate shaker. The reactions were solubilized by a 20-fold dilution with water, quenched by a 5-fold dilution with acetonitrile with 0.2% formic acid, clarified by centrifugation, and diluted 20-fold with water for analysis. A similar one-pot reaction was also performed using 10 μL of crude shake flask lysate after 20-fold dilution in 50 mM potassium phosphate buffer, pH 6, and incubation at 75.1° C. for 24 hours. [Table 7-5]

[0213] In these experiments, at least four variants in Table 7.3 produced more rebaudioside M from rebaudioside A60 than SEQ ID NO: 20, and three variants also produced more rebaudioside A from stevioside and rebaudioside M from rebaudioside D. All variants were less thermostable than SEQ ID NO: 20. SEQ ID NO: 36 was selected as the starting point for further enzyme engineering due to its superior performance in the one-pot assay and slightly reduced thermostability.

[0214] Example 8 Beta-1,3-ADP-glycosyltransferase variant of SEQ ID NO: 36 This example describes an evolution and screening experiment of β1,3-glycosyltransferase (β1,3GT) polypeptides derived from SEQ ID NO: 36 for improved glucosylation of steviol glycosides using in situ synthesized ADP-glucose. Directed evolution of the GT encoded by SEQ ID NO: 35 (i.e., SEQ ID NO: 36) was performed by constructing libraries of variant genes that incorporated mutations associated with improved production identified during development of the present invention and targeted the N-terminal coding region. These libraries were then plated, grown, and screened using the high-throughput (HTP) assay described below to obtain another round of 58 engineered GT variant polypeptides with glucosyltransferase activity toward ADP-glucose and steviol glycosides.

[0215] HTP assay for glucose transfer from sucrose to ADP, followed by glucose transfer from ADP-glucose to rebaudioside A60 The assay was performed using 96-well plates of clarified E. coli culture lysates expressing SEQ ID NO: 35 (i.e., a variant of SEQ ID NO: 36). The pellets were lysed and the lysates were clarified as described in Example 6 and then diluted 20-fold into 50 mM potassium phosphate buffer, pH 6. To heat challenge the lysates, they were preincubated at 75°C for 2 hours with shaking at 300 RPM in a THERMOTRON® titer plate shaker. Assays were performed using 10 μL of preincubated lysate in a 100 μL reaction, with 20 g / L rebaudioside A 60% substrate, 0.02 g / L ADP (Amresco, Ultra Pure Grade) cosubstrate, 0.03 g / L SUS SFP SEQ ID NO: 22, 0.08 g / L β-1,2-glycosyltransferase (β12GT) SEQ ID NO: 858, and 30 g / L sucrose. The following reaction conditions were used: 50 mM potassium phosphate buffer, pH 6, 60°C, 16 hours with shaking at 300 RPM in a THERMOTRON® titer plate shaker. Reactions were solubilized by 20-fold dilution with water, quenched by 5-fold dilution with acetonitrile with 0.2% formic acid, and diluted 20-fold with water for analysis. Samples were analyzed by RapidFire-MS / MS as described in Example 5, Table 5.1. Glycosyltransferase variant polypeptides were identified that produced higher amounts of rebaudioside M from rebaudioside A60 using in situ synthesized ADP-glucose than SEQ ID NO: 36. These engineered polypeptides are listed in Table 8.1. Four additional variants with modified N-terminal DNA coding sequences but no amino acid mutations were also identified: SEQ ID NOs: 277 / 278, 279 / 280, 281 / 282, and 283 / 284. For analysis of the variants shown in Table 8.2 compared to SEQ ID NO: 36, shake-flask-scale cultures were grown, lysed, clarified, and lyophilized to a powder as described in Example 1. [Table 8-1] [Table 8-2]

[0216] SFP characterization assay and analysis of glucosyl transfer from sucrose to ADP, followed by glucosyl transfer from ADP-glucose to stevioside and rebaudioside D Shake flask powder (SFP) was reconstituted to a concentration of 20 g / L and diluted to 0.005–0.15 g / L of SFP in a 100 μL total reaction volume with 50 mM potassium phosphate buffer, pH 6, 15 mM stevioside (purity >95%) or rebaudioside D, 0.02 g / L ADP (Amresco, Ultra Pure Grade) cosubstrate, 0.05 g / L SUS SFP SEQ ID NO: 22, and 37.5 mM sucrose. Reactions were incubated at 60°C for 4 hours with shaking at 300 RPM in a Thermotron® titer plate shaker. Reactions were solubilized by a 20-fold dilution with water, quenched by a 5-fold dilution with acetonitrile with 0.2% formic acid, clarified by centrifugation, and diluted 15-fold with water for analysis. Glycosylation products were detected by SPE-QQQ as described in Example 5, Table 5.1. One-pot reactions were performed using 0.01-0.3 g / L of SFP in a total reaction volume of 100 μL with 50 mM potassium phosphate buffer, pH 6, 20 g / L RebA60, 0.02 g / L ADP (Amresco, Ultra Pure Grade) cosubstrate, 0.03 g / L SUS SFP SEQ ID NO:22, 0.08 g / L β1,2GT SFP SEQ ID NO:858, and 30 g / L sucrose. The reactions were incubated at 60°C for 16 hours with shaking at 300 RPM in a THERMOTRON® titer plate shaker. The reactions were solubilized by a 20-fold dilution with water, quenched by a 5-fold dilution with acetonitrile with 0.2% formic acid, clarified by centrifugation, and diluted 20-fold with water for analysis. A similar one-pot reaction was also performed using 10 μL of crude shake flask lysate after 20-fold dilution in 50 mM potassium phosphate buffer, pH 6, and incubation at 75.2° C. for 24 hours. [Table 8-3] [Table 8-4]

[0217] In these experiments, the two N-terminal modified sequences in Table 8.2 performed identically to SEQ ID NO: 36, and the six combined variants performed better with all three substrates. SEQ ID NO: 174 was chosen as the starting point for further enzyme engineering due to its superior performance with all three substrates.

[0218] Example 9 Beta-1,3-ADP-glycosyltransferase variant of SEQ ID NO: 174 This example describes an evolution and screening experiment of β1,3-glycosyltransferase (β1,3GT) polypeptides derived from SEQ ID NO: 174 for improved glucosylation of steviol glycosides using in situ synthesized ADP-glucose. Directed evolution of the GT encoded by SEQ ID NO: 173 (i.e., SEQ ID NO: 174) was performed by constructing libraries of variant genes that incorporated mutations associated with improved production identified during development of the present invention and that underwent saturation mutagenesis of certain structural features. These libraries were then plated, grown, and screened using the high-throughput (HTP) assay described below to obtain another round of 60 engineered GT variant polypeptides with glucosyltransferase activity toward ADP-glucose and steviol glycosides.

[0219] HTP assay for glucose transfer from sucrose to ADP, followed by glucose transfer from ADP-glucose to rebaudioside A60 Assays were performed using 96-well plates of clarified E. coli culture lysates expressing the SEQ ID NO:173 variant (i.e., the variant of SEQ ID NO:174). The pellets were lysed and the lysates were clarified as described in Example 6 and then diluted 25-33.3 times in 50 mM potassium phosphate buffer, pH 6. To heat challenge the lysates, they were preincubated at 75°C for 2 hours with shaking at 300 RPM in a THERMOTRON® titer plate shaker. Assays were performed using 10 μL of preincubated lysate in a 100 μL reaction, with 20 g / L rebaudioside A 60% substrate, 0.02 g / L ADP (Amresco, Ultra Pure Grade) cosubstrate, 0.03 g / L SUS SFP SEQ ID NO: 1652, 0.08 g / L β-1,2-glycosyltransferase (β12GT) SEQ ID NO: 858, and 30 g / L sucrose. The following reaction conditions were used: 50 mM potassium phosphate buffer, pH 6, 60°C, 16 hours with shaking at 300 RPM in a THERMOTRON® titer plate shaker. Reactions were solubilized by 20-fold dilution with water, quenched by 5-fold dilution with acetonitrile with 0.2% formic acid, and diluted 20-fold with water for analysis. Samples were analyzed by RapidFire-MS / MS as described in Example 5, Table 5.1. Glycosyltransferase variant polypeptides were identified that produce higher amounts of rebaudioside M from rebaudioside A60 using in situ synthesized ADP-glucose than SEQ ID NO: 174. These engineered polypeptides are listed in Tables 9.1 and 9.2. In addition, the saturation mutagenesis variants listed in Table 9.2 were assayed under four additional conditions. One was identical to the assay above, except that the incubation was at 70°C for 16 hours. Another was identical to the assay above, except that 40 g / L of RebA60 was included in the potassium phosphate dilution buffer preincubation.The other two were single-substrate reaction conditions in which the clarified lysate was diluted 25-fold into 50 mM potassium phosphate buffer, pH 6, preincubated at 75°C for 2 hours, and then diluted 10-fold to 100 μL reactions containing 15 mM steviol glycosides 95% or rebaudioside D, 30 g / L sucrose, 0.02 g / L ADP, 50 mM potassium phosphate pH 6, and 0.03 g / L SUS SFP SEQ ID NO: 1652. These reactions were incubated for 16 hours at 60°C, solubilized by 20-fold dilution with water, quenched by 5-fold dilution by addition to acetonitrile with 0.2% formic acid, and precipitated by low-temperature centrifugation. The supernatant was then diluted 15-fold with water and analyzed by RapidFire-MS / MS. For analysis of the variants shown in Table 9.3 compared to SEQ ID NO: 174, shake flask scale cultures were grown, lysed, clarified and lyophilized to a powder as described in Example 1. [Table 9-1] [Table 9-2] [Table 9-3] [Table 9-4]

[0220] SFP characterization assay and analysis of glucosyl transfer from sucrose to ADP, followed by glucosyl transfer from ADP-glucose to stevioside and rebaudioside D Shake flask powder (SFP) was reconstituted to a concentration of 20 g / L and diluted to 0.005–0.15 g / L SFP in a 100 μL total reaction volume with 50 mM potassium phosphate buffer, pH 6, 15 mM stevioside (purity >95%) or rebaudioside D, 0.02 g / L ADP (Amresco, Ultra Pure Grade) cosubstrate, 0.03 g / L SUS SFP SEQ ID NO: 1652, and 37.5 mM sucrose. Reactions were incubated at 60°C for 4 hours with shaking at 300 RPM in a THERMOTRON® titer plate shaker. Reactions were solubilized by 20-fold dilution with water, quenched by 5-fold dilution with acetonitrile with 0.2% formic acid, clarified by centrifugation, and diluted 15-fold with water for analysis. Glycosylation products were detected by SPE-QQQ as described in Example 5, Table 5.1. One-pot reactions were performed using 50 mM potassium phosphate buffer, pH 6, 20 g / L RebA60, 0.02 g / L ADP (Amresco, Ultra Pure Grade) cosubstrate, 0.03 g / L SUS SFP SEQ ID NO: 1652, 0.08 g / L β1,2GT SFP SEQ ID NO: 858, and 30 g / L sucrose (cane sugar) at 0.01-0.3 g / L in a total reaction volume of 100 μL. Reactions were incubated at 60°C for 16 hours with shaking at 300 RPM in a THERMOTRON® titer plate shaker. Reactions were solubilized by 20-fold dilution with water, quenched by 5-fold dilution with acetonitrile with 0.2% formic acid, clarified by centrifugation, and diluted 20-fold with water for analysis. A similar one-pot reaction was also performed using 10 μL of crude shake flask lysate after 20-fold dilution in 50 mM potassium phosphate buffer, pH 6, and incubation at 75.2° C. for 24 hours. [Table 9-5] [Table 9-6]

[0221] In these experiments, five variants in Table 9.3 produced more rebaudioside M from rebaudioside A60 than SEQ ID NO: 174, four variants also produced more rebaudioside A from stevioside, and three of these also produced more rebaudioside M from rebaudioside D. Several variants were significantly more thermostable than SEQ ID NO: 190. The most thermostable variant, SEQ ID NO: 350, was recloned with the best N-terminal DNA sequence from Example 8 (SEQ ID NOs: 279 / 280), and this enzyme, SEQ ID NO: 406, was used as the starting point for further enzyme engineering.

[0222] Example 10 Beta-1,3-ADP-glycosyltransferase variant of SEQ ID NO: 406 This example describes an evolution and screening experiment of β1,3-glycosyltransferase (β1,3GT) polypeptides derived from SEQ ID NO:406 for improved glucosylation of steviol glycosides using in situ synthesized ADP-glucose. Directed evolution of the GT encoded by SEQ ID NO:405 (i.e., SEQ ID NO:406) was performed by constructing libraries of variant genes engineered with mutations associated with improved production identified during development of the present invention. These libraries were then plated, grown, and screened using the high-throughput (HTP) assay described below to obtain another round of 16 engineered GT variant polypeptides with glucosyltransferase activity toward ADP-glucose and steviol glycosides.

[0223] HTP assay for glucose transfer from sucrose to ADP, followed by glucose transfer from ADP-glucose to rebaudioside A60 The assay was performed using 96-well plates of clarified E. coli culture lysates expressing the SEQ ID NO:405 variant (i.e., the variant of SEQ ID NO:406). The pellets were lysed and the lysates were clarified as described in Example 6, then diluted 15-fold into 50 mM potassium phosphate buffer, pH 6, and separately diluted 15-fold into the same buffer with 40 g / L rebaudioside A 60% substrate. To heat-challenge the lysates, they were preincubated at 75°C for 2 hours with shaking at 300 RPM in a THERMOTRON® titer plate shaker. Assays were performed using 10 μL of preincubated lysate in a 100 μL reaction, with 20 g / L rebaudioside A 60% substrate, 0.02 g / L ADP (Amresco, Ultra Pure Grade) cosubstrate, 0.03 g / L SUS SFP SEQ ID NO: 1822, 0.06 g / L β-1,2-glycosyltransferase (β12GT) SEQ ID NO: 994, and 30 g / L sucrose. The following reaction conditions were used: 50 mM potassium phosphate buffer, pH 6, 60°C, 16 hours with shaking at 300 RPM in a THERMOTRON® titer plate shaker. The reaction was solubilized by 20-fold dilution with water, quenched by 5-fold dilution with acetonitrile with 0.2% formic acid, and diluted 20-fold with water for analysis. Samples were analyzed by RapidFire-MS / MS as described in Example 5, Table 5.1. Glycosyltransferase variant polypeptides were identified that produce higher amounts of rebaudioside M from rebaudioside A60 using in situ synthesized ADP-glucose than SEQ ID NO: 406. These engineered polypeptides are listed in Table 10.1. [Table 10]

[0224] SEQ ID NO:408 from the variants listed in Table 10.1 was selected as the starting point for further enzyme engineering based on its improved stability upon pre-incubation in potassium phosphate buffer with and without 60% rebaudioside A, as well as the benefits associated with two mutations, A85V and E259T.

[0225] Example 11 Beta-1,3-ADP-glycosyltransferase variant of SEQ ID NO: 408 This example describes an evolution and screening experiment of β1,3-glycosyltransferase (β1,3GT) polypeptides derived from SEQ ID NO:408 for improved glucosylation of steviol glycosides using in situ synthesized ADP-glucose. Directed evolution of the GT encoded by SEQ ID NO:407 (i.e., SEQ ID NO:408) was performed by constructing libraries of variant genes that incorporated mutations associated with improved production identified during development of the present invention and that underwent saturation mutagenesis of certain structural features. These libraries were then plated, grown, and screened using the high-throughput (HTP) assay described below to obtain another round of 39 engineered GT variant polypeptides with glucosyltransferase activity toward ADP-glucose and steviol glycosides.

[0226] HTP assay for glucose transfer from sucrose to ADP, followed by glucose transfer from ADP-glucose to rebaudioside A60 The assay was performed using 96-well plates of clarified E. coli culture lysates expressing the SEQ ID NO:407 variant (i.e., the variant of SEQ ID NO:408). The pellets were lysed and the lysates were clarified as described in Example 6 and then diluted 20-fold into 50 mM potassium phosphate buffer, pH 6, with 60 g / L rebaudioside A 60%. To heat challenge the lysates, they were preincubated at 75°C for 2 hours with shaking at 300 RPM in a THERMOTRON® titer plate shaker. Assays were performed using 10 μL of pre-incubated lysate in 100 μL reactions, with 20 g / L rebaudioside A 60% substrate, 0.02 g / L ADP (Amresco, Ultra Pure Grade) cosubstrate, 0.03 g / L SUS SFP SEQ ID NO: 1822, 0.06 g / L β-1,2-glycosyltransferase (β12GT) SEQ ID NO: 1080, and 30 g / L sucrose. The following reaction conditions were used: 50 mM potassium phosphate buffer, pH 6, 60°C, 16 hours with shaking at 300 RPM in a THERMOTRON® titer plate shaker. The reaction was solubilized by 20-fold dilution with water, quenched by 5-fold dilution with acetonitrile with 0.2% formic acid, and diluted 20-fold with water for analysis. Samples were analyzed by RapidFire-MS / MS as described in Example 5, Table 5.1. Glycosyltransferase variant polypeptides were identified that produced higher amounts of rebaudioside M from rebaudioside A60 using in situ synthesized ADP-glucose than SEQ ID NO: 408. These engineered polypeptides are listed in Tables 11.1 and 11.2. For analysis of the variants shown in Table 11.3 compared to SEQ ID NO: 408, shake flask-scale cultures were grown, lysed, clarified, and lyophilized to a powder as described in Example 1. [Table 11-1] [Table 11-2] [Table 11-3]

[0227] SFP characterization assay and analysis of glucosyl transfer from sucrose to ADP, followed by glucosyl transfer from ADP-glucose to stevioside and rebaudioside D Shake flask powder (SFP) was reconstituted to a concentration of 20 g / L and diluted to 0.005–0.15 g / L SFP in a 100 μL total reaction volume with 50 mM potassium phosphate buffer, pH 6, 15 mM stevioside (purity >95%) or rebaudioside D, 0.02 g / L ADP (Amresco, Ultra Pure Grade) cosubstrate, 0.03 g / L SUS SFP SEQ ID NO: 1822, and 37.5 mM sucrose. Reactions were incubated at 60°C for 4 hours with shaking at 300 RPM in a THERMOTRON® titer plate shaker. Reactions were solubilized by 20-fold dilution with water, quenched by 5-fold dilution with acetonitrile with 0.2% formic acid, clarified by centrifugation, and diluted 15-fold with water for analysis. Glycosylation products were detected by SPE-QQQ as described in Example 5, Table 5.1. One-pot reactions were performed using 50 mM potassium phosphate buffer, pH 6, 20 g / L RebA60, 0.02 g / L ADP (Amresco, Ultra Pure Grade) cosubstrate, 0.03 g / L SUS SFP SEQ ID NO: 1822, 0.06 g / L β1,2GT SFP SEQ ID NO: 1080, and 30 g / L sucrose at 0.01–0.3 g / L in a total reaction volume of 100 μL. One set of SFP dilutions was preincubated in 50 mM potassium phosphate buffer, pH 6, for 2 hours at 75°C, while the other set was not. Reactions were incubated at 60°C for 16 hours with shaking at 300 RPM in a THERMOTRON® titer plate shaker. The reaction was solubilized by 20-fold dilution with water, quenched by 5-fold dilution with acetonitrile with 0.2% formic acid, clarified by centrifugation, and diluted 20-fold with water for analysis. A similar one-pot reaction was also performed using 10 μL of crude shake-flask lysate after 20-fold dilution with 50 mM potassium phosphate buffer, pH 6, and incubation for 24 hours at 75.2°C. [Table 11-4]

[0228] In these experiments, all four variants in Table 11.3 produced more rebaudioside M from rebaudioside A60, more rebaudioside A from stevioside, and more rebaudioside M from rebaudioside D than SEQ ID NO: 408. The most thermostable variant, SEQ ID NO: 440, was used as the starting point for further enzymatic engineering.

[0229] Example 12 Beta-1,3-ADP-glycosyltransferase variant of SEQ ID NO: 440 This example describes an evolution and screening experiment of β1,3-glycosyltransferase (β1,3GT) polypeptides derived from SEQ ID NO:440 for improved glucosylation of steviol glycosides using in situ synthesized ADP-glucose. Directed evolution of GT encoded by SEQ ID NO:439 (i.e., SEQ ID NO:440) was performed by constructing libraries of variant genes that incorporated mutations associated with improved production identified during development of the present invention and that underwent saturation mutagenesis of certain structural features. These libraries were then plated, grown, and screened using the high-throughput (HTP) assay described below to obtain another round of 36 engineered GT variant polypeptides with glucosyltransferase activity toward ADP-glucose and steviol glycosides.

[0230] HTP assay for glucose transfer from sucrose to ADP, followed by glucose transfer from ADP-glucose to rebaudioside A60 Assays were performed using 96-well plates of clarified E. coli culture lysates expressing SEQ ID NO: 440 variants. Pellets were lysed and lysates were clarified as described in Example 6 and then diluted 20-fold into 50 mM potassium phosphate buffer, pH 6, with 80 g / L rebaudioside A 60%. To heat challenge the lysates, they were preincubated at 75°C for 2 hours with shaking at 300 RPM in a THERMOTRON® titer plate shaker. Assays were performed using 10 μL of pre-incubated lysate in 100 μL reactions, with 20 g / L rebaudioside A 60% substrate, 0.02 g / L ADP (Amresco, Ultra Pure Grade) cosubstrate, 0.03 g / L SUS SFP SEQ ID NO: 1822, 0.06 g / L β-1,2-glycosyltransferase (β12GT) SEQ ID NO: 1080, and 30 g / L sucrose. The following reaction conditions were used: 50 mM potassium phosphate buffer, pH 6, 60°C, 16 hours with shaking at 300 RPM in a THERMOTRON® titer plate shaker. The reaction was solubilized by 20-fold dilution with water, quenched by 5-fold dilution with acetonitrile with 0.2% formic acid, and diluted 20-fold with water for analysis. Samples were analyzed by RapidFire-MS / MS as described in Example 5, Table 5.1. Glycosyltransferase variant polypeptides were identified that produced higher amounts of rebaudioside M from rebaudioside A60 using in situ synthesized ADP-glucose than SEQ ID NO: 440. These engineered polypeptides are listed in Tables 12.1 and 12.2. For analysis of the variants shown in Table 12.3 compared to SEQ ID NO: 440, shake flask-scale cultures were grown, lysed, clarified, and lyophilized to a powder as described in Example 1. [Table 12-1] [Table 12-2] [Table 12-3] [Table 12-4]

[0231] SFP characterization assay and analysis of glucosyl transfer from sucrose to ADP, followed by glucosyl transfer from ADP-glucose to stevioside and rebaudioside D Shake flask powder (SFP) was reconstituted to a concentration of 20 g / L and diluted to 0.005–0.15 g / L SFP in a 100 μL total reaction volume with 50 mM potassium phosphate buffer, pH 6, 15 mM stevioside (purity >95%) or rebaudioside D, 0.02 g / L ADP (Amresco, Ultra Pure Grade) cosubstrate, 0.03 g / L SUS SFP SEQ ID NO: 1822, and 37.5 mM sucrose. Reactions were incubated at 60°C for 4 hours with shaking at 300 RPM in a Thermotron® titer plate shaker. Reactions were solubilized by 20-fold dilution with water, quenched by 5-fold dilution with acetonitrile with 0.2% formic acid, clarified by centrifugation, and diluted 15-fold with water for analysis. Glycosylation products were detected by SPE-QQQ as described in Example 5, Table 5.1. One-pot reactions were performed using 0.01-0.3 g / L of SFP in a total reaction volume of 100 μL with 50 mM potassium phosphate buffer, pH 6, 20 g / L Rebaudioside A60, 0.02 g / L ADP (Amresco, Ultra Pure Grade) cosubstrate, 0.03 g / L SUS SFP SEQ ID NO: 1822, 0.06 g / L β1,2GT SFP SEQ ID NO: 1080, and 30 g / L sucrose. One set of SFP dilutions was preincubated with 80 g / L rebaudioside A60 in 50 mM potassium phosphate buffer, pH 6, for 2 hours at 75°C, while the other set was not preincubated. Reactions were incubated at 60°C for 16 hours with shaking at 300 RPM in a THERMOTRON® titer plate shaker. Reactions were solubilized by a 20-fold dilution with water, quenched by a 5-fold dilution with acetonitrile with 0.2% formic acid, clarified by centrifugation, and diluted 20-fold with water for analysis. A similar one-pot reaction was also performed using 10 μL of 1.5 mg / mL shake-flask powder in 50 mM potassium phosphate buffer, pH 6, incubated at 78.5°C for 24 hours. [Table 12-5] [Table 12-6]

[0232] In these experiments, all eight variants in Table 12.3 produced more rebaudioside M from rebaudioside A60 and from rebaudioside D than SEQ ID NO:440. All of the variants were also less active at catalyzing the glucosylation of stevioside to form rebaudioside A. The most active variant on the three substrates, SEQ ID NO:520, was used as the starting point for further enzyme engineering.

[0233] Example 13 Beta-1,3-ADP-glycosyltransferase variant of SEQ ID NO: 520 This example describes an evolution and screening experiment of β1,3-glycosyltransferase (β1,3GT) polypeptides derived from SEQ ID NO:520 for improved glucosylation of steviol glycosides using in situ synthesized ADP-glucose. Directed evolution of the GT encoded by SEQ ID NO:519 (i.e., SEQ ID NO:520) was performed by constructing libraries of variant genes that incorporated mutations associated with improved production identified during development of the present invention and that underwent saturation mutagenesis of certain structural features. These libraries were then plated, grown, and screened using the high-throughput (HTP) assay described below to obtain another round of 44 engineered GT variant polypeptides with glucosyltransferase activity toward ADP-glucose and steviol glycosides.

[0234] HTP assay for glucose transfer from sucrose to ADP, followed by glucose transfer from ADP-glucose to rebaudioside A60 Assays were performed using 96-well plates of clarified E. coli culture lysates expressing the SEQ ID NO:519 variant (i.e., the variant of SEQ ID NO:520). The pellets were lysed and the lysates were clarified as described in Example 6 and then diluted 49-fold into 50 mM potassium phosphate buffer, pH 6, with 100 g / L rebaudioside A 60%. To heat challenge the lysates, they were preincubated at 75°C for 2 hours with shaking at 300 RPM in a THERMOTRON® titer plate shaker. Assays were performed using 10 μL of pre-incubated lysate in 100 μL reactions, with 40 g / L rebaudioside A 60% substrate, 0.02 g / L ADP (Amresco, Ultra Pure Grade) cosubstrate, 0.06 g / L SUS SFP SEQ ID NO: 2182, 0.12 g / L β-1,2-glycosyltransferase (β12GT) SEQ ID NO: 1216, and 60 g / L sucrose. The following reaction conditions were used: 50 mM potassium phosphate buffer, pH 6, 60°C, 16 hours with shaking at 300 RPM in a THERMOTRON® titer plate shaker. The reactions were solubilized by a 40-fold dilution with water, quenched by a 5-fold dilution with acetonitrile with 0.2% formic acid, and diluted 20-fold with water for analysis. Samples were analyzed by RapidFire-MS / MS as described in Example 5, Table 5.1. Glycosyltransferase variant polypeptides were identified that produced higher amounts of rebaudioside M from rebaudioside A60 using in situ synthesized ADP-glucose than SEQ ID NO: 520. These engineered polypeptides are listed in Tables 13.1 and 13.2. For analysis of the variants shown in Table 13.3 compared to SEQ ID NO: 520, shake flask-scale cultures were grown, lysed, clarified, and lyophilized to a powder as described in Example 1. [Table 13-1] [Table 13-2] [Table 13-3]

[0235] SFP characterization assay and analysis of glucosyl transfer from sucrose to ADP, followed by glucosyl transfer from ADP-glucose to stevioside and rebaudioside D Shake flask powder (SFP) was reconstituted to a concentration of 20 g / L and diluted to 0.005–0.15 g / L SFP in a 100 μL total reaction volume with 50 mM potassium phosphate buffer, pH 6, 15 mM stevioside (purity >95%) or rebaudioside D, 0.02 g / L ADP (Amresco, Ultra Pure Grade) cosubstrate, 0.03 g / L SUS SFP SEQ ID NO: 2182, and 37.5 mM sucrose. Reactions were incubated at 60°C for 4 hours with shaking at 300 RPM in a THERMOTRON® titer plate shaker. Reactions were solubilized by 20-fold dilution with water, quenched by 5-fold dilution with acetonitrile with 0.2% formic acid, clarified by centrifugation, and diluted 15-fold with water for analysis. Glycosylation products were detected by SPE-QQQ as described in Example 5, Table 5.1. One-pot reactions were performed using 0.01-0.3 g / L of SFP in a total reaction volume of 100 μL with 50 mM potassium phosphate buffer, pH 6, 40 g / L Rebaudioside A60, 0.02 g / L ADP (Amresco, Ultra Pure Grade) cosubstrate, 0.03 g / L SUS SFP SEQ ID NO: 2182, 0.12 g / L β1,2GT SFP SEQ ID NO: 1216, and 60 g / L sucrose. One set of SFP dilutions was preincubated with 100 g / L rebaudioside A60% in 50 mM potassium phosphate buffer, pH 6, for 2 hours at 75°C, while the other set was not preincubated. Reactions were incubated at 60°C for 16 hours with shaking at 300 RPM in a THERMOTRON® titer plate shaker. Reactions were solubilized by a 40-fold dilution with water, quenched by a 5-fold dilution with acetonitrile with 0.2% formic acid, clarified by centrifugation, and diluted 20-fold with water for analysis. A similar one-pot reaction was also performed using 10 μL of crude clarified lysate diluted 25-fold in 50 mM potassium phosphate buffer, pH 6, with 100 g / L rebaudioside A 60% and incubated for 24 hours at 75.2°C. [Table 13-4] [Table 13-5]

[0236] In these experiments, all seven variants in Table 13.3 produced more rebaudioside M from rebaudioside A60 and from rebaudioside D, and more rebaudioside A from stevioside, than SEQ ID NO: 520. Four variants had similar thermal stability to SEQ ID NO: 520. SEQ ID NO: 626, the variant with the highest activity against stevioside and RebA60 without preincubation, was used as the starting point for further enzyme engineering.

[0237] Example 14 Beta-1,3-ADP-glycosyltransferase variant of SEQ ID NO: 626 This example describes an evolution and screening experiment of β1,3-glycosyltransferase (β1,3GT) polypeptides derived from SEQ ID NO:626 for improved glucosylation of steviol glycosides using in situ synthesized ADP-glucose. Directed evolution of the GT encoded by SEQ ID NO:625 (i.e., SEQ ID NO:626) was performed by constructing libraries of variant genes that incorporated mutations associated with improved production identified during development of the present invention and that underwent saturation mutagenesis of certain structural features. These libraries were then plated, grown, and screened using the high-throughput (HTP) assay described below to obtain another round of 43 engineered GT variant polypeptides with glucosyltransferase activity toward ADP-glucose and steviol glycosides.

[0238] HTP assay for glucose transfer from sucrose to ADP, followed by glucose transfer from ADP-glucose to rebaudioside A60 Assays were performed using 96-well plates of clarified E. coli culture lysates expressing the SEQ ID NO:625 variant (i.e., the variant of SEQ ID NO:626). The pellets were lysed and the lysates were clarified as described in Example 6 and then diluted 100-fold into 50 mM potassium phosphate buffer, pH 6, with 100 g / L rebaudioside A 60%. To heat challenge the lysates, they were preincubated at 75°C for 2 hours with shaking at 300 RPM in a THERMOTRON® titer plate shaker. Assays were performed using 10 μL of pre-incubated lysate in 100 μL reactions, with 40 g / L rebaudioside A 60% substrate, 0.02 g / L ADP (Amresco, Ultra Pure Grade) cosubstrate, 0.06 g / L SUS SFP SEQ ID NO: 2182, 0.09 g / L β-1,2-glycosyltransferase (β12GT) SEQ ID NO: 1488, and 60 g / L sucrose. The following reaction conditions were used: 50 mM potassium phosphate buffer, pH 6, 60°C, 16 hours with shaking at 300 RPM in a THERMOTRON® titer plate shaker. The reaction was solubilized by 40-fold dilution with water, quenched by 5-fold dilution with acetonitrile with 0.2% formic acid, and diluted 20-fold with water for analysis. Samples were analyzed by RapidFire-MS / MS as described in Example 5, Table 5.1. Glycosyltransferase variant polypeptides were identified that produced higher amounts of rebaudioside M from rebaudioside A60 using in situ synthesized ADP-glucose than SEQ ID NO: 626. These engineered polypeptides are listed in Tables 14.1 and 14.2. For analysis of the variants shown in Table 14.3 compared to SEQ ID NO: 626, shake flask-scale cultures were grown, lysed, clarified, and lyophilized to a powder as described in Example 1. [Table 14-1] [Table 14-2] [Table 14-3] [Table 14-4]

[0239] SFP characterization assay and analysis of glucosyl transfer from sucrose to ADP, followed by glucosyl transfer from ADP-glucose to stevioside and rebaudioside D Shake flask powder (SFP) was reconstituted to a concentration of 20 g / L and diluted to 0.005–0.15 g / L SFP in a 100 μL total reaction volume with 50 mM potassium phosphate buffer, pH 6, 15 mM stevioside (purity >95%) or rebaudioside D, 0.02 g / L ADP (Amresco, Ultra Pure Grade) cosubstrate, 0.03 g / L SUS SFP SEQ ID NO: 2182, and 37.5 mM sucrose. Reactions were incubated at 60°C for 4 hours with shaking at 300 RPM in a THERMOTRON® titer plate shaker. Reactions were solubilized by 20-fold dilution with water, quenched by 5-fold dilution with acetonitrile with 0.2% formic acid, clarified by centrifugation, and diluted 15-fold with water for analysis. Glycosylation products were detected by SPE-QQQ as described in Example 5, Table 5.1. One-pot reactions were performed using 50 mM potassium phosphate buffer, pH 6, 50 g / L Rebaudioside A60, 0.025 g / L ADP (Amresco, Ultra Pure Grade) cosubstrate, 0.075 g / L SUS SFP SEQ ID NO: 2182, 0.09 g / L β1,2GT SFP SEQ ID NO: 1488, and 75 g / L sucrose at 0.01–0.3 g / L SFP in a total reaction volume of 100 μL. One set of SFP dilutions was preincubated with 100 g / L rebaudioside A60 in 50 mM potassium phosphate buffer, pH 6, for 2 hours at 75°C, while the other set was not preincubated. Reactions were incubated at 60°C for 16 hours with shaking at 300 RPM in a THERMOTRON® titer plate shaker. Reactions were solubilized by 50-fold dilution with water, quenched by 5-fold dilution with acetonitrile with 0.2% formic acid, clarified by centrifugation, and diluted 20-fold with water for analysis. A similar one-pot reaction was also performed using 10 μL of crude clarified lysate diluted 25-fold in 50 mM potassium phosphate buffer, pH 6, with 100 g / L rebaudioside A 60% and incubated for 24 hours at 75.2°C. [Table 14-5] [Table 14-6]

[0240] In these experiments, the five variants in Table 14.3 produced more rebaudioside M from rebaudioside A60 than SEQ ID NO: 626. Of these, one variant, SEQ ID NO: 678, also had improved catalysis of the glucosylation of stevioside to rebaudioside A and rebaudioside D to rebaudioside M and was more thermostable than SEQ ID NO: 626. This active and thermostable variant, SEQ ID NO: 678, was used as the starting point for further enzyme engineering.

[0241] Example 15 Beta-1,3-ADP-glycosyltransferase variant of SEQ ID NO: 678 This example describes an evolution and screening experiment of β1,3-glycosyltransferase (β1,3GT) polypeptides derived from SEQ ID NO:678 for improved glucosylation of steviol glycosides using in situ synthesized ADP-glucose. Directed evolution of the GT encoded by SEQ ID NO:677 (i.e., SEQ ID NO:678) was performed by constructing libraries of variant genes engineered with mutations associated with improved production identified during development of the present invention. These libraries were then plated, grown, and screened using the high-throughput (HTP) assay described below to obtain another round of 47 engineered GT variant polypeptides with glucosyltransferase activity toward ADP-glucose and steviol glycosides.

[0242] HTP assay for glucose transfer from sucrose to ADP, followed by glucose transfer from ADP-glucose to rebaudioside A60 Assays were performed using 96-well plates of clarified E. coli culture lysates expressing the SEQ ID NO:677 variant (i.e., the variant of SEQ ID NO:678). The pellets were lysed and the lysates were clarified as described in Example 6 and then diluted 70-fold into 50 mM potassium phosphate buffer, pH 6, with 100 g / L rebaudioside A 60%. To heat challenge the lysates, they were preincubated at 75°C for 2 hours with shaking at 300 RPM in a THERMOTRON® titer plate shaker. Assays were performed using 10 μL of pre-incubated lysate in 100 μL reactions, with 50 g / L rebaudioside A 60% substrate, 0.025 g / L ADP (Amresco, Ultra Pure Grade) cosubstrate, 0.075 g / L SUS SFP SEQ ID NO: 2322, 0.09 g / L β-1,2-glycosyltransferase (β12GT) SEQ ID NO: 1488, and 75 g / L sucrose. The following reaction conditions were used: 16 hours with shaking at 300 RPM in a THERMOTRON® titer plate shaker, 50 mM potassium phosphate buffer, pH 6, 60°C. Reactions were solubilized by 50-fold dilution with water, quenched by 5-fold dilution with acetonitrile with 0.2% formic acid, and diluted 20-fold with water for analysis. Samples were analyzed by RapidFire-MS / MS as described in Example 5, Table 5.1. Glycosyltransferase variant polypeptides were identified that produced higher amounts of rebaudioside M from rebaudioside A60 using in situ synthesized ADP-glucose than SEQ ID NO: 678. These engineered polypeptides are listed in Table 15.1. For analysis of the variants shown in Table 15.2 compared to SEQ ID NO: 678, shake flask-scale cultures were grown, lysed, clarified, and lyophilized to a powder as described in Example 1. [Table 15-1] [Table 15-2] [Table 15-3]

[0243] SFP characterization assay and analysis of glucosyl transfer from sucrose to ADP, followed by glucosyl transfer from ADP-glucose to stevioside and rebaudioside D Shake flask powder (SFP) was reconstituted to a concentration of 20 g / L and diluted to 0.0125-0.2 g / L SFP in a 100 µL total reaction volume with 50 mM potassium phosphate buffer, pH 6, 15 mM stevioside (purity >95%) or rebaudioside D or rebaudioside E (prepared in-house from β1,2GT-treated stevioside), 0.02 g / L ADP (Amresco, Ultra Pure Grade) cosubstrate, 0.025 g / L SUS SFP SEQ ID NO: 2322, and 37.5 mM sucrose. Reactions were incubated at 60 °C for 4 h with shaking at 300 RPM in a THERMOTRON® titer plate shaker. The reaction mixture was solubilized by 20-fold dilution with water, quenched by 5-fold dilution with acetonitrile with 0.2% formic acid, clarified by centrifugation, and diluted 15-fold with water for analysis. Glycosylated products were detected by SPE-QQQ as described in Example 5, Table 5.1. A one-pot reaction was performed using 50 mM potassium phosphate buffer, pH 6, 100 g / L RebA60, 0.05 g / L ADP (Amresco, Ultra Pure Grade) cosubstrate, 0.2 g / L SUS SFP SEQ ID NO: 2322, 0.2 g / L β1,2GT SFP SEQ ID NO: 1516, and 150 g / L sucrose (cane sugar) at 0.0125-0.2 g / L SFP in a total reaction volume of 100 μL. One set of SFP dilutions was preincubated with 100 g / L rebaudioside A 60% in 50 mM potassium phosphate buffer, pH 6 for 2 hours at 75°C, while the other set was not preincubated. Reactions were incubated at 60°C for 16 hours with shaking at 300 RPM in a THERMOTRON® titer plate shaker. Reactions were solubilized by 100-fold dilution with water, quenched by 5-fold dilution with acetonitrile with 0.2% formic acid, clarified by centrifugation, and diluted 20-fold with water for analysis. A similar one-pot reaction was also performed using 10 μL of crude clarified lysate diluted 25-fold in 50 mM potassium phosphate buffer, pH 6 with 100 g / L rebaudioside A 60% and incubated for 24 hours at 75.2°C. [Table 15-4]

[0244] In these experiments, the three variants in Table 15.2 produced more rebaudioside M from rebaudioside A60 than SEQ ID NO: 678. Of these, one variant, SEQ ID NO: 768, also had thermostability at least similar to SEQ ID NO: 678. Therefore, SEQ ID NO: 768 was selected as the best enzyme for catalyzing the glycosyl transfer from ADP-glucose to stevioside and rebaudioside D to form rebaudioside A and rebaudioside M, respectively.

[0245] Example 16 Beta-1,2-ADP-glycosyltransferase variant of SEQ ID NO: 24 This example describes experiments in evolving and screening GT polypeptides derived from SEQ ID NO:24 for improved glucosylation of steviol glycosides using ADP-glucose. Directed evolution of GT, encoded by SEQ ID NO:23, was performed by constructing libraries of variant genes. The libraries recombined mutations associated with improved production identified during development of the present invention and were subjected to saturation mutagenesis of certain structural features of the enzyme. These libraries were then plated, grown, and screened using the HTP assay described below to obtain another round of engineered GT variant polypeptides with glucosyltransferase activity toward ADP-glucose and steviol glycosides. Sixteen engineered variants were identified from the combinatorial library (Table 16.1), and 51 from the saturation mutagenesis library (Table 16.2).

[0246] HTP binding assay for glucose transfer from sucrose to ADP and then to rebaudioside A60 Assays were performed using 96-well plates of clarified E. coli culture lysates expressing the SEQ ID NO:23 variant (i.e., the SEQ ID NO:24 variant). The volume of the lysis buffer was 400 μL, and the lysates were diluted 150-fold in 50 mM potassium phosphate, pH 6.0, and pre-incubated at 75° C. for 1 hour. Assays were then performed using 10 μL of the diluted lysate, 0.03 g / L SUS SFP SEQ ID NO:22, and 0.1 g / L β-1,3-glycosyltransferase (β1,3GT) SFP SEQ ID NO:20 in a 100 μL reaction volume with 20 g / L rebaudioside A 60% (RebA60) substrate, 0.02 g / L ADP (Amresco, Ultra Pure Grade) cosubstrate, and 30 g / L sucrose. The following reaction conditions were used: 50 mM potassium phosphate buffer, pH 6, 60°C, 16-18 hours with shaking at 300 RPM in a THERMOTRON® titer plate shaker. Reactions were solubilized by 20-fold dilution into water, quenched by 5-fold dilution into acetonitrile with 0.2% formic acid, precipitated by centrifugation, and diluted 20-fold into water for analysis as described above. The resulting engineered variants with glucosyltransferase activity toward RebA60 are listed in Tables 16.1 and 16.2. For the variants listed in Table 16.3, shake-flask-scale cultures were grown, lysed, and lyophilized to powder. [Table 16-1] [Table 16-2] [Table 16-3] [Table 16-4] [Table 16-5]

[0247] Shake flask powder characterization assay and analysis of glucosyl transfer from sucrose to ADP and then to rebaudioside A60 Shake flask powder (SFP) was reconstituted to a concentration of 4 g / L and diluted to 0.0013–0.04 g / L in a 100 μL total reaction volume containing 50 mM potassium phosphate buffer, pH 6, 20 g / L RebA97 (single substrate) or RebA60 (one-pot), 0.02 g / L ADP, 20 g / L (single substrate) or 30 g / L (one-pot) sucrose, 0.04 g / L SUS SFP SEQ ID NO: 22, and, for the one-pot reaction only, 0.15 g / L β-1,3-glycosyltransferase (β1,3GT) SFP SEQ ID NO: 36. Reactions were carried out at 60 °C in a THERMOTRON® titer plate shaker at 300 RPM for 4 h (single substrate) or 16–18 h (one-pot). One set of SFP dilutions was preincubated in 50 mM potassium phosphate buffer, pH 6, for 1 hour at 75°C, while the other set was not. Reactions were solubilized by 20-fold dilution with water, quenched by 5-fold dilution with acetonitrile with 0.2% formic acid, clarified by centrifugation, and diluted 20-fold with water for analysis. Glycosylated products were detected by SPE-QQQ as described in Example 5, Table 5.1. To assess thermal stability, similar single-substrate rebaudioside A reactions were also performed using 10 μL of crude clarified lysate diluted 200-fold in 50 mM potassium phosphate buffer, pH 6, and incubated at 66.2°C for 24 hours. The thermal stability results and production levels of single-substrate rebaudioside D and one-pot rebaudioside M by these variants at 0.01 g / L SFP loading are shown in Table 16.3. [Table 16-6] [Table 16-7]

[0248] In these experiments, three variants in Table 16.3 showed improved catalysis of the glucosylation of rebaudioside A to rebaudioside D and the β1,2-glucosylation involved in the conversion of 60% of rebaudioside A to rebaudioside M compared to SEQ ID NO: 24. Two of these variants were also more thermostable than SEQ ID NO: 24. Of these, the variant with the greatest improvement after pre-incubation, SEQ ID NO: 858, was selected as the starting point for further enzyme engineering.

[0249] Example 17 Beta-1,2-ADP-glycosyltransferase variant of SEQ ID NO: 858 This example describes experiments in evolving and screening GT polypeptides derived from SEQ ID NO:858 for improved glucosylation of steviol glycosides using ADP-glucose. Directed evolution of GT, encoded by SEQ ID NO:857, was performed by constructing libraries of variant genes. The libraries recombined mutations associated with improved production identified during the development of the present invention. These libraries were then plated, grown, and screened using the HTP assay described below to obtain another round of engineered GT variant polypeptides with glucosyltransferase activity toward ADP-glucose and steviol glycosides. 44 engineered variants were identified from the combinatorial library (Table 17.1).

[0250] HTP binding assay for glucose transfer from sucrose to ADP and then to rebaudioside A60 Assays were performed using a 96-well plate of clarified E. coli culture lysate expressing the SEQ ID NO:857 variant (i.e., the variant of SEQ ID NO:858). The volume of lysis buffer was 400 μL, and the lysate was diluted 200-fold in 50 mM potassium phosphate, pH 6.0, and pre-incubated at 75° C. for 2 hours. Assays were then performed using 10 μL of the diluted lysate, 0.03 g / L SUS SFP SEQ ID NO:1652, and 0.1 g / L β-1,3-glycosyltransferase (β1,3GT) SFP SEQ ID NO:174 in a 100 μL reaction volume with 20 g / L rebaudioside A 60% (RebA60) substrate, 0.02 g / L ADP (Amresco, Ultra Pure Grade) cosubstrate, and 30 g / L sucrose. The following reaction conditions were used: 50 mM potassium phosphate buffer, pH 6, 60°C, 16-18 hours with shaking at 300 RPM in a THERMOTRON® titer plate shaker. Reactions were solubilized by 20-fold dilution into water, quenched by 5-fold dilution into acetonitrile with 0.2% formic acid, precipitated by centrifugation, and diluted 20-fold into water for analysis as described above. The resulting engineered variants with glucosyltransferase activity toward RebA60 are listed in Table 17.1. For the variants listed in Table 17.2, shake-flask-scale cultures were grown, lysed, and lyophilized to a powder. [Table 17-1] [Table 17-2]

[0251] Shake flask powder characterization assay and analysis of glucosyl transfer from sucrose to ADP and then to rebaudioside A60 Shake flask powder (SFP) was reconstituted to a concentration of 4 g / L and diluted to 0.0013–0.04 g / L in a 100 μL total reaction volume containing 50 mM potassium phosphate buffer, pH 6, 20 g / L RebA97 (single substrate) or RebA60 (one-pot), 0.02 g / L ADP, 20 g / L (single substrate) or 30 g / L (one-pot) sucrose, 0.03 g / L SUS SFP SEQ ID NO: 1652, and, for the one-pot reaction only, 0.1 g / L β-1,3-glycosyltransferase (β1,3GT) SFP SEQ ID NO: 174. Reactions were carried out at 60 °C in a THERMOTRON® titer plate shaker at 300 RPM for 4 h (single substrate) or 16–18 h (one-pot). One set of SFP dilutions was preincubated in 50 mM potassium phosphate buffer, pH 6, for 2 hours at 75°C, while the other set was not. Reactions were solubilized by 20-fold dilution with water, quenched by 5-fold dilution with acetonitrile with 0.2% formic acid, clarified by centrifugation, and diluted 20-fold with water for analysis. Glycosylation products were detected by SPE-QQQ as described in Example 5, Table 5.1. To assess thermal stability, similar single-substrate rebaudioside A reactions were also performed using 10 μL of crude clarified lysate diluted 70-fold with 50 mM potassium phosphate buffer, pH 6, and incubated at 71.8°C for 24 hours. The thermal stability results and production levels of single-substrate rebaudioside D and one-pot rebaudioside M by these variants at an SFP loading of 0.005 g / L are shown in Table 17.2. [Table 17-3]

[0252] In these experiments, all eight variants in Table 17.2 showed improved catalysis of the glucosylation of rebaudioside A to rebaudioside D and the β1,2-glucosylation involved in the conversion of rebaudioside A 60% to rebaudioside M compared to SEQ ID NO: 858. The most active variant for both substrates, SEQ ID NO: 994, was selected as the starting point for further enzyme engineering.

[0253] Example 18 Beta-1,2-ADP-glycosyltransferase variant of SEQ ID NO: 994 This example describes experiments in evolving and screening GT polypeptides derived from SEQ ID NO:994 for improved glucosylation of steviol glycosides using ADP-glucose. Directed evolution of the GT encoded by SEQ ID NO:994 was performed by constructing libraries of variant genes. The libraries recombined mutations associated with improved production identified during development of the present invention and were subjected to saturation mutagenesis of certain structural features of the enzyme. These libraries were then plated, grown, and screened using the HTP assay described below to obtain another round of engineered GT variant polypeptides with glucosyltransferase activity toward ADP-glucose and steviol glycosides. Nineteen engineered variants were identified from the combinatorial library (Table 18.1), and 25 were identified from the saturation mutagenesis library (Table 18.2).

[0254] HTP binding assay for glucose transfer from sucrose to ADP and then to rebaudioside A60 Assays were performed using 96-well plates of clarified E. coli culture lysates expressing SEQ ID NO: 994 variants (i.e., variants of SEQ ID NO: 994). The volume of lysis buffer was 400 μL, and the lysates were diluted 100-fold into 50 mM potassium phosphate, pH 6.0, with or without 60% rebaudioside A at 20 g / L (combinatorial library) or 30 g / L (saturation mutagenesis library), and pre-incubated for 2 hours at 75° C. Assays were then performed using 10 μL of the diluted lysate, 0.03 g / L SUS SFP SEQ ID NO:1822, and 0.1 g / L β-1,3-glycosyltransferase (β1,3GT) SFP SEQ ID NO:350 in a 100 μL reaction volume with 20 g / L rebaudioside A60% (RebA60) substrate, 0.02 g / L ADP (Amresco, Ultra Pure Grade) cosubstrate, and 30 g / L sucrose. The following reaction conditions were used: 50 mM potassium phosphate buffer, pH 6, and 60°C for 16-18 hours with shaking at 300 RPM in a THERMOTRON® titer plate shaker. Reactions were solubilized by 20-fold dilution in water, quenched by 5-fold dilution in acetonitrile with 0.2% formic acid, precipitated by centrifugation, and diluted 20-fold in water for analysis as described above. The resulting engineered variants with glucosyltransferase activity towards RebA60 are listed in Tables 18.1 and 90.2. For the variants listed in Table 18.3, shake flask scale cultures were grown, thawed, and lyophilized to a powder. [Table 18-1] [Table 18-2] [Table 18-3] [Table 18-4]

[0255] Shake flask powder characterization assay and analysis of glucosyl transfer from sucrose to ADP and then to rebaudioside A60 Shake flask powder (SFP) was reconstituted to a concentration of 4 g / L and diluted to 0.0013–0.04 g / L in a 100 μL total reaction volume containing 50 mM potassium phosphate buffer, pH 6, 20 g / L RebA97 (single substrate) or RebA60 (one-pot), 0.02 g / L ADP, 20 g / L (single substrate) or 30 g / L (one-pot) sucrose, 0.03 g / L SUS SFP SEQ ID NO: 1822, and, for the one-pot reaction only, 0.1 g / L β-1,3-glycosyltransferase (β1,3GT) SFP SEQ ID NO: 350. Reactions were carried out at 60 °C in a THERMOTRON® titer plate shaker at 300 RPM for 4 h (single substrate) or 16–18 h (one-pot). One set of SFP dilutions was preincubated with 10 g / L rebaudioside A60% in 50 mM potassium phosphate buffer, pH 6, for 2 hours at 75°C, while the other set was not. The reactions were solubilized by a 20-fold dilution with water, quenched by a 5-fold dilution with acetonitrile with 0.2% formic acid, clarified by centrifugation, and diluted 20-fold with water for analysis. Glycosylated products were detected by SPE-QQQ as described in Example 5, Table 5.1. To assess thermal stability, a similar one-pot RebA60 reaction was also performed using 10 μL of crude clarified lysate diluted 70-fold in 50 mM potassium phosphate buffer, pH 6, with 10 g / L RebA60 and incubated for 24 hours at 71.8°C. The thermostability results and production levels of rebaudioside D with single substrate and rebaudioside M in one-pot reaction by these variants at 0.005 g / L SFP loading are shown in Table 18.3. [Table 18-5]

[0256] In these experiments, the three variants in Table 18.3 showed significantly improved catalysis of the glucosylation of rebaudioside A to rebaudioside D compared to SEQ ID NO: 994 after pre-incubation. The most thermostable variant, SEQ ID NO: 1080, was selected as the starting point for further enzyme engineering.

[0257] Example 19 Beta-1,2-ADP-glycosyltransferase variant of SEQ ID NO: 1080 This example describes experiments to evolve and screen GT polypeptides derived from SEQ ID NO:1080 for improved glucosylation of steviol glycosides using ADP-glucose. Directed evolution of GT, encoded by SEQ ID NO:1079, was performed by constructing libraries of variant genes. The libraries recombined mutations associated with improved production identified during development of the present invention and were subjected to saturation mutagenesis of certain structural features of the enzyme. These libraries were then plated, grown, and screened using the HTP assay described below to obtain another round of engineered GT variant polypeptides with glucosyltransferase activity toward ADP-glucose and steviol glycosides. Thirty-three engineered variants were identified from the combinatorial library (Table 19.1), and 38 were identified from the saturation mutagenesis library (Table 19.2).

[0258] HTP binding assay for glucose transfer from sucrose to ADP and then to rebaudioside A60 Assays were performed using 96-well plates of clarified E. coli culture lysates expressing the SEQ ID NO: 1079 variant (i.e., the variant of SEQ ID NO: 1080). The volume of lysis buffer was 400 μL, and the lysates were diluted 100-fold into 50 mM potassium phosphate, pH 6.0, with 30 g / L (combinatorial library) or 10 g / L (saturation mutagenesis retest) rebaudioside A 60% and pre-incubated for 2 hours at 75° C. Assays were then performed using 10 μL of the diluted lysate, 0.03 g / L SUS SFP SEQ ID NO:1822, and 0.1 g / L β-1,3-glycosyltransferase (β1,3GT) SFP SEQ ID NO:350 in a 100 μL reaction volume with 20 g / L rebaudioside A60% (RebA60) substrate, 0.02 g / L ADP (Amresco, Ultra Pure Grade) cosubstrate, and 30 g / L sucrose. The following reaction conditions were used: 50 mM potassium phosphate buffer, pH 6, and 60°C for 16-18 hours with shaking at 300 RPM in a THERMOTRON® titer plate shaker. Reactions were solubilized by 20-fold dilution in water, quenched by 5-fold dilution in acetonitrile with 0.2% formic acid, precipitated by centrifugation, and diluted 20-fold in water for analysis as described above. The resulting engineered variants with glucosyltransferase activity towards RebA60 are listed in Tables 19.1 and 19.2. For the variants listed in Table 19.3, shake flask scale cultures were grown, thawed, and lyophilized to a powder. [Table 19-1] [Table 19-2] [Table 19-3] [Table 19-4] [Table 19-5]

[0259] Shake flask powder characterization assay and analysis of glucosyl transfer from sucrose to ADP and then to rebaudioside A60 Shake flask powder (SFP) was reconstituted to a concentration of 4 g / L and diluted to 0.0013–0.04 g / L in a 100 μL total reaction volume containing 50 mM potassium phosphate buffer, pH 6, 20 g / L RebA97 or steviol glycoside 95% (single substrate) or RebA60 (one-pot), 0.02 g / L ADP, 20 g / L (single substrate) or 30 ...

Claims

1. 1. An engineered glycosyltransferase comprising a polypeptide sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to SEQ ID NO: 20, 36, 174, 406, 408, 440, 520, 626, or 678, wherein the polypeptide sequence of the engineered glycosyltransferase is: (a) comprising at least one mutation at one or more of positions 146, 221, 16, 196, 232, and / or 410, or comprising one or more mutations at 153C, 204M, 170T, 175D, 207V, 285S, 289A, 338A, and / or 402I, said positions being numbered with reference to SEQ ID NOs: 20, 36, 174, 408, 440, or 520; (b) 41E / 72P / 233Q / 338A, 41E / 72P / 338A, 41E / 144Q / 233T, 41E / 233Q, 41E / 233Q / 338V, 41E / 233T, 41E / 233T / 338V, 61D, 61D / 87K / 91 L / 107L, 61D / 87K / 91L / 259T, 61D / 107V, 61D / 259T / 428I, 61D / 407T / 428I, 61E / 87K / 91L / 107V, 61E / 91L / 431M, 61E / 411T, 72P, 72P / 76S, 72P / 76S / 163A / 197K, 72P / 76S / 207V / 338V, 72P / 76T, 72P / 76T / 195Q / 233T, 72P / 76T / 197K / 204T, 72P / 76T / 207V / 233Q, 72P / 81 T, 72P / 81T / 195Q / 233Q, 72P / 139N / 195Q / 204T, 72P / 144Q / 338V, 72P / 200R / 204T / 207V, 72P / 207V, 76S / 144Q / 197K / 200R, 76S / 195Q / 197K / 204T / 207V / 233T, 76S / 197K / 207V / 233Q, 76S / 233T, 81T / 139N / 144Q / 195Q / 200R / 204T / 207V / 233Q, 81T / 144Q / 233Q, 81T / 19 7K / 200R / 207V / 233Q / 338A, 81T / 233Q / 338V, 81T / 338V, 107V, 107V / 259T, 139N / 144Q / 233Q, 144Q / 233T, 144Q / 233T / 338V, 156S / 40 at least one mutation or set of mutations selected from: 7T, 163A / 233T / 338A, 200R / 204T / 207V / 233T, 233Q / 338V, 259T, 71G, 71T, 80D, 80P, 80Q, 81A, 81L, 81M, 81S, 81T, 81V, 81V / 270K, 83D, 85T, 85V, 97V, 124P, 263C, 286L, 334V, 402I, 420R and 456K, said positions being numbered with reference to SEQ ID NO:20; (c)73S / 81T / 144Q / 207V / 259T、73S / 81T / 144Q / 207V / 285S / 451Q、73S / 81T / 259T / 285S / 426I / 451Q、73S / 81T / 259T / 451Q、73S / 111T / 285S / 451Q、73S / 144Q / 207V / 252P / 426I / 451Q、73S / 144Q / 207V / 259T / 285S / 426I / 451Q、73S / 144Q / 207V / 259T / 285S / 451Q、73S / 144Q / 207V / 259T / 426I / 451Q、73S / 144Q / 259T / 285S、73S / 259T / 426I / 451Q、73S / 259T / 451Q、81T / 111T / 144Q / 207V / 285S / 451Q、81T / 111T / 259T / 451Q、81T / 144Q / 207V / 252P / 285S / 426I、81T / 144Q / 207V / 259T / 451Q、81T / 144Q / 252P / 259T / 285S / 451Q、81T / 144Q / 259T、81T / 144Q / 259T / 285S、81T / 144Q / 259T / 451Q、81T / 207V / 252P / 259T / 451Q、81T / 207V / 285S / 426I / 451Q、81T / 285S、81T / 285S / 451Q、111T / 144Q / 207V / 252P / 285S / 426I / 451Q、111T / 144Q / 252P / 259T / 285S / 451Q、111T / 144Q / 259T / 285S / 426I / 451Q、111T / 207V / 285S、144Q / 207V / 252P / 259T、144Q / 207V / 259T、144Q / 207V / 259T / 285S / 451Q、144Q / 207V / 259T / 426I / 451Q、144Q / 207V / 285S / 426I、144Q / 207V / 451Q、144Q / 252P / 259T / 285S、144Q / 252P / 259T / 285S / 451Q、144Q / 252P / 259T / 426I、144Q / 252P / 259T / 426I / 451Q、144Q / 259T / 285S、144Q / 285S、144Q / 285S / 451Q、144Q / 451Q、207V、207V / 252P / 259T / 451Q、207V / 252P / 451Q、207V / 259T、207V / 259T / 426I / 451Q、At least one mutation or set of mutations selected from 207V / 285S / 426I / 451Q, 207V / 451Q, 252P / 259T, 259T, 259T / 285S / 451Q, 285S and 285S / 451Q, said positions being numbered with reference to SEQ ID NO:36; (d) 80D / 81A, 80D / 81A / 85V, 80D / 81A / 85V / 238G, 80D / 81A / 85V / 251M / 259T, 80D / 81A / 85V / 252P / 256G / 259T, 80D / 85V, 80D / 85V / 238G, 80D / 85V / 238G / 251M / 259T, 80D / 85V / 251I / 252P / 256G / 259T, 80D / 85 V / 251I / 259T, 80D / 85V / 251M, 80D / 85V / 251M / 252P, 80D / 85V / 251M / 252P / 256G / 259T, 80D / 85V / 259T, 80D / 259T, 80P / 81A / 85V / 259T, 80P / 81A / 251I / 252P / 259T, 80P / 85V, 80P / 85V / 251M / 252P / 259T, 81A / 85V, 81A / 85V / 251M / 252P, 81A / 85V / 259T, 85V, 85V / 238G, 85V / 251F, 85V / 251F / 259T, 85V / 251M / 252 P / 256G, 85V / 256G / 259T, 175D / 402I, 251I / 252P / 259T, 259T, 270K / 402I, 420R, 3S, 5A, 5H, 5L, 5T, 7A, at least one mutation or set of mutations selected from: 7Q, 99V, 153C, 232I / 317L, 252A, 273K, 299M, 326A, 326E, 326N, 326S, 393I, 404M, 404V, 409S, 422I, 443A, 451E, 451V, 455M, and 455R, said positions being numbered with reference to SEQ ID NO: 174; (e) 81A / 85V, 81A / 85V / 175E / 259T / 402E, 81A / 85V / 251I, 81A / 85V / 251I / 259T, 81A / 85 V / 259T, 81A / 85V / 259T / 402E, 85V, 85V / 175E, 85V / 175E / 251I, 85V / 175E / 251I / 259T / 4 02E, 85V / 175E / 259T, 85V / 175E / 259T / 402E, 85V / 175E / 402E, 85V / 259T, 85V / 259T / 402E and 85V / 402E, wherein said positions are numbered with reference to SEQ ID NO:406; (f) 153C, 153C / 326S, 153C / 326S / 443A, 153C / 326S / 443A / 455M, 232I, 232I / 273K / 299M, 232I / 393I / 451E, 299M / 451E, 326E, 326S, 404V, 451E, 25A, 116D, 116R, 116S, 146G, 170C, 170G, 170P , 170S, 170T, 173S, 227T, 296V, 300S, 315T, 327Y, 330G, 330T, 361C, 408C, 408T, 412A, 412K, 412S, 438Q, 448H and 449S, wherein said positions are numbered with reference to SEQ ID NO:408; (g) 146G / 170S / 196I, 146G / 170S / 232I, 146G / 170S / 232I / 423K / 448H / 451E / 455M , 146G / 170T / 196I / 232I, 146G / 170T / 196I / 232I / 423K, 146G / 170T / 196I / 232I / 45 1E / 455R, 146G / 170T / 196I / 408T / 451E, 146G / 170T / 232I / 423K, 146G / 170T / 259E , 146G / 196I, 146G / 196I / 232I, 146G / 196I / 232I / 259E / 448H / 451E, 146G / 196I / 45 at least one mutation or set of mutations selected from: 5R, 146G / 232I / 259E / 455M, 146G / 232I / 315S, 146G / 232I / 315S / 423K / 451E / 455M, 146G / 232I / 326E, 146G / 232I / 448H, 146G / 232I / 451E, 146G / 413M / 451E / 455M, 9L, 12Q, 107C, 131A, 156S, 161E, 169T, 199S, 204M, 209Y, 233K, 262A, 289A, 337N, 337W and 417V, wherein said positions are numbered with reference to SEQ ID NO:440; (h) 9L / 12Q / 107C / 161E / 199S / 209Y / 337N, 9L / 12Q / 161E / 169T / 199S / 209Y / 337W, 9L / 12Q / 199S / 204M / 209Y / 337N / 455R, 9 L / 12Q / 199S / 209Y / 337W / 451E / 455R, 9L / 107C / 131A / 204M / 259E / 417V / 451E, 9L / 107C / 156S / 161E / 199S / 204M / 417V / 455R , 9L / 107C / 161E / 209Y / 259E / 289A / 451E / 455R, 9L / 131A / 156S / 209Y / 289A / 337N, 9L / 131A / 204M / 337N / 451E, 9L / 156S / 169 T / 204M / 337N, 9L / 169T / 204M / 289A / 337W / 451E / 455R, 9L / 204M, 9L / 204M / 259E / 289A, 9L / 337W, 12Q / 14I / 107C / 204M / 289A / 455R, 12Q / 107C / 131A / 204M / 289A / 337W / 417V / 451E / 455R, 12Q / 107C / 156S / 209Y / 289A / 455R, 107C / 161E / 169T / 199S / 2 04M / 259E / 451E, 107C / 199S / 204M / 289A, 107C / 199S / 209Y / 259E / 451E / 455R, 107C / 204M, 156S / 169T / 199S / 204M / 209Y / 25 or at least one mutation or set of mutations selected from 9E / 289A, 161E / 204M / 417V, 204M / 451E / 455R, 289A, 451E / 455R, 16M, 53Q, 54P, 78V, 80A, 95W, 111C, 111G, 111S, 221A, 257A, 336R, 349V, 391R, 410V, 413L, 426S, and 430Q, said positions being numbered with reference to SEQ ID NO:520; or (i) 16M, 16M / 59Q / 80A / 413L, 16M / 80A, 16M / 80A / 111C, 16M / 80A / 111S / 257A , 16M / 80A / 221A / 257A / 336R / 410V, 16M / 80A / 221A / 336R / 410V, 16M / 80A / 25 7A, 16M / 111C / 221A / 257A / 391R, 16M / 111S / 221A, 16M / 221A, 16M / 221A / 257 A, 16M / 221A / 257A / 336R / 391R, 16M / 221A / 410V, 16M / 257A, 16M / 257A / 336R / at least one mutation or set of mutations selected from 413L / 420G, 80A / 111S / 221A / 257A / 410V, 111S / 221A / 257A / 336R / 391R, 111S / 221A / 257A / 391R, 221A, 221A / 257A, 5L, 5M, 5N, 5Q, 7L, 14L, 65V, 91V, 99L, 99S, 102R, 118S, 118V, 138I, 194P, 254G, 254T, 254V, 286L, 416E, 418D, and 420A, wherein said positions are numbered with reference to SEQ ID NO:626; (j) 5L / 14L / 99L, 5L / 14L / 416E, 5N, 5N / 91V, 5N / 91V / 102R / 118V, 5N / 91V / 102R / 254T / 418D, 5N / 91V / 106I / 254T / 286L, 5N / 91V / 118S / 194P / 254T / 418D, 5N / 91V / 118S / 254T / 286L / 418D, 5N / 91V / 118S / 286L, 5N / 91V / 118V / 194P / 254T / 286L, 5N / 91V / 118V / 194P / 418D, 5N / 91V / 194P / 254T, 5N / 91V / 194P / 418D, 5N / 91V / 254T, 5N / 91V / 254T / 286 L, 5N / 102R / 418D, 5N / 118S / 194P / 286L / 418D, 5N / 118S / 286L, 5N / 118V / 254T, 5N / 194P, 5N / 254T / 286L, 5N / 418D, 7L / 14L, 7L / 14L / 65V / 99L, 7L / 14L / 99S / 416E, 14L, 14L / 65V / 99L / 416E, 14L / 99L, 14L / 99L / 254G, 14L / 99L / 254G / 416E, 14L / 99L / 254G / 416E / 455R, 14L / 99L / 416E, 14L / 99S / 416E, 14L / 167E, 14L / 254G, 14L / 455R, 91V, 91V / 102 R / 194P, 91V / 118V, 91V / 118V / 194P, 91V / 118V / 194P / 286L, 91V / 118V / 194P / 418D, 91V / 118V / 286L, 91V / 194P / 254T / 286L, 91V / 286L and 118V / 286L / 418D, wherein said positions are numbered with reference to SEQ ID NO: 678; Where: the engineered glycosyltransferase is a beta-1,3-glycosyltransferase and an ADP-glucose dependent glycosyltransferase; the engineered glycosyltransferase is characterized by improved glucosyltransferase activity to ADP-glucose and increased production of rebaudioside M from rebaudioside A or rebaudioside D, and / or increased production of rebaudioside A from steviol, compared to an engineered glycosyltransferase having the sequence of SEQ ID NO:

20. Engineered glycosyltransferases.

2. 2. The engineered glycosyltransferase of claim 1, wherein the polypeptide sequence of the engineered glycosyltransferase comprises at least one mutation at one or more of positions 146, 16, 196, 221, 232, and / or 410, wherein the mutations are 146G, 16M, 196I, 221A, 232I, and / or 410V, and wherein the positions are numbered with reference to SEQ ID NOs: 20, 36, 174, 408, 440, or 520.

3. 2. The engineered glycosyltransferase of claim 1, wherein the polypeptide sequence of the engineered glycosyltransferase comprises one or more mutations of 153C, 204M, 170T, 175D, 207V, 285S, 289A, 338A, and / or 402I, and the positions are numbered with reference to SEQ ID NOs: 20, 36, 174, 408, 440, or 520.

4. The engineered glycosyltransferases are selected from the group consisting of SEQ ID NOs: 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, 128, 130, 132, 134, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, , 156, 158, 160, 162, 164, 166, 168, 170, 172, 174, 176, 178, 180, 182, 184, 186, 188, 190, 192, 194, 196, 198, 200, 202, 204, 206, 208, 210, 212, 214, 216, 218, 220, 222, 224, 226, 228, 230, 232, 234, 236, 238, 240, 242, 244, 246, 248, 250, 252, 254, 256, 258, 260, 262, 264, 266, 268, 270, 272, 274, 276, 278, 2 86, 288, 290, 292, 294, 296, 298, 300, 302, 304, 306, 308, 310, 312, 314, 316, 318, 320, 322, 324, 326, 328, 330, 332, 334, 336, 338, 340, 342, 344, 346, 3 48, 350, 352, 354, 356, 358, 360, 362, 364, 366, 368, 370, 372, 374, 376, 378, 380, 382, ​​384, 386, 388, 390, 392, 394, 396, 398, 400, 402, 404, 406, 408, 41 0, 412, 414, 416, 418, 420, 422, 424, 426, 428, 430, 432, 434, 436, 438, 440, 442, 444, 446, 448, 450, 452, 454, 456, 458, 460, 462, 464, 466, 468, 470, 472 , 474, 476, 478, 480, 482, 484, 486, 488, 490, 492, 494, 496, 498, 500, 502, 504, 506, 508, 510, 512, 514, 516, 518, 520, 522, 524, 526, 528, 530, 532, 534,536, 538, 540, 542, 544, 546, 548, 550, 552, 554, 556, 558, 560, 562, 564, 566, 568, 570, 572, 574, 576, 578, 580, 582, 584, 586, 588, 590, 592, 594, 596, 598, 600, 602, 604, 606, 608, 610, 612, 614, 616, 618, 620, 622, 624, 626, 628, 630, 632, 634, 636, 638, 640, 642, 644, 646, 648, 650, 652, 654, 656, 658, 660, 662, 664, 666, 668, 670, 672, 674, 676, 678, 680, 682, 684, 686, 688, 690, 692, 694, 696, 698, 700, 702, 704, 706, 708, 710, 712, 714, 716, 718, 720, 722, 724, 726, 728, 730, 732, 734, 736, 738, 740, 742, 744, 746, 748, 750, 752, 754, 756, 758, 760, 762, 764, 766, 768, 770, 772, 774, 776, 778, 780, 782, 784, 786, 788, 790, 792, 794, 796, 798, 800, 802, 804, 806, 808, 810, 812, 814, 816, 818, 820, 822, 824, 826, 828, 830, 832, 834, 836, 838, 840, 842, 844, 846, 848, 850, 852, 854, or 856.

5. 5. The engineered glycosyltransferase of claim 1, wherein the engineered glycosyltransferase is characterized by increased thermostability compared to an engineered glycosyltransferase having the sequence of SEQ ID NO:

36.

6. 6. An engineered polynucleotide encoding at least one engineered glycosyltransferase polypeptide provided in any one of claims 1 to 5.

7. A vector comprising at least one engineered polynucleotide according to claim 6.

8. The vector of claim 7 further comprising at least one regulatory sequence.

9. A host cell comprising at least one engineered polynucleotide according to claim 6, or a vector according to claim 7 or 8.

10. The host cell of claim 9 , selected from a eukaryote and a prokaryote.

11. 11. A method for producing at least one engineered glycosyltransferase of claims 1 to 5, comprising culturing a host cell of claim 9 or 10 under conditions such that the engineered glycosyltransferase is produced by the host cell.

12. 12. The method of claim 11, further comprising recovering the engineered glycosyltransferase.

13. 6. A composition comprising at least one engineered glycosyltransferase according to any one of claims 1 to 5.

14. (a) a method for glycosylation of a substrate, the method comprising the steps of providing at least one substrate, at least one engineered glycosyltransferase according to any one of claims 1 to 5, and contacting said substrate with said glycosyltransferase under conditions such that said substrate is glycosylated to produce at least one glycosylated product; (b) a method for producing rebaudioside M, the method comprising the steps of providing a rebaudioside D substrate, NDP-glucose, and at least one engineered glycosyltransferase of any one of claims 1-5, combining the rebaudioside D substrate, NDP-glucose, and the glycosyltransferase under conditions such that rebaudioside M is produced; (c) a method for producing rebaudioside A and / or rebaudioside I, comprising the steps of providing a stevioside substrate, NDP-glucose, and at least one engineered glycosyltransferase of any one of claims 1-5, combining the stevioside substrate, NDP-glucose, and glycosyltransferase under conditions such that rebaudioside A and / or rebaudioside I are produced; (d) a method for producing rebaudioside D, the method comprising the steps of providing a stevioside substrate, NDP-glucose, at least one engineered glycosyltransferase of any one of claims 1-5, and a beta-1,2-glycosyltransferase, combining the stevioside substrate, NDP-glucose, and glycosyltransferase under conditions such that rebaudioside D is produced; wherein said NDP-glucose is ADP-glucose.

15. 15. The method of claim 14, wherein for (a), the substrate comprises at least one steviol glycoside; and / or the glycosylation product comprises at least one mono- and / or poly-glycosylated product.

16. (a) a method of producing rebaudioside M, the method comprising the steps of providing a rebaudioside D substrate, an NDP, sucrose, sucrose synthase, and at least one engineered glycosyltransferase of any one of claims 1-5, combining the rebaudioside D substrate, NDP, sucrose, sucrose synthase, and glycosyltransferase under conditions such that rebaudioside M is produced; (b) a method of producing rebaudioside A and / or rebaudioside I, comprising the steps of providing a stevioside substrate, an NDP, sucrose, sucrose synthase, and at least one engineered glycosyltransferase of any one of claims 1-5, combining the stevioside substrate, NDP, sucrose, sucrose synthase, and glycosyltransferase under conditions such that rebaudioside A and / or rebaudioside I are produced; (c) a method of producing rebaudioside D, the method comprising the steps of providing a stevioside substrate, an NDP, sucrose, a sucrose synthase, at least one engineered glycosyltransferase of any one of claims 1-5, and a beta-1,2-glycosyltransferase, combining the stevioside substrate, an NDP, sucrose, sucrose synthase, and glycosyltransferase under conditions such that rebaudioside D is produced; (d) a method of producing rebaudioside M, comprising providing a stevioside substrate comprising at least one stevioside and / or a mixture of stevioside and rebaudioside A, an NDP, sucrose, a sucrose synthase, at least one engineered glycosyltransferase of any one of claims 1-5, and a beta-1,2-glycosyltransferase, combining the stevioside substrate, NDP, sucrose, sucrose synthase, and glycosyltransferase under conditions such that rebaudioside M is produced; or (e) a method of producing rebaudioside M, the method comprising the steps of providing a stevioside substrate, an NDP, sucrose, at least one sucrose synthase, at least one engineered glycosyltransferase of any one of claims 1-5, and a beta-1,2-glycosyltransferase, combining the stevioside substrate, NDP, and glycosyltransferase under conditions such that rebaudioside A is produced first, followed by rebaudioside D and / or rebaudioside I, and finally by rebaudioside M; wherein the NDP is ADP and the beta-1,2-glycosyltransferase is an engineered beta-1,2-glycosyltransferase that can utilize ADP-glucose.

17. 17. The method of claim 16, wherein the sucrose synthase is an engineered sucrose synthase.

18. (i) the process is carried out as a one-pot reaction; (ii) the process is performed sequentially; and / or 17. The method of claim 14 or 16, further comprising the step of: (iii) repeating said steps of said method.

19. 18. The method of any one of claims 14 to 17, wherein the stevioside substrate is extracted from Stevia rebaudiana or synthetically produced.

20. 18. The method of any one of claims 14 to 17, wherein the glycosyltransferase is immobilized.

21. 18. The method of claim 16 or 17, which produces a reaction product comprising fructose.

22. 22. The method of claim 21 , wherein the fructose is removed from the reaction product.

Citation Information

Patent Citations

  • Non-caloric sweeteners and methods for synthesizing

    WO2016054534A1

  • Mutant sucrose synthases and their uses

    WO2017207484A1

  • Enzymatic glycosylation of steviol glycosides and other compounds with glucose-1-phosphate

    WO2017218324A1